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Abstract 
 
Objectives. The cognitive domain that is most consistently improved by smoking and nicotine 
application is attentional performance. However, there are still a number of unanswered 
questions concerning the possible procognitive effects of nicotine and nicotine-like substances 
on executive functioning. Moreover, more insight is needed into what predicts the 
effectiveness of cholinergic treatment. Therefore, in the present investigations the antisaccade 
task, a paradigm of executive control, was chosen to examine cholinergic effects. Methods. 
The aim of Study 1 was to investigate whether genetic polymorphisms in the cholinergic 
system, the CHRFAM7A copy number and 2bp deletion polymorphisms, were associated with 
antisaccade performance. Study 2 tested the hypothesis that baseline performance level may 
be a behavioral predictor of the effects of nicotine on antisaccade performance. Results. In 
Study 1, no significant associations were observed of 2-bp deletion or CHRFAM7A copy 
number with antisaccade performance. Study 2 demonstrated that the administration of 
nicotine enhanced antisaccade performance in low-performing subjects, whereas it had no 
effect in high-performing subjects. Conclusions. The failure to observe an association 
between antisaccade performance and polymorphisms in the CHRFAM7A gene in Study 1 
provides evidence of the specificity of the effects of the CHRFAM7A gene on hippocampal 
and memory functions. The results from Study 2 suggest that stimulation of the nicotinic 
acetylcholine receptor (nAChR) system might be an effective way of improving executive 
functioning in people with poor baseline performance, such as patients with dementia, 
ADHD, or schizophrenia. 
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1. Introduction 
1.1 Smoking behavior and nicotine 
It is estimated that 29% of the world’s population aged 15 years and over smoke 
cigarettes daily (Rigbi et al., 2011). In Germany, the population’s daily smoking rate in adults 
aged 15 and over is 27% (German Federal Statistical Office, 2005), in the UK, 21 % of adults 
aged 16 or over smoke cigarettes (UK Office for National Statistics, 2009), and in the USA 
the smoking prevalence in adults 18 years of age and over is 21% (US Department of Health 
and Human Services, Centers for Disease Control and Prevention, 2009). Motives for 
smoking are diverse: People smoke to reduce tension, relax or stimulate themselves, and for 
social reasons (i.e. to feel more confident and find it easier to talk and interact with people) 
(Berlin et al., 2003). Other reasons for smoking identified by factor analysis include “pleasure 
from smoking,” “habit/automatism,” “addictive smoking,” and “handling/need to hold 
something in hands” (i.e. handling a cigarette, lighting up, watching exhaled smoke) (Berlin et 
al., 2003). The subjective effects of nicotine intake are as multifaceted as the motives for 
smoking. The key findings from a study by Kalman (2002) were that nicotine can induce 
positive effects, such as a drug high (which manifests itself in a head rush and euphoria), but 
also negative effects, such as an increase in tension. A more recent meta-analysis by Kalman 
and Smith (2005) further suggests that nicotine produces an increase in vigor in smokers and 
an increase of fatigue in non-smokers and, contrary to expectations, nicotine decreases 
relaxation and increases tension/jitteriness in both smokers and non-smokers. The authors 
suggest that stronger effects of nicotine on mood emerge when different individual variables 
(e.g., neuroticism) and situational contingencies (e.g., exposure to stressful stimuli) are 
examined (Kalman, 2002). These variables (such as personality variables) could play an 
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important role in the subjective effect of nicotine on mood, as there is considerable variability 
in the effects of nicotine across studies for a given nicotine dose and route of administration 
(Kalman & Smith, 2005). 
Although statistics show that about three quarters of today’s population in high-
income countries are non-smokers, cigarette smoking remains a significant health problem. 
Approximately half of the smoking population dies from a disease associated with smoking 
(Ortells & Arias, 2010). The health consequences causally linked to smoking and exposure to 
second-hand smoke include (amongst others) respiratory diseases, lung cancer and other 
forms of cancer, cardiovascular diseases, reproductive effects in women such as reduced 
fertility and low-birth weight in newborns. Despite the health hazards caused by smoking, 
smokers' attempts to quit are mostly unsuccessful as cigarette smoking is highly addictive. 
Nicotine is so powerful that adolescent smokers already present the first symptoms of nicotine 
dependence such as withdrawal, craving, and relapse, within the first weeks of smoking 
(DiFranza, 2008; Ortells & Arias, 2010). 
Though cigarette smoke contains more than 4000 ingredients, nicotine is the substance 
that causes addiction to tobacco (Greenbaum & Lerer, 2009).  Nicotine reaches the brain 10-
60 seconds after a puff on a cigarette, making cigarettes an ideal drug delivery system, 
enabling smokers to titrate brain nicotine levels each time they smoke (Greenbaum & Lerer, 
2009). After inhalation, a peak of around 0.3 µM nicotine can be attained in the brain (Ortells 
& Arias, 2010; Picciotto et al., 2008), a concentration sufficient to activate nicotinic 
acetylcholine receptors (nAChRs), mostly the α4β2 nAChR sub-type and the α7 nAChR sub-
type. Over the course of a day of smoking, the accumulation of nicotine is enough to produce 
nAChR desensitization (Ortells & Arias, 2011). Furthermore, there is a second desensitization 
process at work: the so-called “high-affinity desensitization,” that is, even low agonist 
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concentrations can induce desensitization without nAChR activation (Giniatullin et al., 2005). 
Desensitization further triggers nAChR upregulation, mainly upregulation of the α4β2 nAChR 
(Picciotto et al., 2008). The combined effects of receptor activation, desensitization and 
upregulation by regular nicotine intake finally modulate dopamine release in the 
mesocorticolimbic system, and thus the rewarding properties of nicotine (Ortells & Arias, 
2010), which eventually leads to the development of nicotine addiction. The 
mesocorticolimbic pathway is part of the “brain reward circuitry” and projects from the 
ventral tegmental area to the nucleus accumbens. Normally, these sites in the brain mediate 
the pleasurable effects of natural rewards (e.g. food, water, and sex), but they are also 
responsible for the motivating and rewarding properties of drugs (Pinel, 1999). As with most 
other drugs, dopamine release in the nucleus accumbens in particular accounts for the 
rewarding effect of nicotine (Dani, 2003). The most important nAChRs expressed in the 
mesocorticolimbic pathway are α4α5β2 and α7 nAChR in the ventral tegmental area as well 
as α4β2 and α6β2β3 nAChRs in the nucleus accumbens – particularly the α4β2 nAChR seems 
to play a major role in the development of nicotine addiction (Buisson & Bertrand, 2002). For 
an elaborate neuronal and molecular model of nicotine addiction, please refer to the review by 
Ortells and Arias (2010). 
The highly addictive properties of nicotine are also reflected in the poor quit rates: In 
2008, 45% of smokers in the US tried to quit smoking, but only 4-7% were successful 
(Heishman et al., 2010).  In most smokers trying to quit, withdrawal symptoms and various 
non-pharmacological factors (e.g., cigarette availability) typically lead to relapse within a few 
days or weeks (Heishman et al., 2010). Smoking withdrawal symptoms include irritability, 
restlessness, anxiety, increased appetite or weight gain, depressed mood, and difficulty 
concentrating. The difficulties in concentration are regarded not only as a relapse factor but 
also as a factor in the maintenance of smoking in tobacco-dependent individuals who are not 
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attempting to quit (Heishman et al., 1994). Furthermore, smokers report that one of the 
reasons they smoke is the perceived cognitive benefit of nicotine (West, 1993). Nicotine’s 
ability to enhance cognition has been the subject of several experimental studies in recent 
decades which showed that nicotine has positive effects on some aspects of attention, such as 
alerting attention and orienting attention, on fine motor abilities, on short-term episodic 
memory, and on working memory (Heishman et al., 2010). The cognitive effects of nicotine 
are likely to be mediated by the action of nicotinic acetylcholine receptors (nAChR) in the 
brain and the subsequent reactions at these receptor sites. 
1.2 The nicotinic acetylcholine receptor (nAChR) 
Nicotine binds to acetylcholine receptors in the brain. Acetylcholine receptors 
(AChRs) are usually classified according to their “pharmacology,” that is to say according to 
their relative affinities and sensitivities to different substances apart from the endogenous 
neurotransmitter acetylcholine, the substance naturally produced in the body. Human AChRs 
are classified into two main sub-types: muscarinic acetylcholine receptors (mAChRs), which 
are particularly responsive to muscarine (the natural and poisonous substance in the fly agaric 
mushroom Amanita muscaria var. Muscaria) and nicotinic acetylcholine receptors (nAChRs), 
which are specifically responsive to nicotine (an alkaloid found in the tobacco plant and in 
smaller amounts in other plants of the nightshade family). The nAChRs are ionotropic 
receptors; this means they form ligand-gated ion-channels in the plasma membranes of 
neurons (neuronal-type nAChRs) and at the neuromuscular junction (muscle-type nAChRs). 
The neuronal-type nAChRs are a structurally and functionally diverse group of receptors, in 
each case composed of five sub-units of polypeptide chains arranged symmetrically around an 
axis perpendicular to the cell membrane (Le Novere et al., 2002). Neuronal or brain nAChRs 
can be composed of either five identical (homopentamers) or different (heteropentamers) sub-
Introduction 
 
 
11 
units. An example of a homopentameric nAChR in the brain is the α7 nAChR which is 
composed of five identical α7 sub-units with five identical acetylcholine binding sites (Court 
et al., 2000). The α4β2 nAChR is an example for a heteropentameric nAChR consisting of 
two α4 sub-units and three β2 sub-units. 
 
 
 
Figure 1-1 
Schematic representation of the α7 nAChR and the α4β2 nAChR (NIAAA, 2011). 
(Graphics Gallery of the National Institute on Alcohol Abuse and Alcoholism, USA. 
Retrieved July 15, 2011, from 
http://www.niaaa.nih.gov/Resources/GraphicsGallery/Neuroscience/Pages/default.aspx). 
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In the human brain, the α7 nAChR and the α4β2 nAChR are the two most common 
sub-types of nAChRs (Boess et al., 2007). As shown in Figure 1-1, in both nAChRs, the sub-
units are arranged around a central pore (= the ion-channel) that opens when acetylcholine or 
nicotine bind to the nAChR, allowing positively charged ions (cations) to flow through the 
channel into the cell. The α7 nAChR allows passage of calcium (Ca2+) ions, whereas the α4β2 
nAChR allows passage of both calcium and sodium (Na
+
) (Court et al., 2000; Le Novere et 
al., 2002). Because some neuronal nAChRs like the α7 nAChR and the α4β2 nAChR are 
permeable to Ca
2+
, they can affect the release of other neurotransmitters (Itier & Bertrand, 
2001). This might be how nicotine facilitates the release of other neurotransmitters such as 
acetylcholine, dopamine, serotonin, and glutamate (Di Matteo et al., 2007). It is possible that  
nicotine’s ability to enhance cognitive processing is mediated by this subsequent release of 
other neurotransmitters (Di Matteo et al., 2007, Heishman et al., 2010). 
1.3 A link between smoking and cognition? 
 The idea that there might be a link between smoking and cognition originally stems 
from several observations within neuropsychiatric disease states, especially from 
schizophrenia spectrum disorders. Eventually, clinical observation led to the systematic study 
of the effects of smoking and nicotine on cognitive functioning both in psychiatric patients 
and in healthy populations. 
1.3.1 The self-medication hypothesis in schizophrenia 
One well-replicated clinical observation in schizophrenia is the elevated smoking rate 
in this disorder: The prevalence of smoking in schizophrenia is about 60-80%, which is two- 
to four-fold the rate of smoking in the general population (Dalack et al., 1998). Moreover, the 
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smoking rate in schizophrenia is also higher in comparison to other psychiatric disease states: 
The prevalence of smoking in major depression is about 49% and it is about 45% in anxiety 
disorders (de Leon et al., 2002; de Leon & Diaz 2005). There is also some evidence that 
schizophrenia patients who smoke consume more cigarettes per day than normal smokers 
(Kumari & Postma 2005, Ucok et al., 2004). Smokers with schizophrenia also favor stronger 
cigarettes (Olincy et al., 1997) and extract more nicotine from their cigarettes than normal 
smokers (Kumari & Postma, 2005; Olincy et al., 1997; Strand & Nyback, 2005). 
What are the possible reasons for this heavy smoking behavior in schizophrenia 
patients? One reason might be that smoking reduces some of the psychiatric symptoms in 
patients with schizophrenia. Evidence for this notion comes from self-reports of schizophrenia 
patients (Glynn & Sussman, 1990), yet there are few empirical studies supporting this claim. 
In one study by Smith and colleagues (2002), smoking high-nicotine cigarettes compared to 
smoking de-nicotinized cigarettes was found to reduce negative symptoms (such as alogia and 
affective flattening) without affecting positive symptoms (such as delusions and 
hallucinations) (Smith et al., 2002, Kumari & Postma, 2005). Perhaps the reduction in 
negative symptoms is achieved via nicotine’s ability to raise dopamine levels in the nucleus 
accumbens and in the prefrontal cortex (Kumari & Postma, 2005). 
Another possible reason for heavy smoking in schizophrenia might be that smoking 
may help to reduce unpleasant side effects of neuroleptic medication, specifically the 
Parkinsonian symptoms (Goff et al., 1992; Kumari & Postma, 2005). Further evidence for this 
hypothesis stems from studies demonstrating that neuroleptic-induced akathisia is reduced by 
nicotine administration via patches (Anfang & Pope, 1997; Yang et al., 2002). Typical 
antipsychotic drugs such as haloperidol have a strong dopamine blocking action, and it is 
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thought that smoking can provide relief from the related side effects because it stimulates a 
release of dopamine (Kumari & Postma, 2005). 
Finally, there is strong empirical evidence that nicotine ameliorates cognitive deficits 
in schizophrenia; thus, schizophrenia patients might also smoke heavily to self-medicate their 
cognitive impairments (Kumari & Postma, 2005). The wide range of cognitive deficits 
reliably associated with schizophrenia include deficits in prepulse inhibition (PPI) of the 
startle response, in gating of the acoustically evoked P50 wave, in antisaccade eye 
movements, in the Continuous Performance Test (CPT), in spatial working memory, in 
declarative memory, and in other neuropsychological measures of attention and memory such 
as in the Wisconsin Card Sorting Test, a widely applied measure of executive functioning 
(Allen et al., 2009; Reichenberg & Harvey, 2007). To date, several studies have shown that 
nicotine improves (at least some of) these cognitive deficits in schizophrenia patients. For 
instance, Depatie and colleagues (2002) found that nicotine improves antisaccade eye 
movements and performance on the CPT. Harris and coworkers (2004) found that nicotine 
improved measures of attention from the RBANS (Repeatable Battery for the Assessment of 
Neuropsychological Status). In another study by Smith et al. (2006), performance on the CPT 
and spatial working memory were improved by nicotine. Finally, Hong and colleagues (2008) 
showed that nicotine improved PPI.  
One drawback of these studies on the effects of nicotine on schizophrenia is that they 
were all conducted on schizophrenia patients who smoked and healthy controls who smoked. 
Studying smoking subjects is disadvantageous because in such a study design, one has to 
deprive subjects of cigarettes and/or smoking for a certain amount of time in order to be able 
to apply a sufficient dose of nicotine. Studying satiated smokers instead is not 
recommendable, for in satiated smokers, nicotinic acetylcholine receptors (nAChRs) are very 
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likely to be occupied and an additional dose of nicotine would unlikely show an effect. It is 
possible that the majority of the studies on smokers only demonstrated that nicotine 
application reversed withdrawal-induced performance deficits (Heishman et al., 2010). 
Therefore, it is recommended to study the effects of nicotine in minimally deprived smokers 
(less than 2 hours of withdrawal) or in non-smoking subjects. Studying non-smokers offers 
the further advantage that they are free of long term-induced neuronal changes that could be 
caused by nicotine dependence.  
There are, however, a few studies which tested the effects of nicotine in non-smoking 
schizophrenia patients and non-smoking controls. For example, a study by Barr and 
colleagues (2008) showed that nicotine delivered by a nicotine patch improved performance 
on the CPT in non-smoking schizophrenia patients and non-smoking controls. The study by 
Sherr and colleagues (2002) tested the effect of nicotine nasal spray on specific eye tracking 
measures in smoking and non-smoking schizophrenia patients and in smoking and non-
smoking control subjects. Nicotine significantly improved eye acceleration during smooth 
pursuit initiation in both smoking and non-smoking patients but had no effects on healthy 
subjects (Sherr et al., 2002). Avila and colleagues (2003) conducted a similar eye tracking 
study with smoking and non-smoking schizophrenia patients and controls. They found that 
nicotine reduced the abnormal elevated number of leading saccades during a smooth pursuit 
eye movement (SPEM) task in schizophrenia patients. Particularly, the beneficial effects of 
nicotine were not restricted to smoking patients, as non-smoking patients exhibited the 
greatest number of leading saccades in a drug-free state and the most pronounced 
improvements after nicotine administration (Avila et al., 2003). Another study that 
demonstrated that effects of nicotine are not dependent on whether someone smokes or not is 
a study by Ettinger et al. (2009). Ettinger and colleagues (2009) administered nicotine and 
placebo on two separate occasions and tested healthy light-to-moderate smokers and healthy 
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non-smokers with the antisaccade task. Nicotine significantly reduced antisaccade latencies in 
both smokers and non-smokers (Ettinger et al., 2009). In addition, the amount of the nicotine-
induced reduction in antisaccade latency in smokers was comparable to the reduction in 
antisaccade latency caused by nicotine in non-smokers (Ettinger et al., 2009). 
Taken together, the evidence from the experimental nicotine application studies in 
schizophrenia patients indicates that nicotine improves some of the cognitive deficits (i.e. 
mainly measures of attention) in schizophrenia and that smoking might represent an attempt 
by patients with schizophrenia to self-medicate these cognitive deficits (Kumari & Postma, 
2005). Analogous to nicotine’s beneficial effects on psychiatric symptoms and on 
antipsychotic-induced side-effects, it seems that nicotine acts as a cognitive enhancer via its 
interaction with dopaminergic as well as glutamatergic transmitter systems (Kumari & 
Postma, 2005). Moreover, the observations that both typical (Mishara & Goldberg, 2004) and 
atypical antipsychotics (Hill et al., 2010) do not sufficiently ameliorate the cognitive deficits 
in schizophrenia further strengthen the self-medication hypothesis. Finally, Dolan et al. 
(2004) found that those smokers with schizophrenia who exhibited pronounced 
neuropsychological deficits in an executive task (i.e. the Wisconsin Card Sorting Test) and in 
a visuo-spatial working memory task before they took part in a smoking cessation program 
were less able to quit smoking than schizophrenia patients without these cognitive deficits 
(Dolan et al., 2004). The results from that study can be interpreted as indirect evidence for the 
notion that smoking might be a way of self-medicating cognitive deficits in schizophrenia 
patients. Indeed, the authors conclude that schizophrenia patients may continue to smoke 
cigarettes because of specific neuropsychological benefits they may receive from smoking 
(Dolan et al., 2004), and thus interventions aimed at remediating prefrontal cortex-related 
neuropsychological deficits may lead to improved smoking cessation outcomes in 
schizophrenia patients (Dolan et al., 2004). 
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1.3.2 The self-medication hypothesis in ADHD 
Studies of the effects of nicotine on cognition showed that attentional performance is 
the most likely candidate to be positively influenced by nicotine (Heishman et al., 2010; 
Newhouse et al., 2004; Rezvani & Levin, 2001). Therefore, it is tempting to adapt the self-
medication hypothesis to other pathological disease states with attentional deficits besides 
schizophrenia. Attention deficit/hyperactivity disorder (ADHD) is one neuropsychiatric 
disorder of interest as it is characterized by inappropriate levels of inattention, hyperactivity, 
and impulsivity (McClernon & Kollins, 2008). A recent review on smoking and ADHD 
suggests that the smoking rate is increased both in adolescents and adults with ADHD 
(McClernon & Kollins, 2008). Prevalence of smoking in ADHD is about twofold higher than 
in non-ADHD individuals (41-42% for ADHD adolescents vs. 26% for non-ADHD, 19-46% 
for ADHD adults vs. 10-24% for non-ADHD) (McClernon & Kollins, 2008). Furthermore, 
there is evidence that individuals with ADHD start smoking at an earlier age and are more 
likely to progress to regular smoking (McClernon & Kollins, 2008). In addition, the self-
reported number of ADHD symptoms, independent of clinical diagnosis, is associated with 
greater cigarette consumption and higher levels of nicotine dependence. Individuals with 
ADHD or elevated ADHD symptoms retrospectively report greater difficulty quitting 
smoking and exhibit greater problems with inhibitory control following quitting (McClernon 
& Kollins, 2008). Together, these findings speak in favor of increased comorbidity of severe 
smoking and ADHD.  
One reason for severe smoking behavior in ADHD might be that nicotine improves 
ADHD symptomatology. A study employing a single dose of transdermal nicotine (7 mg) 
showed that nicotine improved ADHD symptoms measured with the Clinical Global 
Impressions (CGI) scale (Levin et al., 1996; McClernon & Kollins, 2008). A more recent 
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study by the same research group confirmed that nicotine administration over four weeks of 
treatment reduced clinician ratings of ADHD symptoms (measured with the CGI) (Levin et 
al., 2001). Furthermore, self-reported symptoms of depression (measured with the Profile of 
Mood States test, POMS) were decreased by nicotine (Levin et al., 2001). Two other studies 
with novel nAChR agonists, ABT-418 and ABT-089, also demonstrated that these 
compounds displayed efficacy in reducing both inattentive and hyperactive-impulsive 
symptoms in adults with ADHD (McClernon & Kollins, 2008; Wilens et al., 1999; Wilens et 
al., 2006).  
Besides these therapeutic effects of nicotinic stimulation on the symptoms of ADHD, 
there is also strong evidence that  nicotine and nicotine-like substances have a positive effect 
on cognition in ADHD. The cognitive deficits in attention in ADHD are mainly failures of 
cognitive/behavioral inhibition (Barkley, 1997; Newhouse et al., 2004). In the aforementioned 
study by Levin and colleagues (2001) it was also examined how nicotine treatment over four 
weeks affected performance on an attention task. Acute and chronic nicotine treatment 
significantly attenuated the rise in hit reaction time standard error over session blocks on the 
Continuous Performance Test (CPT) (Levin et al., 2001). This result also underlines that 
nicotine affects measures of intra-subject variability – a parameter which discriminates well 
between ADHD-individuals and non-ADHD-individuals and which might even reflect a 
unitary construct in ADHD (Klein et al., 2006). Another study on nicotine and cognition in 
ADHD found that both nicotine and methylphenidate treatment improved stop signal reaction 
time (an estimate of the speed of inhibiting a response) in non-smoking adolescents with 
ADHD aged 13-17 years (Potter & Newhouse, 2004). A similar study by the same researchers 
showed that nicotine also had the same significant positive effect on the stop signal reaction 
time measure in non-smoking young adults with ADHD (Potter & Newhouse, 2008). 
Furthermore, there was also a trend (p=.06) for nicotine to improve recognition memory in a 
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verbal recognition memory task (Potter & Newhouse, 2008). The study by Wilens and 
coworkers (2006) which evaluated the effectiveness of ABT-089 in treating ADHD also 
included neuropsychological test measures. Researchers found that ABT-089 improved 
spatial working memory, ABT-089 improved numeric working memory by trend, and ABT-
089 reduced errors of commission in the CPT (Wilens et al., 2006). In summary, nicotine and 
nicotinic compounds show a procognitive effect in ADHD, speaking in favor of the notion 
that heavy smoking in ADHD might be (at least partially) explained by its remediating effects 
on cognitive deficits in ADHD. 
1.3.3 Procognitive effects of nicotine in Parkinson’s and 
Alzheimer’s diseases 
In addition to schizophrenia and ADHD, Parkinson’s disease (PD) and Alzheimer’s 
disease (AD) are two disorders in which treatment with nicotinic compounds might help to 
improve cognitive deficits. PD is primarily considered a movement disorder with a typical 
onset after age 55 (Levin et al., 2006). The main symptoms of PD include shaking, rigidity, 
slowness of movement and difficulty walking (Jankovic, 2008). Patients with PD might also 
exhibit cognitive (dementia-like) symptoms, sleep disorders and sensory abnormalities 
(Jankovic, 2008). AD is the most common form of dementia, characterized by a late onset, 
typically after the age of 60, with the main symptoms being long-term memory loss, the 
inability to acquire new memories, confusion, irritability and aggression, mood swings, and a 
breakdown of language abilities (Waldemar et al., 2007).  
In PD and AD there is no strong evidence for smoking being an attempt to self-
medicate and treat cognitive symptoms (Levin et al., 2006). Further, there is no evidence that 
individuals with AD or PD are at a higher risk for smoking (Levin et al., 2006). Nevertheless, 
nicotinic receptors might play a role in the pathophysiology of both diseases (Levin et al., 
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2006). That is why nicotine-like substances might also be useful in these conditions as an 
adjunctive treatment for attenuating cognitive deficits. Indeed, there is some experimental 
evidence that nicotine administration improves measures of attention in AD (Newhouse et al., 
1988; Sahakian & Coull, 1994; White & Levin, 1999). However, there is no evidence for 
nicotine-induced improvement in memory functions in AD; so far, four published studies 
demonstrated negative findings (Sahakian & Coull, 1994; Snaedal et al., 1996; White & 
Levin, 1999; Wilson et al., 1995). The review by Levin et al. (2006) nicely summarizes these 
findings on AD. It also offers an overview about the findings on the possible procognitive 
effects of nicotine in PD. For example, a study by Kelton and colleagues (2000) showed that 
patients with PD exhibited improvements in measures of attention after nicotine was 
administered intravenously. In summary, the evidence in AD and PD further underlines the 
notion that nicotine mainly affects the attentional domain. Therefore, nicotine-like compounds 
might be of interest whenever the treatment of attentional deficits is not successful with 
traditional medication. 
1.3.4 Self-medication in a sub-population of “normal” smokers? 
The idea that patients with various disease states smoke to self-medicate their 
cognitive impairments can be extended to the hypothesis that even in so-called “normal” 
smokers, there might be a sub-population of smokers who also attempt to self-medicate 
(subclinical) attentional deficits. Indeed, in recent years, this hypothesis has received growing 
interest. For instance, a research group from Israel published several papers on the question 
“Why do young women smoke?” addressing the question why smoking rates in women from 
high income countries increase although global trends indicate an overall decline in cigarette 
smoking (Yakir et al., 2007). In the third paper of this series of publications by Yakir and 
colleagues (2007) tested female current smokers, occasional smokers, past smokers, and non-
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smokers with a computerized neurocognitive battery, which tested the domains of attention, 
memory, impulsivity, planning, information processing, and motor performance. Current and 
occasional smokers were not in a withdrawal state, as all smoking subjects smoked their last 
cigarette less than 90 min before testing (Yakir et al., 2007). Results from this study showed 
that current smokers made significantly more errors than non-smokers on the Continuous 
Performance Task (CPT), Matching Familiar Figures Test (MFFT), and Tower of London 
(TOL) test (Yakir et al., 2007). Interestingly, past smokers did not differ significantly from 
current smokers on any test (Yakir et al., 2007). Furthermore, there was no association 
between duration of smoking and neurocognitive performance (Yakir et al., 2007). All 
subjects in this study were young adults, between 20 and 30 years of age who had been 
smoking for a few years, but not for many years (mean number of smoking years was 5.56 
years (SD=2.32 years)). Therefore, these results suggest that poorer cognitive performance in 
current and past smokers might not be a consequence of the neurotoxic and deleterious long-
term effects of the consumption of nicotine. Instead, these results indicate that a priori 
neurocognitive deficits may be one of several factors that influence young women to smoke 
(Yakir et al., 2007). Indeed, the authors further concluded from their study that individuals 
who have attentional and impulse control difficulties may find nicotine consumption 
beneficial and use this substance as a form of self-medication that eventually leads to 
addiction (Yakir et al., 2007). 
The authors also acknowledge that these effects of nicotine on cognitive performance 
may be subtle and covert in comparison to other factors that influence the individual when he 
or she initially starts to smoke (e.g. social factors). Once the habit is established, the cognitive 
effects of nicotine may become more salient and contribute both to smoking maintenance and 
difficulties with quitting (Yakir et al., 2007). Conducting longitudinal studies including non-
smokers and smokers would be a plausible approach to disentangle the issue whether 
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cognitive deficits already exist before the onset of smoking or whether cognitive deficits are 
acquired over the course of time after decades of smoking. However, such a project would 
require repeated testing of the study subjects for a time period of about 30 or 40 years and 
would, of course, be a very costly and challenging project. Another (and more feasible) 
research approach to test the hypothesis that a priori cognitive deficits might be one 
predisposing factor to initiative smoking behavior is genetic studies.  
1.4 Genetic evidence for the role of cholinergic 
neurotransmission in cognition 
Genetic variation (i.e. polymorphisms) within the nicotinic acetylcholine receptor 
genes might be (partially) responsible for inter-individual variation in attentional 
performance. Moreover, it is likely that carriers of certain polymorphisms in the nAChR 
system react differently to nicotinic stimulation than individuals who do not carry these 
polymorphisms. It is possible that carriers of a “disadvantageous” polymorphism of the 
nAChR (e.g. the receptor function is suboptimal) benefit from nicotine intake to a greater 
extent than non-carriers of such a polymorphism. Therefore, it is likely that some 
polymorphisms in the nAChR system increase the vulnerability of developing nicotine 
addiction. In recent years, several candidate gene association studies of nAChR genes and 
nicotine addiction have been published. Furthermore, association studies of nAChR genes and 
attentional performance (or other cognitive phenotypes) have underlined the possible link 
between nicotine addiction and attentional functioning. 
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1.4.1 Polymorphisms in the CHRNA4 gene 
To date, the nAChR sub-unit genes CHRNA4 (which codes for the α4 component of 
the α4β2 receptor) and CHRNA7 (which codes for the α7 sub-unit of the α7 nAChR) are the 
most frequently studied genes in connection with nicotine addiction and cognitive 
functioning.  So far, the CHRNA4  single nucleotide polymorphism (SNP) rs1044396 (C/T) 
has received a lot of attention, as it has been repeatedly associated with nicotine addiction in 
Chinese and European-American subjects (Li et al., 2005, Feng et al., 2004, Breitling et al., 
2009). However, there is also one negative finding of rs1044396 and nicotine addiction (Etter 
et al., 2009). The CHRNA4 gene is located on chromosome 20q13.3 and consists of six exons. 
SNP rs1044396 is a synonymous SNP located in exon 5; the SNP has not been functionally 
characterized. This SNP has also been associated with various aspects of attention in several 
studies. Therefore, the SNP rs1044396 is likely to play a role in the triad of nicotine 
addiction, attentional deficits and nAChR variation. 
Parasuraman and colleagues (2005) studied the association of rs1044396 with 
performance on a cued visuospatial attention task in healthy adults. An increasing "gene dose" 
of the C allele (i.e., no C alleles, one C allele, and two C alleles) was associated with larger 
benefits of valid attentional cuing (Parasuraman et al., 2005). The researchers also tested their 
subjects on a working memory task, but did not find an association of rs1044396 with 
working memory performance (Parasuraman et al., 2005). A similar study by the same 
research group replicated the finding that visuospatial task performance increased with the 
number of C alleles in a slightly different paradigm (Greenwood et al., 2005). In a more 
recent study, this research group also examined the combined or epistatic effects of CHRNA4 
and APOE (APOE being a major susceptibility gene for late-onset Alzheimer's disease) 
(Espeseth et al., 2006). (An epistatic gene effect – or epistasis – decribes the nonadditive 
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interaction between genes at different loci. The effect of one gene depends on that of another 
(Plomin et al., 2001).) Subjects were healthy middle aged (53-64 years) and older (65-75 
years) adults. Carriers of the APOE-ε4 allele (the risk allele for Alzheimer’s disease) who 
were also TT homozygotes for the rs1044396 CHRNA4 SNP showed poorer performance on a 
visuospatial attention task involving letter discrimination (Espeseth et al., 2006). In a follow-
up study, the research group demonstrated further epistatic effects of APOE and CHRNA4. 
Being an APOE- ε4/CHRNA4 TT carrier was associated with slower and less efficient 
neuropsychological test performance, with steeper decline in speed tasks and in delayed recall 
(Reinvang et al., 2010). Age dependent genetic effects were found for both APOE and 
CHRNA4 , where elderly participants (60–79 years) showed a negative influence of TT carrier 
status on initial memory performance, but a tendency for steeper memory decline in ε4 
carriers (Reinvang et al., 2010). 
There is also evidence for that rs1044396 is associated with physiological phenotypes 
of attention. Espeseth and colleagues (2007) genotyped their subjects for rs1044396 and 
conducted a study with auditory and visual oddball paradigms measuring event-related 
potentials. Results showed that TT homozygotes displayed increased amplitudes in the 
auditory N1 and visual P1 components (both components being present 100-150 ms after 
stimulus onset) (Espeseth et al., 2007). Later ERP components peaking 300-500 ms post-
stimulus appeared to be unrelated to this CHRNA4 polymorphism (Espeseth et al., 2007). 
Finally, there is evidence from imaging data that the SNP rs1044396 affects 
attentional processing. Winterer et al. (2007) assessed attentional network function in healthy 
subjects with functional magnetic resonance imaging (fMRI) during an attention-requiring 
visual oddball task. The SNP rs1044396 showed genotype effects on attentional network 
function in both the supplementary motor area/anterior cingulate and the parietal cortex in the 
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absence of overt behavioral effects. In the parietal cortex, a gene-dosage effect was seen: 
Stronger BOLD (blood oxygen level-dependent) response was seen with an increasing 
number of A alleles (which corresponds to an increasing number of T alleles) (Winterer et al., 
2007). 
An association study by Todd and coworkers (2003) provides further genetic evidence 
for a possible connection of the nAChR system and attentional functioning: The researchers 
found that an intronic CHRNA4 polymorphism was associated with attention problems. Todd 
et al. (2003) divided ADHD subjects into two ADHD sub-types: combined ADHD and 
inattentive ADHD. They demonstrated a significant association of the G allele of their so-
called marker “SNP3” (located in Intron 2 of CHRNA4) with inattentive ADHD. The possible 
functionality of this intronic SNP has not been determined yet, however, the authors speculate 
about the SNP3 polymorphism affecting pre-mRNA stability and/or splicing (Todd et al., 
2003). 
1.4.2 Polymorphisms in the CHRNA3 gene 
There is also evidence that polymorphisms within the α3/α5 nAChR sub-unit 
(CHRNA3/CHRNA5) gene cluster on chromosome 15q25.1 are associated with (pre-
)attentional functioning. Research from our own laboratory demonstrated that two common 
CHRNA3 polymorphisms (rs1051730/rs1317286) influenced prepulse inhibition (PPI) of the 
acoustic startle response (Petrovsky et al., 2010). PPI is a measure of inhibitory function and 
time-linked information processing by which a weak sensory stimulus (the prepulse) inhibits 
the elicitation of the startle response caused by a sudden intense stimulus (the pulse) (Braff et 
al., 2001). PPI is commonly viewed as an operational measure of a process called 
“sensorimotor gating,” by which excess or trivial stimuli are screened or “gated out” of 
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awareness so that an individual can focus attention on the most salient aspects of the stimulus-
laden environment (Braff et al., 2001). In our study, the TT genotype of rs1051730 and the 
GG genotype of rs1317286 were associated with decreased PPI levels in both healthy 
volunteers and schizophrenia patients (Petrovsky et al., 2010). Our findings from this study 
further support the view that the cholinergic system plays a key role in pre-attentional and 
attentional mechanisms. Interestingly, these SNPs (the CHRNA3 rs1051730 T allele and 
rs1317286 G allele) have been firmly established as risk alleles for nicotine dependence 
(Berrettini et al., 2008, Bierut et al., 2008, Caporaso et al., 2009, Saccone et al., 2009). For an 
elaborate review on the involvement of nAChR genes in nicotine dependence, please refer to 
Greenbaum and Lerer (2009): They also stress the pivotal role of α3 and α5 sub-unit-encoding 
genes for nicotine dependence. 
1.4.3 Polymorphisms in the CHRNA7 gene 
Regarding polymorphisms within the CHRNA7 gene, most evidence for a possible 
connection between smoking behavior and attentional functioning is provided by studies that 
test subjects with schizophrenia. The CHRNA7 gene is located on chromosome 15q13-q14 
which is also a presumed susceptibility locus for schizophrenia. A microsatellite 
polymorphism (D15S1360) in intron 2 of the CHRNA7 gene is associated with P50 sensory 
gating deficits in schizophrenia patients and in their first-degree relatives (Freedman et al., 
1997). The P50 wave is an EEG-based averaged event-related potential (ERP) that can be 
elicited in the context of the auditory “paired click” paradigm (Potter et al., 2006). In the 
paired click paradigm, two auditory clicks are presented within 500 ms of each other. P50 
sensory gating or P50 suppression describes the phenomenon by which the occurrence of the 
first sound click inhibits the P50 response to the second sound click (Potter et al., 2006). 
Therefore, P50 suppression reflects the inhibition of responsiveness to repetitive stimulation 
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and provides the individual with the ability to negotiate a sensory-laden environment by 
blocking out redundant stimuli (Potter et al., 2006). 
Recently, the D15S1360 microsatellite polymorphism was also associated with 
smoking in schizophrenia (De Luca et al., 2004). However, a similar study by Stassen et al. 
(2000) did not find the D15S1360 polymorphisms to be associated with smoking. 
Furthermore, polymorphisms in the promoter of CHRNA7 are associated with schizophrenia 
and P50 sensory gating (Leonard et al., 2002). The -86T variant of the -86CT promoter 
polymorphism was associated with schizophrenia and with P50 gating deficits in 
schizophrenia patients and controls (Leonard et al., 2002). Carrying the -86T variant causes a 
20% reduction in promoter activity (Leonard et al., 2002), indicating that transcription is 
reduced. Moreover, the prevalence of other promoter polymorphisms was also greater in 
schizophrenia patients than in controls (Leonard et al., 2002). Another study by Houy and 
colleagues (2004) exploring the association of promoter polymorphisms within the CHRNA7 
gene and P50 gating in schizophrenia could not replicate the results by Leonard et al. (2002). 
However, they found a protective effect of the -194C variant for the sensory gating deficit 
(Houy et al., 2004).  The authors suggest that such conflicting results can be reconciled if one 
considers that the -194C polymorphism has no causative effect, but is in linkage 
disequilibrium with other causal variations for the P50 sensory gating deficit, and that 
different alleles are in disequilibrium in different populations (Houy et al., 2004). A study by 
Faraone et al. (2004) tested the involvement of 16 nAChR genes as risk factors for smoking in 
schizophrenia families. The CHRNA2 gene and the CHRNB2 gene were significant in this 
study (Faraone et al., 2004). In addition, the CHRNA7 gene and the CHRNA1 gene were 
marginally significant (Faraone et al., 2004). The results from the study by Faraone et al. 
(2004) further underline the notion that nAChR dysfunction may mediate susceptibility to 
smoking in schizophrenia. 
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There is also evidence in the aforementioned “Why do young women smoke?” 
(WDYWS) sample that polymorphisms of the CHRNA7 gene influence attentional processing 
in healthy subjects. Rigbi and colleagues (2008) demonstrated that impulsivity/response 
inhibition as measured with the Matching Familiar Figures Test (MFFT) in the WDYWS 
sample was associated with polymorphisms in the nAChR system. The C allele of SNP 
rs891398 in CHRNA2 was associated with significantly increased errors (poorer response 
inhibition) in both smokers and non-smokers. However, SNP rs2337980 in CHRNA7 had the 
opposite effects on smokers and non-smokers: The T allele was associated with decreased 
errors (better response inhibition) in smokers, while in non-smokers it was associated with 
increased errors (poorer response inhibition) (Rigbi et al., 2008). In a more recent study by 
Rigbi et al. (2011), the research group extended their findings to a pharmacogenetic study: 
placebo or nicotine (4mg as gum) serving as the within factor and genetic profile (SNP 
rs2337980 in CHRNA7) as the between factor. In the MFFT task carriers of the CC variant of 
SNP, rs2337980 benefited more from nicotine than CT/TT carriers as predicted by their 
previous findings (i.e. Rigbi et al., 2008) in which CC carriers manifested poorer MFFT 
performance (Rigbi et al., 2011). 
Finally, the hybrid gene CHRFAM7A is an interesting genetic marker to be 
investigated in connection with attentional phenotypes. The gene CHRFAM7A is a hybrid 
gene of CHRNA7 which contains exons 5-10 of CHRNA7 and four exons of an unrelated 
gene, FAM7A. Most individuals carry the CHRFAM7A duplicon; an individual can carry no 
copy, one copy, or two copies of CHRFAM7A, i.e. the CHRFAM7A polymorphism is a so-
called copy number variation (CNV) polymorphism (Flomen et al., 2006). In addition, the 
CHRFAM7A gene contains a 2bp deletion polymorphism located in exon 6 (Raux et al., 
2002). That means carriers of the CHRFAM7A gene might also be carriers of no deletion, one 
deletion, or two deletions. 
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In an association study by Raux et al. (2002), carrying at least one CHRFAM7A 2bp 
deletion polymorphism was associated with deficient P50 sensory gating both in 
schizophrenia and in control subjects. Moreover, most of the effect detected in the entire 
group was contributed by the non-schizophrenic sub-group (Raux et al., 2002). Furthermore, 
there is a weak but significant association of psychosis with reduced CHRFAM7A copy 
number (Flomen et al., 2006). Flomen et al. (2006) found that for a combined psychosis 
phenotype (i.e. for a sample consisting of individuals with the diagnoses of either 
schizophrenia, bipolar affective disorder, schizoaffective or other psychotic disorder) there 
was an association with only one copy of CHRFAM7A, regardless of presence or absence of 
the 2bp deletion. Dempster and colleagues (2006) also found an association of the 2bp 
deletion with episodic memory: The presence of the deletion predicted poorer performance. 
The functional consequences of CHRFAM7A remain to be investigated; currently, it is 
unknown how CHRFAM7A affects P50 gating and episodic memory. Flomen et al. (2008) 
hypothesize that the translation products of CHRFAM7A may interact with those of CHRNA7 
e.g. via the competition for transcriptional factors. 
1.5 Clinical trials searching for nicotinic agonists to treat 
attentional impairments 
Evidence from experimental studies with nicotine administration suggests that nicotine 
enhances some aspects of cognition with the attentional domain being most consistently 
positively influenced by nicotine (Heishman et al., 2010; Levin et al., 2006; Newhouse et al., 
2004,). This holds true both for patient populations (Levin et al., 2006; Newhouse et al., 
2004) with clinically relevant attentional problems and for healthy subjects (Heishman et al., 
2010). These findings, along with the evidence from genetic studies indicating that the 
nAChR system plays a major role in attentional processing, led to the (ongoing) search for 
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new nicotinic substances for the treatment of attentional and other cognitive deficits. 
Currently, there are several nicotinic compounds under investigation which might be useful in 
the adjunctive treatment in various disease states. So far, three α4β2 nAChR agonists (ABT-
418, AZD3480, varenicline) and the α7 nAChR agonist DMXB-A have been employed in 
clinical trials testing their efficacy on cognitive functioning (see Table 1-1). Moreover, the 
effectiveness of the acetylcholinesterase inhibitors (AChEIs, licensed for the treatment of 
Alzheimer’s diseases) galantamine, donepezil, and rivastigmine have been tested as 
adjunctive treatment in schizophrenia (Ribeiz et al., 2010) (see Table 1-1). Galantamine has 
also been tested in Mild Cognitive Impairment (MCI) (Koontz & Baskys, 2005) (see Table 1-
1). 
 While α4β2 agonists showed effectiveness in healthy subjects (Dunbar et al., 2007; 
Loughead et al., 2010), in patients with Alzheimer’s disease (Potter et al., 1999), in patients 
with ADHD (Wilens et al., 1999), and in patients with schizophrenia (Hong et al., 2011), the 
results for the partial α7 nAChR agonist DMXB-A is more ambiguous. Although there is 
evidence for specific α7 nAChR pathophysiology in schizophrenia, the evidence on 
adjunctive DMXB-A treatment in schizophrenia remains ambiguous. While DMXB-A 
improved some aspects of attention and memory in healthy subjects (Kitagawa et al., 2003) 
and in patients with schizophrenia (Olincy et al., 2006), it showed no effects in another 
extensive study with schizophrenia patients (Freedman et al., 2008). Given that in a novel 
study by Hong et al. (2011) the partial α4β2 nAChR agonist varenicline demonstrated 
beneficial effects on antisaccade performance, P50 sensory gating and startle reactivity in 
patients with schizophrenia or schizoaffective disorder, the stimulation of α4β2 subunits 
(beside the α7 subunits) might also be responsible for beneficial nicotinic effects in 
schizophrenia patients. It is reasonable to assume that there a several nicotinic mechanisms 
which are responsible for procognitive effects in patients and in healthy subjects. This also 
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Compound Mechanism 
of Action 
Study 
Population 
Cognitive Domain Effects Reference 
ABT-418 α4β2 agonist Alzheimer’s 
Disease 
Learning/Memory + Potter et al., 
1999 
ABT-418 α4β2 agonist ADHD Attention + Wilens et al., 
1999 
AZD3480 
(TC-1734) 
α4β2 agonist Healthy 
subjects 
Attention 
EEG/MMN 
Episodic memory  
+ 
+ 
+ 
Dunbar et al., 
2007 
Varenicline partial α4β2 
agonist 
Healthy 
subjects 
N-back working 
memory task 
+ Loughead et 
al., 2010 
Varenicline partial α4β2 
agonist 
Schizophrenia Antisaccades 
Attention 
P50 sensory gating 
Prepulse inhibition 
Startle reactivity 
SPEM 
Speed of processing 
Working memory 
+ 
0 
+ 
0 
+ 
0 
0 
0 
Hong et al., 
2011 
DMXB-A partial α7 
agonist 
Healthy 
subjects 
Attention 
Episodic memory 
Working memory 
+ 
+ 
+ 
Kitagawa et 
al., 2003 
DMXB-A partial α7 
agonist 
Schizophrenia P50 sensory gating  
RBANS total score  
+ 
+ 
Olincy et al., 
2006 
DMXB-A partial α7 
agonist 
Schizophrenia Attention 
Learning 
Reasoning/Problem 
solving 
Speed of processing 
Working memory 
0 
0 
0 
 
0 
0 
Freedman et 
al., 2008 
Galantamine AChEI MCI Executive functions  
Learning/Memory  
+ 
+ 
Koontz & 
Baskys, 2005 
Galantamine, 
Donepezil, 
Rivastigmine 
AChEI Schizophrenia Attention 
Executive functions 
Memory 
Language 
+ 
0 
+ 
0 
Ribeiz et al., 
2010 (meta-
analysis) 
 
Table 1-1 
The efficacy of nAChR agonists on cognition in human subjects. 
Legend: AChEI = acetylcholinesterase inhibitor, ADHD = attention deficit/hyperactivity disorder, 
SPEM = smooth pursuit eye movement, MCI = Mild Cognitive Impairment, “+” = positive effect on 
cognitive performance i.e. cognitive improvement, “0” = no effect on cognitive performance, AChEI = 
acetylcholinesterase inhibitor. 
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 becomes apparent when looking at other drugs which are able to increase acetylcholine 
levels:  acetylcholinesterase inhibitors and serotonergic drugs that act indirectly on the 
acetylcholine system. 
The acetylcholinesterase inhibitor galantamine improved learning and memory as well 
as executive functioning in patients with Mild Cognitive Impairment (MCI) (Koontz & 
Baskys, 2005). A recent meta-analysis by Ribeiz and coworkers (2010) also showed that the 
adjunctive treatment with acetylcholinesterase inhibitors might be an effective way to treat 
cognitive deficits in schizophrenia. Amelioration of cognitive deficits by acetylcholinesterase 
inhibitors was found for memory and attentional functions (Ribeiz et al., 2010). However, 
confirmatory studies are needed to determine the clinical utility of this treatment strategy 
(Ribeiz et al., 2010). This also holds true for the nAChR agonistic compounds currently being 
tested. Two compounds that have been assessed in humans have used alternative strategies 
involving the use of nicotinic agonists to increase the endogenous release of acetylcholine 
(Olincy & Stevens, 2007): Ondansetron and Tropisetron (both are licensed antiemetics). 
Ondansetron increases acetylcholine levels via 5-HT3 receptors antagonism and enhances P50 
auditory suppression in patients with schizophrenia (Adler et al., 2005). 
Ondansetron also reduced negative symptoms and some adverse side effects of 
antipsychotic therapy (such as Parkinsonism and akathisia) (Zhang et al., 2006) and enhanced 
memory functioning in schizophrenia patients (Akhondzadeh et al., 2009). Although 
ondansetron was well tolerated in a study with patients with Alzheimer’s disease, the study 
failed to demonstrate any significant cognitive improvement (Dysken et al., 2002). 
Tropisetron, also a 5-HT3 receptor antagonist, also acts as a partial α7 nAChR agonist (Macor 
et al., 2001; Papke et al., 2005). In a study by Koike and colleagues (2005), tropisetron 
improved P50 sensory gating in schizophrenia patients. 
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In summary, the existing evidence on nAChR agonists indicates that these compounds 
have some positive effects on attention and memory both in healthy and in clinical 
populations. However, more research is needed to clarify which nAChR sub-types should be 
targeted. At present, no nAChR agonist is ready to be released for marketing. Therefore, more 
clinical trials are needed, especially to develop adjunctive nicotinic treatment for the severe 
cognitive impairments seen in schizophrenia. 
1.6 Cholinergic modulation of executive control 
Limitations of the existing studies on the effect of nicotine on cognitive functioning 
include the fact that there are only a few studies on nicotine and executive control (Heishman 
et al., 2010). Moreover, very few studies on the efficacy of new nAChR agonists on cognition 
assessed executive functioning and those that did, did not show an effect (Ribeiz et al., 2010). 
However, it would be important to further test whether cholinergic substances are able to 
improve executive functioning, as a treatment is needed for executive control deficits in 
schizophrenia. Moreover, in schizophrenia, deficits in executive control have the most 
substantial impact on the outcome of the illness (Friedman et al., 1999). Executive deficits 
prevent the schizophrenia patient from retaining or relearning skills that are necessary in order 
for them to function within and be re-integrated into the community. Therefore, it is 
hypothesized that improvement of these executive deficits would lead to an improved 
outcome (Friedman et al., 1999). Thus, it is of particular relevance to find new ways of 
treating executive dysfunctions. The following paragraphs illustrate the involvement of 
cholinergic neurotransmission in executive functions and why the cholinergic system might 
be a target system for enhancing executive functioning. The terms “executive control” and 
“cognitive control” describe the same phenomenon and will be used interchangeably. 
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Executive control involves the activation of internal representations that correspond to 
the goals of a behavior and the rules for achieving it (Miller & Cohen, 2001). Various 
cognitive functions are engaged in carrying out executive control: top-down selective 
attention (biasing in favor of task-relevant information and inhibiting irrelevant information), 
working memory (maintaining information online, i.e. in an activated state), and inhibitory 
control (inhibit a prepotent response, i.e. impulsive, inappropriate, or disorganized behavior) 
(Miller & Cohen, 2001). The executive control system is assumed to be represented in the 
prefrontal cortex (PFC) (Miller & Cohen, 2001). In addition, Miller and Cohen (2001) 
propose that cognitive control stems from the active maintenance of patterns of activity in the 
PFC that represent goals and the means needed to achieve them. However, cognitive control 
no doubt involves neural circuitry that extends over much of the brain. The PFC is a 
collection of interconnected neocortical areas that sends and receives projections from 
virtually all cortical sensory systems, motor systems, and many subcortical structures, such as 
limbic areas. These wide-ranging inputs and intrinsic connections provide a substrate for 
synthesizing and representing diverse forms of information needed to guide performance in 
complex tasks (Miller & Cohen, 2001). 
Currently, it remains largely unknown which role the cholinergic system plays in 
executive control. The review by Sarter and Parikh (2005) offers the intriguing idea that the 
prefrontal cortex might be able to systematically recruit cholinergic transmission in order to 
initiate executive functioning. Initially, the cortical cholinergic input system has been 
described as a diffuse, modulatory input system that innervates the entire cortical mantle and 
is primarily designed to enhance sensory input processing (Sarter & Parikh, 2005). However, 
more recent evidence and conceptualizations indicate that the cortical cholinergic input 
system consists of modules that target specific cortical areas and have individual afferent 
organizations, and therefore have the potential to regulate cortical functions in a region-
Introduction 
 
 
35 
specific manner (Sarter & Parikh, 2005). This hypothesis further predicts that individual 
modules of the cholinergic system can be recruited by the prefrontal cortex, for example, to 
enhance the detection and processing of stimuli of a particular modality (Sarter & Parikh, 
2005). As cholinergic inputs to the prefrontal cortex are predicted to contribute to the 
initiation of such executive functions, increases in prefrontal cholinergic transmission, 
particularly during conditions that tax attentional resources, might trigger complex patterns of 
recruitment of cholinergic modules that project to sensory and sensory-associational cortical 
regions (Sarter & Parikh, 2005). 
1.7 The antisaccade task as a measure of executive control 
In the laboratory, executive functioning can be measured with several tasks. The 
Stroop task and the Wisconsin card sort test (WCST) are two classic examples (Miller & 
Cohen, 2001). In the Stroop task, subjects either read words or name the color in which they 
are written. To perform this task, subjects must pay attention to one attribute (Miller & 
Cohen, 2001). This is especially so when naming the color of a conflict stimulus (e.g. the 
word GREEN displayed in red), because there is a strong prepotent tendency to read the word 
(“green”), which competes with the response to the color (“red”) (Miller & Cohen, 2001). 
This illustrates one of the most fundamental aspects of cognitive control and goal-directed 
behavior: the ability to select a weaker, task relevant response (or source of information) in 
the face of competition from an otherwise stronger, but task-irrelevant one. Patients with 
frontal impairment have difficulty with this task, which suggests that they have difficulty 
adhering to the goal of the task or its rules in the face of a competing stronger (i.e. more 
salient or habitual) response (Miller & Cohen, 2001). Furthermore, when the instructions in 
the Stroop test vary frequently, patients with frontal lesions also exhibit pronounced 
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difficulties with this task (Miller & Cohen, 2001) – they have difficulties with “task 
switching,” another aspect of cognitive control. 
 Similar findings are evident in the WCST. Subjects are instructed to sort cards 
according to the shape, color, or the number of symbols that appear on them, and the sorting 
rule varies periodically. Thus, any given card can be associated with several possible actions, 
no single stimulus-response mapping will work, and the correct one changes and is dictated 
by whichever rule is currently in effect (Miller & Cohen, 2011). Humans with PFC damage 
show stereotyped deficits in the WCST. They are able to acquire the initial mapping without 
much difficulty but are unable to adapt their behavior when the rule varies, which results in 
perseverative behavior (Miller & Cohen, 2011). 
The Stroop task and the WCST constitute relative complex tasks in contrast to the 
antisaccade task which represents a relatively simple paradigm, which serves as a model 
system for executive control of oculomotor responses (Hutton & Ettinger, 2006; Reuter & 
Kathmann, 2004). The ability to control behavior flexibly, responding automatically to stimuli 
in one situation and suppressing this automatic response in favor of an alternative response in 
a different situation, is one of the key components of executive control. The saccadic eye 
movement system provides an excellent model for investigating this ability of the brain 
because eye movements are easy to measure in the laboratory and because we have 
considerable knowledge of the neural networks that participate in controlling gaze (Klein & 
Ettinger, 2008; Munoz & Everling, 2004). 
The instruction of the antisaccade task for a subject is that, after presentation of a 
peripheral target, he or she must look away from it to its mirror image position. Correct 
performance on the antisaccade task requires two steps. The subject must first suppress the 
automatic response to look at the target (that is making a prosaccade) and then transform the 
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location of the stimulus into a voluntary motor command to look away from the target (i.e. 
conducting an antisaccade). Thus, performance on the antisaccade task can be contrasted with 
performance on the prosaccade task in which the location of the sensory stimulus and the goal 
of the saccade are compatible (see Figure 1-2, left), requiring a direct sensory-motor 
transformation. In the antisaccade task (see Figure 1-2, right), however, stimulus location and 
saccade goal are decoupled: The direct response must be suppressed and the stimulus vector 
must be inverted into the saccade vector (Munoz & Everling, 2004). Whenever the subject 
fails to suppress the automatic prosaccade (i.e. the subjects looks towards the target) in an 
antisaccade trial, he or she makes an “antisaccade direction error” or “antisaccade error.” 
Figure 1-3 schematically displays a recorded antisaccade error (on the left side of the figure) 
and a recorded correct antisaccade (on the right side of the figure). Figure 1-3 illustrates that 
subjects often correct their antisaccade error (see left side of the figure) and that the 
performance of a correct antisaccade involves a longer latency than the erroneous gaze at the 
target (i.e. performing a prosaccade) (see right side of the figure). 
 
 
Figure 1-2 
Pro- and antisaccade task. The instruction of the task prompts the subject to either look at the 
peripheral target and generate a prosaccade towards the target (left) or to look away and make 
an antisaccade towards the mirror position of the target (right). 
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A serial model of antisaccade function assumes that the sudden appearance of the 
peripheral target in an antisaccade task automatically triggers a motor program for a 
prosaccade in its direction, and that antisaccade errors occur when subsequent endogenous 
processes fail to inhibit or cancel this program (Hutton & Ettinger, 2006). More recent 
competition models of antisaccade performance emphasize the parallel nature of motor 
programming and suggest that whether an antisaccade error is made or not is determined by 
the relative strength of activation in neural systems supporting the pro- and antisaccade 
(Hutton & Ettinger, 2006; Massen, 2004; Reuter & Kathmann, 2004). More precisely, with 
the onset of the peripheral target, a “competition” ensues between neural processes underlying 
the exogenously triggered prosaccade and the endogenously initiated antisaccade – that is two 
clusters of parallel processes are racing towards threshold (Hutton & Ettinger, 2006; Massen, 
2004; Munoz & Everling, 2004). 
 
 
 
 
 
 
Figure 1-3 
Schematic diagram of an antisaccade error (left) and a correct antisaccade (right). Stimulus 
display = black line, recorded gaze of the subject = grey line. Legend: A) Error latency B) 
Error amplitude C) Time to correct D) Final eye position E) Correct antisaccade latency F) 
correct antisaccade amplitude. Schematic diagram modified in accordance with Hutton and 
Ettinger (2006). 
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If activation in the neural systems supporting the antisaccade reaches threshold fast 
enough, the correct antisaccade is initiated, and the reflexive saccade is cancelled. 
Alternatively, if activation in the neural systems supporting the prosaccade reaches threshold 
first, an erroneous saccade towards the target is made, and the correct antisaccade follows 
(Hutton & Ettinger, 2006). As prosaccade latencies are significantly shorter than antisaccade 
latencies, activation in the neural systems supporting the prosaccade must be somehow 
reduced in order to allow activation in neural systems supporting the more complex 
antisaccade program time to reach threshold first (Hutton & Ettinger, 2006).  
Neurophysiological findings in monkeys as well as fMRI and EEG studies in humans 
demonstrated that antisaccade performance recruits a fronto-parieto-subcortical network. 
Brain areas primarily involved in the antisaccade task include the frontal eye fields (FEF), 
supplementary eye fields, dorsolateral prefrontal cortex (DLPFC), anterior cingulate, posterior 
parietal cortex, thalamus, and striatum (Ettinger et al., 2008a; Munoz & Everling, 2004). The 
FEF plays a crucial role in executing voluntary saccades and the preparation of antisaccade 
eye movements. The DLPFC is important for working memory and suppressing automatic, 
reflexive responses and is involved in the suppression of unwanted reflexive prosaccades in 
the antisaccade task (Pierrot-Deseilligny et al., 2005), for it is believed that the DLPFC 
provides important top-down signals to the FEF and perhaps the superior colliculus to inhibit 
the automatic prosaccade (Munoz & Everling, 2004). 
The top-down control of the DLPFC is particularly important for correctly performing 
the antisaccade task, for studies in patients with discrete lesions of the DLPFC have difficulty 
in suppressing the automatic prosaccade   (Pierrot-Deseilligny et al., 2002) and a fMRI study 
in patients with schizophrenia and control subjects revealed that schizophrenia subjects did 
not demonstrate the increased BOLD contrast in the right DLPFC during antisaccade 
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performance that was apparent in the healthy subjects (McDowell et al., 2002). Interestingly, 
there is also a correlation between antisaccade direction errors and performance on the WCST 
(Crawford et al., 1995; Rosse et al., 1993); this further underlines the executive control 
component of the antisaccade task. Furthermore, the correlation between antisaccade and 
WCST performance indicates that solving these tasks recruits the same or similar prefrontal 
brain areas, including the DLPFC. 
 
1.7.1 The antisaccade task as a useful tool for investigating 
cholinergic effects 
The antisaccade task is also particularly interesting in connection with the need for 
treatment of executive control deficits in schizophrenia. Several sources of evidence indicate 
that the antisaccade task might be a useful laboratory test for investigating cholinergic effects 
on executive control mechanisms. 
First, the task has several general advantages: the measurement of antisaccades is 
highly reliable, the antisaccade task is easy to administer, the instructions are simple, making 
failure to comprehend unlikely, and, with the prosaccade and fixation conditions, there are 
suitable oculomotor control conditions available (Ettinger et al., 2003a; Hutton & Ettinger, 
2006). 
Second, the neural correlates of the oculomotor system are well-known; the brain 
areas engaged in the antisaccade task include the frontal eye fields, supplementary eye fields, 
dorsolateral prefrontal cortex, anterior cingulate, posterior parietal cortex, thalamus, and 
striatum (Munoz & Everling, 2004). 
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Third, in the case of schizophrenia, antisaccades are particularly interesting as 
antisaccade performance deficits are considered to be schizophrenia endophenotypes, i.e. 
antisaccade performance deficits mark genetic liability for schizophrenia (Calkins et al., 2008; 
Hutton & Ettinger, 2006). 
Finally, it has been shown previously that antisaccade performance is sensitive to 
cholinergic manipulation. Nicotine enhanced antisaccade performance in studies with 
schizophrenia patients (Depatie et al., 2002; Larrison-Faucher et al., 2004) and in healthy 
subjects (Bowling & Donnelly 2010; Dawkins et al., 2007; Depatie et al., 2002; Ettinger et 
al., 2009; Rycroft et al., 2006; Rycroft et al., 2007), while the anticholinergic substance 
procyclidine worsened antisaccade performance in schizophrenia patients (Ettinger et al., 
2003b). 
1.8 Hypotheses and aims of the present studies 
As outlined in the previous paragraphs, the abundance of evidence from studies 
investigating nicotine and other cholinergic substances suggests that cholinergic stimulation 
affects mainly the attentional domain. Genetic studies demonstrated the involvement of 
cholinergic polymorphisms in attention and pharmacological studies with nicotinic substances 
showed positive effects on this cognitive domain. However, the possible procognitive effects 
of nicotine and nicotine-like substances on executive functioning needs to be investigated. 
Especially in connection with schizophrenia, possible cholinergic effects on executive 
functions are interesting, as a treatment is needed for executive dysfunction in this disorder. In 
addition, more insight is needed into what predicts the effectiveness of cholinergic treatment. 
Therefore, in the present two investigations, the antisaccade task was chosen, a paradigm of 
executive control and a schizophrenia endophenotype, to examine cholinergic effects. Two 
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research strategies were employed: a molecular genetic strategy and a pharmacological 
strategy. Specifically, the aim of Study 1, the genetic study, was to investigate whether 
genetic polymorphisms in the cholinergic system, the CHRFAM7A copy number and 2bp 
deletion polymorphisms, were associated with antisaccade performance. Study 2, the nicotine 
study, tested the hypothesis that baseline performance level may be a behavioral predictor of 
the effects of nicotine on antisaccade performance. 
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2. Empirical Studies 
 
2.1 Study 1: Genetic study: CHRFAM7A copy number 
and 2bp deletion polymorphisms and antisaccade 
performance (Petrovsky et al., 2009) 
2.1.1 Abstract 
Chromosome 15q13-q14 harbors the gene for the alpha-7 nicotinic acetylcholine receptor sub-
unit (CHRNA7) and a related gene (CHRFAM7A) which arises from a partly duplicated 
portion of CHRNA7. Recent evidence suggests that CHRFAM7A is a locus with a possible 
role in schizophrenia and cognitive functioning. We studied an antisaccade task as a fronto-
parietal measure of executive function that reflects risk for schizophrenia. Association of the 
CHRFAM7A genotype with antisaccade performance was assessed in 103 healthy Caucasian 
individuals. No significant associations of 2bp deletion or CHRFAM7A copy number with 
antisaccade performance parameters were observed. The failure to observe an association 
between antisaccade performance and polymorphisms in the CHRFAM7A gene is consistent 
with specificity of the gene effects on hippocampal and memory functions as previously 
demonstrated. 
2.1.2 Keywords 
CHRNA7, CHRFAM7A, antisaccade, schizophrenia, alpha-7 nicotinic acetylcholine receptor 
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2.1.3 Introduction 
Convergent findings from a number of approaches suggest that the cholinergic system 
may play a role in schizophrenia. For example, an altered neuronal nicotinic acetylcholine 
receptor system may contribute to the pathophysiology of schizophrenia (Freedman et al., 
1995) and the nicotinic acetylcholine receptor α7 sub-unit has been implicated in the genetics 
of this condition. Further, nicotine consumption through cigarette smoking is increased in 
schizophrenia patients and their biological relatives (Lyons et al., 2002) compared with the 
general population. Given that cognitive deficits in schizophrenia benefit from nicotine 
administration (Barr et al., 2008; Depatie et al., 2002), smoking might represent a form of 
self-medication (Kumari & Postma, 2005). 
The antisaccade task is a fronto-parietal measure of executive function that reflects 
risk for schizophrenia (Hutton & Ettinger, 2006). In this task, the subject first fixates a central 
stimulus and then makes a saccade away from a peripheral target to its mirror position. 
Correct performance on this task requires suppression of the reflexive saccade towards the 
target and transformation of the stimulus location into a volitional motor command mediated 
by frontal cortex, posterior parietal cortex, basal ganglia and superior colliculus (SC) (Hutton 
& Ettinger, 2006). Patients with schizophrenia, their relatives, and individuals at risk for 
psychosis show impaired antisaccade performance (Nieman et al., 2007; Petrovsky et al., 
2008), supporting the status of the task as a schizophrenia endophenotype. Endophenotypes 
are biological markers thought to represent a simpler and more direct reflection of genetic risk 
for an illness than the heterogeneous illness phenotype itself. 
So far, little is known about the genetics of antisaccades, but it can be hypothesized 
that genetic polymorphisms relating to the cholinergic system might play a role in inter-
individual differences in performance. It has been shown that antisaccades are influenced by 
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cholinergic modulation. Nicotine improves performance in schizophrenia patients (Depatie et 
al., 2002) and healthy subjects (Rycroft et al., 2006), effects which are similar to those seen 
on other cognitive tasks (Barr et al., 2008). At present, little is known about the molecular 
mechanisms by which cholinergic agents influence antisaccade performance. Agonists of the 
nicotinic acetylcholine receptors (nAChRs) stimulate the activity of these receptors, thereby 
perhaps directly allowing enhanced attention or functioning on this task. It is also possible, 
however, that stimulation of nAChRs evokes the release of other neurotransmitters, such as 
dopamine, which in turn might lead to altered performance. One way of investigating whether 
nAChRs play a role in antisaccade performance would be to search for functional nAChR 
genes which might be responsible for at least some of the differences between individuals in 
antisaccade behavior. To our knowledge, this has not yet been investigated. 
The α7 nicotinic acetylcholine receptor sub-unit gene (CHRNA7) represents a 
promising starting point for this work. CHRNA7 is widely expressed in the central nervous 
system and maps to 15q13-q14. Markers at or near CHRNA7 are strongly linked to another 
endophenotype of schizophrenia, the electrophysiological measure P50 (Freedman et al., 
1997; Leonard et al., 2002). Deficits in P50 sensory gating are normalized by nicotine 
(Freedman et al., 1997) and have been shown to be jointly linked with antisaccades to a locus 
on chromosome 22q11-12 (Myles-Worsley et al., 1999). Weaker linkage to schizophrenia 
itself was demonstrated by Freedman et al. (1997), while the prevalence of functional 
CHRNA7 promoter polymorphisms was also greater in schizophrenia (Leonard et al., 2002). 
Most recently, Stefansson and colleagues (2008) found a significant association of 
schizophrenia with a deletion in chromosome region 15q13.3, between breakpoints BP4 and 
5, which removes CHRNA7 and several other genes, underlining the importance of this region 
in schizophrenia. 
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 In most individuals, the CHRNA7 gene is partially duplicated, giving rise to a hybrid 
gene, CHRFAM7A, which contains exons 5 to 10 of CHRNA7 joined to four exons from an 
unrelated gene, FAM7A. Chromosomes both with and without the CHRFAM7A duplicon have 
been identified, indicating a copy number variation (CNV) with respect to exons 5 to 10 
(Flomen et al., 2006). Reduced copy number has previously shown weak association with 
psychosis (Flomen et al., 2006). Where present, CHRFAM7A exists as a polymorphic 
inversion in either direct or inverted orientation with respect to CHRNA7 (Flomen et al., 
2008). In addition, it contains a polymorphic 2bp deletion within exon 6, which has been 
associated with deficits in P50 sensory gating (Raux et al., 2002) and episodic memory 
performance (Dempster et al., 2006). The 2bp deletion is in strong linkage disequilibrium 
with the direct orientation of CHRFAM7A with respect to CHRNA7 (Flomen et al., 2008), 
which may therefore be the actual variant responsible for the above associations.  
 It is unclear how variants of CHRFAM7A might affect these psychosis 
endophenotypes, as it is unknown whether it is translated or whether it is expressed in the 
same neurons as CHRNA7. Its translation products may interact with those of CHRNA7, 
acting in a dominant negative manner, which would be prevented by the 2bp deletion 
polymorphism truncating the CHRFAM7A product. Alternatively, CHRNA7 expression may 
be modulated by CHRFAM7A expression (e.g. by competition for transcriptional factors), 
which might be influenced by its orientation (Flomen et al., 2008). Interestingly, the direct 
orientation of CHRFAM7A with respect to CHRNA7 is likely to predispose to the 
microdeletions at 15q13.3 associated with schizophrenia (Stefansson et al., 2008) by non-
allelic homologous recombination between the duplicated segments (Makoff & Flomen, 
2009).   
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While both P50 and episodic memory are functions thought to rely on hippocampal 
integrity, associations of the CHRFAM7A genotype with tests of fronto-parietal cognition 
have not been studied. The aim of this study was to explore whether variants in the nicotinic 
receptor gene account for variance in a fronto-parietal schizophrenia endophenotype. We 
therefore investigated the possible association between the CHRFAM7A copy number variant 
with its associated 2bp deletion / inversion polymorphism and antisaccades. We restricted this 
preliminary investigation to healthy individuals, as this allows the study of gene-cognition 
relationships in the absence of clinical and treatment confounds. It also takes into account the 
previous observation of stronger CHRFAM7A genotype effects on cognition in healthy 
compared to schizophrenic individuals (Raux et al., 2002). 
2.1.4 Method 
Subjects 
Healthy volunteers were recruited through advertisements at the university and around 
the local community. Participants provided information regarding age, gender, ethnicity, 
handedness, smoking status (smoker, non-smoker), years spent in full time education, and 
paternal as well as maternal socio-economic status (SES), which was measured on a 1-4 scale 
(1=elementary, 4=professional). Volunteers were screened for the exclusion criteria of DSM-
IV Axis I disorders using the Structured Clinical Interview for DSM-IV Disorders (SCID-I). 
Additional exclusion criteria were a history of head injuries with loss of consciousness of 
more than one minute, any known neurological abnormalities or systemic illness with known 
neurological complication, a first-degree relative with psychosis, a history of substance abuse 
or dependence, or visual impairments. Participants were given a health questionnaire in which 
to provide information pertaining to their general physical health. In addition, participants 
were asked to complete four standardized personality questionnaires: the Rust Inventory of 
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Schizotypal Cognitions (RISC) (Rust, 1988), the World Health Organization (WHO) Adult 
ADHD Self-Report Scale (ASRS) (Kessler et al., 2005), the Obsessive-Compulsive Inventory 
(OCI) (Foa et al., 2002), and the neuroticism scale of the Eysenck Personality Questionnaire – 
Revised (EPQ-R) (Eysenck & Eysenck, 1991) to ascertain possible effects of genotype on 
personality traits. Ethical approval by the local ethics committee was obtained and volunteers 
provided written informed consent. 
Genotyping 
DNA was extracted from venous blood. The 2bp deletion genotype and copy number 
of CHRFAM7A were determined as described previously (Flomen et al., 2006). 
The genotyping yielded 5 groups, consisting of subjects with 1 copy with 0 deletions 
(1C0D), 1 copy with 1 deletion (1C1D), 2 copies with 0 deletion (2C0D), 2 copies with 1 
deletion (2C1D), and 2 copies with 2 deletions (2C2D). We did not observe any examples of 
the rare 6
th
 genotype (subjects having 0 copies of CHRFAM7A). 
Oculography 
Eye movements were recorded using infrared oculography (IRIS Skalar 6500) of the 
left eye and sampled at 500Hz as described previously (Ettinger et al., 2003a). Participants 
were seated 57cm from a 17-in monitor with their heads on a chinrest. The target was a white 
dot (0.3º diameter) presented on a black background. A 3-point calibration (0º, ±12º) was 
carried out, followed by 60 antisaccade trials. A trial consisted of the target in the center of 
the monitor for a random duration of 1000-2000ms and, subsequently, in one of four 
peripheral locations (±6º, ±12º) for 1000ms. Participants were instructed to look at the target 
while in the center and to the exact mirror image location when it jumped to the side. 
Data analysis (Eyemap, AMTech GmbH) involved automatic detection of saccades 
using criteria of minimum amplitude (1°), velocity (30°/s), and latency to target (100ms), and 
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individual categorization into directional correct antisaccades and reflexive error saccades. 
Antisaccade latency (ms), reflexive saccade error rate (% reflexive saccades over total number 
of valid trials), antisaccade gain (% saccade amplitude over target amplitude), and antisaccade 
spatial error were calculated. Spatial error was obtained by subtracting the target amplitude 
from saccade amplitude and dividing the result by the target amplitude. The absolute value of 
this term reflects the residual error and was then averaged across all saccades and multiplied 
by 100. 
 Statistical Analyses 
Statistical analyses were conducted using SPSS15.0. Genotype (1C0D, 1C1D, 2C0D, 
2C1D, 2C2D) was used as an independent variable and the socio-demographic (age, 
education, paternal and maternal SES) and antisaccade (error rate, latency, gain, and spatial 
error) variables were used as dependent variables in separate univariate analyses of variance 
(ANOVA). We also examined the relationship between genotype and gender using χ2 test. 
Finally, we included smoking status (smoker, non-smoker) as an additional independent 
variable in the ANOVA model and investigated whether smoking status was associated with 
genotype (using χ2 test). 
2.1.5 Results 
Socio-demographic and antisaccade variables are summarized in Table 2-1. 111 
participants completed the study. There were 8 genotyping failures, leaving a final sample 
size of N=103 (57 males; 25.87±5.50 years of age; 17.64±3.36 years of education; paternal 
SES=3.12±90 maternal SES=2.83±1.02; 27 smokers). All participants were Caucasian. The 
genotype groups did not differ in any socio-demographic variable or smoking status (all 
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p>0.20). The genotype distribution did not significantly differ from Hardy-Weinberg-
equilibrium (χ2=4.51, df=3, p=0.21). 
 
Analyses of antisaccade variables revealed no association with genotype for the 
combined copy number / 2bp deletion assay (all p>0.37). Grouping subjects by 2bp deletion 
alone (N=31 without deletions; N=72 with at least one deletion) and by copy number alone 
(N=28 with one copy; N=75 with two copies) in separate analyses did not yield any 
significant effects (p>0.34 and p>0.59, respectively). 
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 1C0D 
(N=16) 
1C1D 
(N=12) 
2C0D 
(N=15) 
2C1D 
(N=42) 
2C2D 
(N=18) 
Age (years) 24.88 (4.86) 26.17 (8.18) 25.60 (5.21) 26.17 (5.46) 26.11 (4.66) 
Gender (N male) 9 5 8 28 7 
Education (years) 17.87 (3.58) 17.25 (4.56) 17.27 (3.35) 18.05 (3.25) 17.06 (2.71) 
Paternal SES 2.92 (0.86) 3.00 (0.87) 3.64 (0.67) 2.97 (1.00) 3.33 (0.78) 
Maternal SES 3.00 (0.82) 2.89 (1.17) 3.09 (0.94) 2.69 (1.15) 2.75 (0.87) 
Smoker (N, %) 3 (18.75%) 3 (25%) 5 (33.33%) 13 (30.95%) 3 (16.66%) 
AS Gain (%) -111.79 (22.05) -102.70 (23.50) -105.37 (15.35) -106.15 (25.02) -112.64 (24.66) 
AS Spatial Error (%) 39.54 (11.53) 36.69 (5.35) 33.96 (7.08) 38.97 (10.16) 39.97 (10.93) 
AS Latency (ms) 272.61 (44.47) 291.78 (40.78) 276.27 (41.73) 280.22 (44.39) 284.89 (47.88) 
AS Error Rate (%) 25.91 (15.36) 20.75 (13.33) 27.77 (24.16) 23.84 (20.52) 29.47 (20.49) 
RISC 24.19 (11.86) 21.33 (10.25) 22.87 (6.79) 21.50 (7.14) 21.56 (8.13) 
ASRS 
(N = 78) 
21.15 (7.55) 
(N = 13) 
22.11 (11.36) 
(N = 9) 
24.64 (10.28) 
(N = 11) 
20.19 (7.04) 
(N = 32) 
21.15 (6.94) 
(N = 13) 
OCI 
(N = 78) 
8.77 (9.49) 
(N = 13) 
9.89 (6.90) 
(N = 9) 
8.91 (5.26) 
(N = 11) 
8.03 (7.60) 
(N = 32) 
7.15 (6.30) 
(N = 13) 
EPQ-R N 
(N = 77) 
7.31 (5.09) 
(N = 13) 
8.67 (6.16) 
(N = 9) 
7.30 (6.41) 
(N = 10) 
5.47 (4.75) 
(N = 32) 
7.38 (5.17) 
(N = 13) 
Table 2-1 
Socio-demographic, antisaccade and personality variables by genotype. Note: Data represent means (standard deviation) unless stated otherwise (total N=103). SES = 
socio-economic status; AS = antisaccade; 1C0D = 1 copy 0 deletion; 1C1D = 1 copy 1 deletion; 2C0D = 2 copies 0 deletion; 2C2D = 2 copies 2 deletions. The RISC data was 
available for the total N=103, the data of the other questionnaires was available for the Ns given in the table. RISC = Rust Inventory of Schizotypal Cognitions; ASRS = Adult 
ADHD Self-report Scale; OCI = Obsessive-Compulsive Inventory; EPQ-R N = Neuroticism scale of the Eysenck Personality Questionnaire Revised. 
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The effect sizes for the analyses of antisaccade variables are presented in Table 2-2. 
Finally, given the known effects of smoking on antisaccade performance (Rycroft et al., 2006) 
and the possibility of an interaction between an acetylcholine-related genotype and nicotine 
consumption, smoking status was added into the model as an independent variable. Genotype 
effects remained unchanged, and there were no significant main or interaction effects 
involving smoking status (all p>0.18). 
Data from the personality questionnaires are presented in Table 2-1. There were no 
associations with genotype for the combined copy number / 2bp deletion assay (all p>0.48). 
Grouping subjects by 2bp deletion alone and by copy number alone also did not reveal any 
significant effects (p>0.25 and p>0.22 respectively). Finally, there were no effects of smoking 
status or interactions of smoking status with genotype on questionnaire variables (all p>0.05).
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Table 2-2 
Effect sizes for the analyses of antisaccade variables. Note: The partial Eta squared (ηp
2
)
 
estimates the proportion of variance in the dependent 
variable that is attributable to each effect. CHRFAM7A copy number/deletion = ANOVA with the combined copy number/deletion groups 
(1C0D, 1C1D, 2C0D, 2C1D, 2C2D). CHRFAM7A copy number = ANOVA with copy number only as a factor (one copy, two copies). 
CHRFAM7A deletion = ANOVA with deletion only as a factor (no deletion, at least one deletion). 
 
 
 CHRFAM7A copy 
number/deletion 
CHRFAM7A copy number CHRFAM7A deletion 
F p ηp
2 
F p ηp
2 
F p ηp
2 
AS Gain (%) .554 .697 .022 .004 .947 .00004420 .090 .765 .001 
AS Spatial Error (%) 1.075 .373 .042 .003 .959 .00002678 .908 .343 .009 
AS Latency (ms) .401 .808 .016 .001 .978 .00000781 .903 .344 .009 
AS Error Rate (%) .482 .749 .019 .277 .599 .00273733 .244 .622 .002 
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2.1.6 Discussion 
This is, to our knowledge, the first study to explore the association between 
CHRFAM7A and measures of executive function. We selected the antisaccade task as it 
represents a marker of risk for schizophrenia with well-defined fronto-parietal neural 
correlates and because performance can be modulated by cholinergic agents (Hutton & 
Ettinger, 2006). The CHRFAM7A gene was selected as it is a promising locus in the 
cholinergic system with regard to schizophrenia and cognition (Dempster et al., 2006; Raux et 
al., 2002). 
In this study, no significant association of CHRFAM7A copy number or 2bp deletion / 
inversion polymorphism with antisaccade performance parameters was observed. It should be 
noted, however, that given the relatively small sample size of the present study, we can only 
exclude a large effect size. It is possible that CHRFAM7A does in fact impact aspects of 
executive function and future studies with larger samples are required to address this question. 
A power calculation found that >600 subjects are required to detect effects of d=0.2 with 
>80% power.  
Failure to detect association may actually be consistent with the neurophysiological 
and cognitive specificity of the effects of this genotype, given that previous studies have 
shown evidence for an association with episodic memory and P50 suppression (Dempster et 
al., 2006; Raux et al., 2002). Although episodic memory and P50 suppression involve 
widespread neural correlates and CHRFAM7A is not expressed exclusively during 
hippocampal formation, the results suggest a more specific effect on hippocampally mediated 
memory and inhibitory functions. In this context it is important to note that the hippocampus 
primarily mediates long-term memory processes, while working memory relies more heavily 
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on fronto-parietal networks (however, see Weinberger et al., 1992 for evidence of an 
association between hippocampus and working memory). 
We did not observe any significant associations of the CHRFAM7A polymorphisms 
with questionnaire measures of personality traits indexing variation in schizotypy, 
neuroticism, attention deficit hyperactivity disorder, and obsessive-compulsive disorder. The 
lack of association with personality traits is unlikely to be due to measuring error, as the 
questionnaires used here have established reliability. The same applies to the antisaccade task, 
for which high test-retest reliabilities and internal consistencies have been reported (Ettinger 
et al., 2003a). 
Both smokers and non-smokers were included in the present study. Smoking status 
was not associated with genotype and did not affect antisaccade or personality variables, nor 
did it mediate genotype associations with these measures. 
Given that the antisaccade task is a schizophrenia endophenotype with good 
heritability, future investigations of the specific molecular genetic mechanisms underlying 
inter-individual differences are important. There is strong evidence for cholinergic influences 
on antisaccades, so in addition to assessing the CHRFAM7A CNV and 2bp deletion / 
inversion polymorphism genotype in a much larger sample, it would be worthwhile to 
investigate other  polymorphisms in cholinergic system genes associated with schizophrenia 
or frontal lobe functioning, including CHRFAM7A and CHRNA. 
A related issue concerns the possible role of CHRFAM7A and other cholinergic 
genotypes in the effects of cholinergic manipulation on neurocognitive performance. Even in 
the absence of a main effect of genotype on behavioral performance as in this study, it is 
possible that there are modulating pharmacogenetic effects of this polymorphism that become 
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apparent in pharmacological challenge studies. Similarly, it would be interesting to investigate 
whether this polymorphism mediates inter-individual differences in the effects of smoking 
withdrawal on cognitive performance (Powell et al., 2002). 
The main limitation of the present study is the small sample size. Given the power 
calculations presented here, multi-center collaborative efforts will be required to demonstrate 
the operation of small gene effects on performance. Future studies may also wish to examine 
possible associations of CHRFAM7A on standard neuropsychological tests of different 
domains of executive function and memory. 
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2.2 Study 2: Nicotine study: Nicotine differentially 
modulates antisaccade performance in healthy male 
non-smoking volunteers stratified for low and high 
accuracy (Petrovsky et al., in press) 
2.2.1 Abstract 
Rationale: Nicotinergic agents are currently being examined as possible pro-cognitive drugs 
for a variety of clinical conditions marked by cognitive deficits, such as attention deficit 
hyperactivity disorder (ADHD) or schizophrenia. The response to acute nicotine is 
heterogeneous across subjects and samples; however, only a few reliable predictors of 
response have been identified. Objectives: We tested the hypothesis that baseline performance 
level in cognitive control may be a predictor of the cognitive effects of nicotine. Methods: We 
tested 28 healthy Caucasian, male, non-smoking volunteers with the antisaccade task, an 
oculomotor measure of cognitive control. Participants were given a 7-mg nicotine patch in a 
double-blind, placebo-controlled, counterbalanced, within-subjects design. Subjects were 
stratified into high and low performers based on their antisaccade error rate in the placebo 
condition (median-split). Results: Nicotine tended to reduce response time variability of 
prosaccade latency (p=0.06). There was no main effect of nicotine on antisaccade error rate 
(p=0.31). However, nicotine significantly reduced antisaccade error rate in the low-accuracy 
probands while leaving performance of the high-accuracy probands unaffected (interaction 
p<0.05). Furthermore, we found a nicotine-induced reduction of response time variability of 
antisaccade latency at one target location in the low-performing group (interaction p<0.05). 
Conclusions: The present results demonstrate the importance of baseline performance 
differences for the effectiveness of pharmacological enhancement of cognitive control. More 
generally, the results suggest that stimulation of the nicotinic acetylcholine receptor (nAChR) 
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system might be an effective way of improving cognition in people with poor cognitive 
performance, such as patients with ADHD or schizophrenia. 
2.2.2 Keywords 
Nicotine, acetylcholine, executive function, antisaccade, oculomotor control, attention 
2.2.3 Introduction 
In the last decades, growing interest in the pro-cognitive effects of nicotine has 
emerged. Earlier research studied mostly the effects of nicotine or smoking in deprived 
smokers (Heishman et al., 1994). A limitation of studying nicotine effects in smokers is that 
putative genuine cognitive enhancing effects of the compound cannot be disentangled from 
the reversal of withdrawal-induced performance deficits (Heishman et al., 1994). More recent 
studies have taken this methodological problem into account by testing effects of nicotine in 
non-deprived smokers, minimally deprived smokers (deprivation for less than 2 hours), or 
non-smokers (Heishman et al., 2010). A recent meta-analysis by Heishman et al. (2010) found 
significant positive effects of nicotine on six cognitive domains: fine motor, alerting attention-
accuracy and response time (RT), orienting attention-RT, short-term episodic memory-
accuracy, and working memory-RT. Some performance domains could not be included in the 
meta-analysis as there were not sufficient numbers of studies available in these domains, 
which included reasoning, arithmetic and executive function (Heishman et al., 2010). 
Therefore, more studies on the effects of nicotine on executive functioning are needed, 
especially as there is an unmet need for satisfactory treatment of attention and executive 
control deficits in psychiatric disorders. Particularly in schizophrenia, cognitive symptoms 
such as deficits in executive control have the most substantial impact on the outcome of the 
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illness (Friedman et al., 1999) and the adjunctive treatment with cholinergic substances might 
be useful for remediation (Ribeiz et al., 2010).  
Another aspect in nicotine research that has mostly been disregarded concerns inter-
individual differences in treatment response. These inter-individual differences might partially 
explain why some studies showed beneficial effects of nicotine but others did not. Parallel to 
earlier findings regarding the dopamine system, Newhouse et al. (2004) suggest an inverted-U 
shaped function of baseline differences in performance and nicotinic stimulation. Depending 
on the baseline level of cognitive performance, an equivalent degree of nicotinic stimulation 
can either enhance or impair performance. Figure 2-1(a) illustrates the presumed positive 
effect of nicotine intake in low-performing subjects: Nicotine improves performance and 
brings performance closer to the optimum. Figure 2-1(b) shows the presumed 
disadvantageous effect of nicotine administration: Already high-performing subjects are 
impaired by nicotine intake. 
Therefore, in studies of the effects of nicotinic agonists, it would be important to 
systematically consider the role of baseline performance levels in order to explain inter-
individual variability in drug response. So far, there are only a few psychopharmacological 
studies in performance-stratified samples, and only one published study which investigated 
nicotine. Vollenweider et al. (2006) demonstrated that the antipsychotic clozapine 
significantly increased PPI levels in low PPI performers but showed no effect in high PPI 
performers. Likewise, Csomor et al. (2008) found that haloperidol failed to increase PPI in 
low PPI performers, but attenuated PPI in high PPI performers. Moreover, haloperidol 
increased P50 gating in low suppressors and disrupted P50 gating in high suppressors 
(Csomor et al., 2008). A recent study by Knott et al. (2010) demonstrated that nicotine 
reduced P50 gating in high suppressors while P50 in low suppressors remained unaffected by 
nicotine. Allman et al. (2010) found that low antisaccade performers with long-latency 
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antisaccades exhibited shorter antisaccade latencies on D-amphetamine while high-
performing subjects with short-latency antisaccades had longer latencies on D-amphetamine 
(Allman et al., 2010). To our knowledge, there is no study on inter-individual effects of 
nicotine employing the antisaccade task. 
  
 
 
Figure 2-1 
Presumed effect of nicotinic stimulation in (a) low-performing individuals and in (b) high-
performing individuals: Baseline performance level may be a determinant of the cognitive 
effects of nicotine. 
 
 
Therefore, the present study aimed to investigate the effects of nicotine on the 
antisaccade task in performance-stratified sub-groups of healthy, non-smoking volunteers. We 
Study 2: Nicotine and antisaccade performance 
 
 
61 
chose the antisaccade task because this paradigm addresses a relatively simple response 
system, which serves as a particularly useful model system for executive control of 
oculomotor responses (Reuter & Kathmann, 2004). Moreover, the antisaccade task recruits a 
well-defined fronto-parieto-subcortical network (Ettinger et al., 2008a; Munoz & Everling, 
2004) and is considered a schizophrenia endophenotype (Calkins et al., 2008) with high test-
retest reliability (Ettinger et al., 2003a). Furthermore, previous studies demonstrated the 
sensitivity of the antisaccade task to nicotine administration in schizophrenia patients (Depatie 
et al., 2002; Larrison-Faucher et al., 2004) and in healthy subjects (Bowling & Donnelly, 
2010; Dawkins et al., 2007; Depatie et al., 2002; Ettinger et al., 2009; Rycroft et al., 2006; 
Rycroft et al., 2007). Based on the model by Newhouse et al. (2004), we hypothesized that 
participants showing low performance on the antisaccade task would benefit from nicotine 
administration while already high-performing participants would be impaired by nicotinic 
stimulation. 
2.2.4 Methods and materials 
Subjects 
Thirty healthy Caucasian, non-smoking, male volunteers were recruited from the local 
community by advertisement at the university and by contacting a random sample of the 
inhabitants of Bonn based on a list from the city registry. Non-smokers in our sample were 
defined as individuals who had smoked no more than 100 cigarettes during their lifetime and 
had not smoked in the past year. The volunteers were required to be between 18 and 55 years 
old and were screened for the exclusion criteria and interviewed with the Structured Clinical 
Interview for DSM-IV (SCID-I, German version: Wittchen et al., 1997). Exclusion criteria 
were a current or lifetime Axis I disorder, a first-degree relative with psychosis, a history of 
neurological illness or another severe medical condition, head injury with loss of 
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consciousness of >5 min, lifetime history of alcohol or substance abuse or dependence, visual 
impairments, obesity (body mass index (BMI) > 30), intake of any medications which effect 
the CNS. Furthermore, the following exclusion criteria regarding the application of nicotine 
were employed: cardiovascular disease, hypertension, atopic or eczematous dermatitis (due to 
localized patch sensitivity), severe renal or hepatic impairment or active peptic ulcers, 
hyperthyroidism, pheochromocytoma, insulin-dependent diabetes, hypersensitivity to patches, 
hypersensitivity to nicotine or to any of the excipients of the patches. Subjects were allowed 
to drink their usual amount of coffee, tea or other caffeinated beverages in the morning. 
Caffeine consumption was documented for both testing sessions. Verbal IQ was estimated 
with a standardized German vocabulary test, the MWT-B (Mehrfachwahl-Wortschatz-
Intelligenztest, Lehrl, 1989). Approval of the local ethics committee and the German Federal 
Institute for Drugs and Medical Devices (BfArM) was obtained and the study was registered 
with http://www.clinicaltrials.gov (ClinicalTrials.gov Identifier: NCT01315002). Participants 
provided written informed consent before inclusion. 
Experimental design and nicotine application 
Each subject underwent a telephone-screening for a first evaluation regarding the 
inclusion and exclusion criteria of the present study. Subsequently, subjects were invited to 
the laboratory for two testing sessions, preferably with a time interval of one week between 
the two sessions. Before Session 1, researchers measured subjects’ blood pressure to ensure 
that no subject suffered from undetected hypertension (diastolic value no greater than 90, 
World Health Organization, Whitworth et al., 2003). On both testing days, a urine drug 
screening test was conducted before application of the patch to ensure that subjects had 
abstained from amphetamine, benzodiazepine, cocaine, THC cannabinoides, and 
opiate/morphine (nal von minden, Moers, Germany).  
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Nicotine was applied in a double-blind, placebo-controlled, counterbalanced within-
subjects design. Subjects received nicotine via a patch (NiQuitin Clear 7 mg, 
GlaxoSmithKline, Germany) and were given a placebo patch (Fink and Walter GmbH, 
Germany) of similar appearance. Both patches were applied to the upper back of the subject 
by a research assistant who was not running the test sessions in order to ensure double-
blindness. Testing with the antisaccade paradigm commenced 3 hours after patch application. 
Nicotine administration using the NiQuitin patch generates a fast-rising nicotine plasma level 
(a nicotine plateau level is achieved after 2 to 4 hours after the patch has been applied 
according to the Summary of Product Characteristics of NiQuitin Clear). The 7 mg nicotine 
dosage was chosen as prior studies employed similar dosages and found cognitive effects in 
non-smokers in the absence of significant side effects (see Barr et al., 2008; Levin et al., 
1998; Poltavski & Petros, 2006). Therefore, only a low drop-out rate due to side-effects was 
expected. At the end of each testing session, the patch was removed by the research assistant 
and participants were asked which patch they thought they had received. Mood ratings and 
physical symptom ratings were assessed with visual analogue scales (VAS). In each case, 
there was an item beside a horizontal line of 100 mm in length, ranging from “strongly 
disagree” at the one end (0) to “strongly agree” at the other end (100). The participants had to 
indicate their perception of their current state by marking the point on the horizontal line that 
they thought was most appropriate. The following items were included: “relaxed,” “alert,” 
“nervous,” “drowsy,” “comfortable,” “fidgety,” “concentrated,” “dizzy,” “excited,” 
“attentive,” “I like the substance,” “I am in a bad mood,” “I feel nauseous,” and “I am in a 
good mood.” After completing the second session, participants were debriefed and 
compensated with € 80 for their participation. A schematic overview of the timeline is 
depicted in Table 2-3. 
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Before patch 
application: 
Blood pressure measurement 
Visit study physician and give informed consent (at Session 1) 
Urine drug screening test 
Assessment of mood and physical symptoms with visual analogue 
scales  
Patch application (7mg nicotine or placebo) and beginning of 3-hour-waiting time 
During waiting period: 
 
Collect demographic data, verbal IQ testing and SCID-I interview 
Have a light lunch 
Allowed to read 
After 3 hours: 
 
Collect data on caffeine intake 
Assessment of mood and physical symptoms with visual analogue 
scales 
Antisaccade testing 
Patch removal 
Let participant make a guess about which patch he was given 
Debriefing and financial compensation (at Session 2) 
 
Table 2-3 
Timeline of the testing sessions. 
 
 
Saccadic tasks 
Participants were seated 41 cm from a 17-inch monitor, head movements were 
minimized using a chinrest. The testing room was quiet and dimly lit. Experimental stimuli 
were presented using ERTS® (BeriSoft Corporation, Frankfurt, Germany). Participants 
performed one block of prosaccade trials and one block of antisaccade trials. The order was 
fixed beginning with the prosaccade trials. For both tasks, subjects fixated on a white central 
fixation cross on a black background. The fixation cross appeared for 1000, 1500, 2000, or 
2500 ms at random. A peripheral target (a white dot) then appeared at 6° or 12° either to the 
left or to the right of the central fixation cross for a duration of 1000 ms. The central fixation 
cross was extinguished whenever the peripheral target appeared (step paradigm). Altogether, 
there were 96 trials (48 prosaccade and 48 antisaccade trials), in each case consisting of 12 
Study 2: Nicotine and antisaccade performance 
 
 
65 
trials×4 target positions. The sequence of peripheral target presentations was 
pseudorandomised. There were five practice trials before each block which were not included 
in the analysis. The prosaccade instruction was to look toward the peripheral target as quickly 
and as accurately as possible (serving as an easy control task for the antisaccade task). In the 
antisaccade task, subjects were instructed not to look toward the target but to look away from 
the peripheral target to the mirror position on the opposite side of the computer screen as 
quickly and as accurately as possible. 
Eye movement recording and analysis 
Eye movements were recorded using electroocculography (EOG). Five nonpolarizable 
Ag/AgCl electrodes (Easycap GmbH, Herrsching-Breitbrunn, Germany) were employed. Two 
electrodes recorded the horizontal electroocculogram (HEOG) from the outer canthi of the 
eyes, and another two electrodes recorded the vertical electroocculogram (VEOG) from 
supra- to suborbital sites of the right eye to detect eye blinks. A ground electrode was placed 
on the glabella. The electrolyte gel Abralyte® 2000 (Easycap GmbH, Herrsching-Breitbrunn, 
Germany) was used as an abrasive paste to minimize skin impedance level and as a 
conducting agent between skin and electrode. The impedance was kept below 5 kΩ at all 
electrode locations and checked at the beginning of each recording session. The EOG was 
recorded using Neuro Scan Labs™ with a Synamps® 5083 amplifier controlled by Acquire® 
software package (Neurosoft Inc., Sterling USA). EOG data were digitized at 250 Hz and 
stored on hard disk for later analysis. Simultaneously with each presentation of the target dot, 
a trigger marker (indicating at which position the dot was shown) was recorded. Trigger 
markers were stored together with the EOG data for later segmentation and analysis of the eye 
movement data. 
The analysis of the EOG data was performed with Brain Vision Analyzer and Matlab. 
At first, the raw data were pre-processed with Brain Vision Analyzer. Sampling rate was set 
Study 2: Nicotine and antisaccade performance 
 
 
66 
to 250 Hz, and the raw data were segmented relative to the trigger marker positions. That is, a 
segment started 200 ms before the onset of a trigger marker and ended 800 ms after a trigger 
marker (segment length= 1000 ms). Next, the data were filtered with a high cut-off filter of 
30,000 Hz and a notch filter of 50 Hz and baseline correction was employed. 
After initial processing, the data were analyzed by a Brain Vision Analyzer macro-
program searching for the saccadic eye movements in the HEOG channel. The automatic 
detection of saccades used.the criteria of amplitude (1°) and velocity (30°/s). Whenever there 
was such a deviation from the baseline, the onset and offset of the saccade was marked with 
markers categorizing the saccade into directional correct prosaccade, prosaccade direction 
error, directional correct antisaccade, or antisaccade direction error. Subsequently, the data 
were visually inspected by one of two raters blind to experimental condition 
(placebo/nicotine). The rater verified whether saccades were correctly identified by the 
program and changed markers categorizing the saccade where applicable. In addition, the 
rater rejected segments (=trials) if the subject’s latency to respond was below 80 ms 
(=anticipatory response), if the subject did not respond (amplitude less than 3°), or if the 
subject blinked immediately before the target appearance or during the saccade. For the low-
accuracy probands, 47.50±0.81 (98.96±1.68%) of prosaccade trials and 46.82±1.66 
(97.54±3.46%) of antisaccade trials were valid trials. For the high-accuracy probands, 
47.71±0.47 (99.40±0.98%) of prosaccade trials and 47.64±0.46 (99.26±0.95%) of antisaccade 
trials were valid trials. Low- and high-accuracy probands did not differ regarding the number 
of valid trials both for prosaccade trials (F(1,25)=0.90, p=.77) and for antisaccade trials 
(F(1,25)=1.14, p=.30). In addition, there were no main or interaction effects regarding 
nicotine treatment on number of valid trials (all p>.32). 
The dependent variables were percentage saccade errors (an amplitude of the first 
saccade after target appearance greater than 3° in the wrong direction), saccade latencies (time 
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between target appearance and saccade initiation of correct trials), and intra-individual 
coefficient of variation (ICV=standard deviation of saccade latency/mean saccade latency; 
ICV provides a measure of response variability, adjusted for the influence of response speed 
(Nandam et al., 2011)). A prosaccade (direction) error was counted when the first saccade 
after target appearance was away from the target; an antisaccade (direction) error was 
detected when the first saccade after appearance of the peripheral target was performed 
towards the target. The error rate is calculated as the percentage of error trials over the total 
number of valid saccade trials (excluding e.g., eye-blink trials). In addition, the proportion of 
corrected antisaccade errors was collected to control whether the subjects understood the task 
and made an effort to correctly perform the task. A corrected antisaccade error was scored 
when a corrective saccade away from the target was made after the subject had made an 
antisaccade error. 
Statistical analyses 
Statistical analyses were conducted using the software PASW Statistics 18 (SPSS Inc., 
Chicago, IL, USA). To test whether nicotine had a differential effect on subjects with high 
antisaccade error rates (i.e. low accuracy) versus subjects with low antisaccade error rates (i.e. 
high accuracy), subjects were divided by a median-split procedure into low- and high-
accuracy probands. This median-split was based on the mean antisaccade error rate of both 
eccentricities (6° and 12°) of the placebo session. For the statistical analysis of nicotine 
effects on saccadic variables 2×2×2×2 repeated-measures analyses of covariance (ANCOVA) 
with verbal IQ as a covariate were calculated with Treatment (placebo, nicotine) and 
Eccentricity (6° eccentricity, 12° eccentricity) as within-subjects factors and Group (low-
accuracy probands, high-accuracy probands) and Order (nicotine first, placebo first) as 
between-subjects factors. Verbal IQ was entered as a covariate in all analyses as the high- and 
low-accuracy groups differed on this variable (see below). Assessment of the participants’ 
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blindness for patch treatment was evaluated with chi-squared tests. Data from the visual 
analogue scales assessing physical symptoms and mood ratings were analyzed with 2×2×2 
repeated-measures analyses of variance (ANOVA) with Treatment (placebo, nicotine) as 
within-subjects factor, and Time (first assessment, second assessment) and Group (low-
accuracy probands, high-accuracy probands) as a between-subjects factors. The significance 
level of all statistical tests was set at p<.05. 
Power analyses 
Before conducting our study, we performed an a priori power analysis using G*Power 
3.1.2 (Faul et al., 2007). We chose to perform the power calculation on antisaccade error rate 
as the dependent variable because this is the most frequently studied measure of this task. We 
chose a medium effect size of Cohen’s f=0.15 (Cohen, 1988) and took the correlation among 
repeated measures from empirical evidence of a test-retest reliability study (Ettinger et al., 
2003a). The required minimum sample size was N=22 (see Table 2-4). Therefore, we aimed 
to measure approximately 30 subjects to ensure a sufficiently large sample size. We also 
calculated a post-hoc power analysis (see Table 2-5). Our test-retest correlation for 
antisaccade error rate was 0.75 and therefore not quite as high as 0.89 as in the study by 
Ettinger et al. (2003a). However, our effect size was quite large; thus, we achieved very good 
statistical power of 0.99. Regarding ICV of antisaccade latency, the test-retest correlation was 
relatively small with 0.54. Nevertheless, due to a large effect size, we also achieved adequate 
statistical power of 0.99. 
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Antisaccade error rate: 
within-between interaction 
Treatment×Group 
Cohen’s effect size f (assumed) 0.15 
Alpha error (assumed) 0.05 
Power (1- beta error) 0.80 
Critical F 4.35 
Number of groups 2 
Number of measurements 2 
Correlation among repeated measures 0.89 
Total sample size 22 
Table 2-4 
A priori power analysis to compute the required sample size in order to detect a within-
between interaction effect of nicotine treatment and group status on antisaccade error rate. 
 
 
 
 
 
 
 
Antisaccade error rate: 
within-between interaction 
Treatment×Group 
ICV of antisaccade latency: 
within-between interaction 
Treatment×Eccentricity×Group 
Cohen’s effect size f (measured) 0.40 0.48 
Alpha error (assumed) 0.05 0.05 
Power (1- beta error) 0.99 0.99 
Sample size 28 28 
Critical F 4.23 4.23 
Number of groups 2 2 
Number of measurements 2 2 
Correlation among repeated 
measures 
0.75 0.54 
Table 2-5 
Post hoc-power analyses. Computation of achieved power for significant within-between 
interaction effects on antisaccade variables (Treatment: Placebo/Nicotine, Eccentricity: 6° 
condition/12°condition, Group: low-performing probands/high-performing probands). 
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2.2.5  Results 
Sample characteristics 
Two subjects dropped out of the study due to nausea, one of these subjects also 
experienced vomiting. Unblinding showed that in both cases the subjects had been 
administered nicotine. We replaced the two drop-outs by recruiting two additional subjects. 
Thus, data of 30 subjects were analyzed. Exploratory data analysis identified one subject as an 
outlier on the antisaccade error rate (more than three times the interquartile range of the 
boxplot); this subject was excluded from further analyses. The final sample therefore included 
29 subjects. The mean time interval between the two testing sessions was 9.28 days 
(SD=5.18, MIN=4, MAX=28). The median antisaccade error rate was 25.91 %. Removal of 
the median subject led to two groups of n=14 each. The mean age of these 28 subjects was 
28.11 (SD=9.22) years, the median age was 25 years; age ranged from 20 to 55 years. Sample 
characteristics are summarized in Table 2-6. The two groups did not differ in age, years of 
education, or BMI. The two groups differed regarding verbal IQ, indicating lower verbal IQ in 
high-accuracy probands. Therefore, verbal IQ was entered as a covariate in the subsequent 
analyses of variance. Thirteen of the 28 subjects received nicotine first and fifteen received 
placebo first. The frequencies of patch order in the low- and high-accuracy groups did not 
significantly differ from the expected patch order (χ2(1)=1.29; p=.26). 
Blindness for patch treatment and mood/physical symptoms ratings 
Participants were able to correctly identify the nicotine patch. In Session 1, 
participants correctly guessed on the nicotine patch with a probability of 69.2 %, which was 
significantly above the level of chance (χ2(1)=4.14; p=.042). For Session 2, participants 
correctly guessed they had nicotine with a probability of 92.3% (χ2(1)=16.45; p=.0001). These 
results reveal that despite employing a double-blind design, the participants could tell the 
difference between administration of nicotine and placebo, especially after Session 2 when 
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participants were able to compare both sessions. Correct guessing was not associated with 
group status: There was no difference in correct guessing rate in low- and high-accuracy 
probands (Session 1: χ2(1)=0.16; p=.69; Session 2: χ2(1)=0.47; p=.50). 
 
 
 
Low-accuracy probands 
(N=14) 
High-accuracy probands 
(N=14) 
Age (years) 30.50 (11.71) 25.71 (5.21) 
Education (years) 16.21 (2.75) 16.29 (0.73) 
Verbal IQ 126.07 (18.21) 111.57 (15.41) 
BMI 24.04 (3.68) 23.97 (1.53) 
Daily caffeine intake (mg) 31.07 (46.93) 39.00 (68.20) 
Order of patch 
(N nicotine first / N placebo first) 
5/ 9 8/6 
 
Table 2-6  
Sample characteristics by Group. Note: Data represent means (standard deviations) unless 
otherwise specified. The two groups did not differ in age, education, BMI, daily caffeine 
intake and order of patch (all p>.17), but they differed regarding verbal IQ (p=.03), indicating 
a lower verbal IQ in the high-accuracy group. Abbreviations: IQ, intelligence quotient; BMI, 
body mass index.  
 
 
 
Results from the visual analogue scales (VAS) on mood and physical symptoms 
demonstrated that probands experienced side effects from the nicotine administration. 
Significant interaction effects of Time×Treatment indicated that, compared to the first 
assessment without a patch, for the second assessment (i.e after three hours of nicotine patch 
application) probands felt more fidgety (F(1,26)=6.46 p=.017 ηp
2
=.20; placebo: VAS 
mean=1.15, SD=1.54; nicotine: VAS mean=1.69, SD=1.89 ), more nauseous (F(1,26)=5.04 
p=.034 ηp
2
=.16; placebo: VAS mean=0.19, SD=0.28; nicotine: VAS mean=1.14, SD=2.32), 
and, by trend, the probands felt less comfortable (F(1,26)=4.25 p=.050 ηp
2
=.14; placebo: VAS 
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mean=7.91, SD=1.41; nicotine: VAS mean=6.65, SD=2.35 ). Therefore, it is very likely that 
probands correctly identified the nicotine patch on the basis of side effects caused by the 
nicotine treatment. 
There were also some main effects of Time, revealing lower ratings at the time of the 
second assessment – probably reflecting adaptation to the testing situation: Probands felt less 
alert (F(1,26)=13.55 p=.001 ηp
2
=.34; first assessment: VAS mean=7.81, SD=1.67; second 
assessment: VAS mean=6.89, SD=2.30), they were less nervous (F(1,26)=6.76 p=.015 
ηp
2
=.21; first assessment: VAS mean=1.79, SD=2.09; second assessment: VAS mean=1.25, 
SD=1.46), and they felt less attentive F(1,26)=9.67 p=.005 ηp
2
=.28; first assessment: VAS 
mean=7.61, SD=1.66; second assessment: VAS mean=6.82 SD=2.31). Moreover, probands 
felt more drowsy at the time of the second assessment than at the time of first assessment 
(F(1,26)=4.90 p=.036 ηp
2
=.16; first assessment: VAS mean=2.80, SD=2.58; second 
assessment: VAS mean=3.75, SD=2.81).  
Furthermore, there was one interaction effect of Group×Time (F(1,26)=4.51 p=.043 
ηp
2
=.15): For Time 1, the low-accuracy probands gave higher ratings of feeling relaxed (VAS 
mean=7.95, SD=2.64) than the high-accuracy probands (VAS mean=6.77, SD=2.60), at Time 
2 there was no difference between the groups (low-accuracy probands: VAS mean=7.08, 
SD=2.93; high-accuracy probands VAS mean=7.11, SD=1.89). There were no further main or 
interaction effects (all p>.11). 
Reliabilities of saccadic variables 
Saccades were rated by two raters. To assess the consistency of performance in one 
rater (intrarater reliability), internal consistency was assessed using Cronbach’s coefficient 
alpha. Interrater reliability of the two raters was assessed by computing intraclass correlations 
(ICC) with ICC (3,2) (two-way mixed average measures, absolute agreement). All reliability 
analyses were performed on 12 randomly chosen subjects. Raters were blind to group and 
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treatment status. Both intrarater and interrater reliabilities were high (all coefficients, >0.97, 
for all coefficients see Table 2-7). 
 
 
Dependent variable Internal consistency 
of Rater A 
(Cronbach’s alpha) 
Internal consistency 
of Rater B 
(Cronbach’s alpha) 
Intraclass 
correlations (ICC) of 
the two raters 
Antisaccade error rate 
6° eccentricity 
0.97 0.98 0.98 
Antisaccade error rate 
12° eccentricity 
0.99 0.99 0.99 
Antisaccade latency 
6° eccentricity 
0.98 0.99 0.98 
Antisaccade latency 
12° eccentricity 
0.99 0.99 0.99 
 
Table 2-7 
Intrarater and interrater reliabilities of the two raters analyzing the saccadic eye movements. 
 
 
 
Saccadic performance: Correction of antisaccade errors 
The average correction rate of antisaccade errors was high (placebo-induced condition: 
mean 95.64%, SD=7.62; nicotine-induced condition: mean 90.82%, SD=17.51). For the low-
accuracy probands, mean correction rate under placebo was 92.97% (SD=9.66); under 
nicotine, it was 89.90% (SD=17.92). The high-accuracy probands exhibited mean correction 
rates of 98.30% (SD=3.46) in the placebo-induced condition and 91.74% (SD=17.72) in the 
nicotine-induced condition. These high proportions of corrected antisaccade errors indicate 
that subjects understood the task and were willing to perform the task. Groups did not differ 
in antisaccade correction rates (F(1,23)=0.80, p=.78), and there were no further main or 
interaction effects for this variable (all p>.35).  
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Saccadic performance: Effects of eccentricity and nicotine  
Exploratory data analysis revealed that there was almost no variance in prosaccade 
error rate, indicating that subjects made virtually no prosaccade errors. Therefore, this 
variable was excluded from further analyses. Antisaccade error rate, pro- and antisaccade 
latencies as well as ICV of pro- and antisaccade latencies were normally distributed (all 
Kolmogorov–Smirnov tests p>.11). Table 2-8 displays means and standard deviations for all 
saccadic variables. In the repeated-measures ANCOVAs, there was neither a significant main 
effect of Order (nicotine first, placebo first) nor interactions of Order with any of the variables 
(all p>.14). 
For prosaccade mean latency, there were no main or interaction effects (all p>.18). For 
ICV of prosaccade latency, there was a trend for a main effect of Treatment (F(1,23)=3.78, 
p=.064, ηp
2
=.14), indicating lower prosaccade response time variability in the nicotine 
condition. No further main or interaction effects were observed for this variable (all p>.15). 
For antisaccade error rate, there was no main effect of Treatment (F(1,23)=1.06, 
p=.31). As expected, due to the median-split procedure, the two groups differed in antisaccade 
error rates (F(1,23)=34.93, p=5×10
-7, ηp
2
=.60), indicating the low-accuracy probands 
performed worse than the high-accuracy probands (Figure 2-2). There was an interaction 
effect of Treatment×Group (F(1,23)=6.45, p=.018, ηp
2
=.14), indicating that low-accuracy 
probands made fewer antisaccade errors in the nicotine-induced condition than in the placebo-
induced condition, whereas the high-accuracy probands’ performance did not differ between 
placebo and nicotine (Figure 2-2). Post hoc comparisons confirmed that nicotine decreased 
antisaccade errors in low-accuracy probands (F(1,12)=6.83, p=.023, ηp
2
=.36) but not in high-
accuracy probands (F(1,12)=0.30, p=.596, ηp
2
=.02). There were no other main or interaction 
effects for this variable (all p>.08). 
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Figure 2-2 
Percentage antisaccade errors in the low- and high-accuracy subgroups during placebo and 
nicotine treatment. Error bars refer to ±SE. Nicotine significantly reduced antisaccade error 
rate in the low-accuracy probands (p=.023), but not in the high-accuracy probands (p=.596). 
 
 
For antisaccade latency, there were no main or interaction effects (all p>.09). For ICV 
of antisaccade latency, there was no main effect of Treatment (F(1,23)=0.04, p=.84); however 
there was a trend for a Treatment×Eccentricity interaction (F(1,23)=4.07, p=.056, ηp
2
=.15). 
Post-hoc comparisons showed a decrease in ICV of antisaccade latency under nicotine for the 
12° eccentricity condition (F(1,27)=4.52, p=.043, ηp
2
=.14) but not for the 6° eccentricity 
condition (F(1,27)=0.03, p=.866, ηp
2
=.001). Moreover, there was a significant triple 
interaction of Treatment×Eccentricity×Group (F(1,23)=5.39, p=.029, ηp
2
=.19), demonstrating 
that the interaction of Treatment×Eccentricity depended on the factor Group. Post hoc 
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comparisons revealed that the interaction of Treatment×Eccentricity was significant in the 
low-accuracy probands (F(1,11)=4.97, p=.048, ηp
2
=.31) but not in the high-accuracy probands 
(F(1,11)=0.10, p=.755, ηp
2
=.009) (see also Figure 2.-3). There were no further main or 
interaction effects (all p>.23). 
 
 
 
 
Figure 2-3 
Intra-individual coefficient of variation (ICV) of antisaccade latency for the 12° eccentricity 
condition in the low- and high-accuracy sub-groups during placebo and nicotine treatment. 
Error bars refer to ±SE. Nicotine significantly decreased ICV of antisaccade latency in the 
low-accuracy probands (p=.048), but not in the high-accuracy probands (p=.755). 
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 Low-accuracy probands (N=14)  High-accuracy probands (N=14) 
Placebo Nicotine  Placebo Nicotine  
6° eccentricity 12° eccentricity 6° eccentricity 12° eccentricity  6° eccentricity 12° eccentricity 6° eccentricity 12° eccentricity p 
Prosaccade error 
rate (%) 
0.00 (0.00) 0.00 (0.00) 0.30 (1.11) 0.60 (1.51)  0.00 (0.00) 0.00 (0.00) 0.30 (1.11) 0.00 (0.00) n/a 
Prosaccade latency 
(ms) 
168.51 (25.76) 182.77 (27.56) 171.35 (24.20) 187.79 (34.05)  173.27 (28.45) 190.84 (28.95) 170.39 (31.71) 189.75 (37.48) n.s. 
ICV of prosaccade 
latency 
.20 (.07) .21 (.06) .21 (.07) .22 (.07)  .22 (.07) .25 (.10) .21 (.09) .22 (.11) .064
a
 
Antisaccade error 
rate (%) 
49.30 (14.65) 36.36 (14.73) 45.88 (17.17) 26.00 (10.88)  19.87 (12.60) 8.93 (7.10) 21.70 (17.17) 11.02 (6.65) .018
b
 
Antisaccade latency 
(ms) 
302.78 (33.64) 294.66 (43.25) 304.66 (30.37) 288.25 (31.36)  288.94 (44.34) 282.92 (49.27) 283.36 (44.81) 280.67 (45.19) n.s. 
ICV of antisaccade 
latency 
.21 (.06) .22 (.05) .23 (.07) .18 (.07)  .20 (.06) .17 (.04) .17 (.04) .15 (.05) .029
c
 
 
Table 2-8  
Descriptive statistics of saccadic variables by Group, Treatment and Eccentricity. 
Note: Table displays means (standard deviation) of all saccadic variables by Group (low-accuracy probands, high-accuracy probands), Treatment 
(placebo, nicotine), and Eccentricity (6° eccentricity, 12° eccentricity). n/a=not applicable, n.s.=not significant. 
a
 Trend for a main effect of Treatment: placebo > nicotine 
b 
Treatment×Group interaction: Nicotine decreased antisaccade error rate in the low-accuracy group (p=.023), but not in the high-accuracy group 
(p=.596) 
c
 Treatment×Eccentricity×Group interaction: Nicotine decreased ICV of antisaccade latency in the 12° eccentricity condition (p=.043), but not in the 
6° eccentricity condition (p=.866). Above interaction of Treatment×Eccentricity was significant in the low-accuracy probands (p=.048), but not in 
the high-accuracy probands (p=.755). 
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2.2.6 Discussion 
The present study investigated the influence of nicotine on prosaccade and antisaccade 
eye movements in healthy, male, non-smoking volunteers stratified for low and high 
antisaccade performance. We did not detect a main effect of nicotine on antisaccade 
performance. However, nicotine enhanced antisaccade performance in low-performing 
subjects, whereas it had no effect in high-performing subjects. 
Concerning antisaccade error rate, we found an interaction effect of nicotine and group 
status: nicotine reduced antisaccade error rate in the low-performing group while leaving the 
performance of the high-performing group unaffected. This finding is in agreement with the 
notion that baseline performance level may be a determinant of the cognitive effects of 
nicotine (Newhouse et al. 2004). However, we did not observe a significant detrimental effect 
of nicotine intake in the already high-performing subjects as proposed by the inverted U-
shaped model by Newhouse et al. (2004). Possibly, our dose of nicotine was comparatively 
low; a larger dose of nicotine might have induced a performance decline in the high-accuracy 
probands and might have led to an even greater performance improvement in the low-
accuracy group. It is also possible that our “high-accuracy participants” exhibiting an average 
antisaccade error rate of about 15% in the placebo condition did not exhibit peak performance 
in this task and for that reason we did not observe a nicotine-induced performance decline in 
these participants. Psychometrically defined, an antisaccade error rate of 0% would represent 
optimal performance (i.e. 100% accuracy) and thus a floor effect leaving no further room for 
improvement by a substance such as nicotine. Therefore, it would be interesting to conduct a 
nicotine study in participants who might actually exhibit peak performance in the antisaccade 
task (i.e. who exhibit a very low error rate of less than 5%, ideally 0%). Possibly, in those 
participants a performance decline with nicotine administration will be more readily 
observable. 
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We also checked our data for a possible statistical phenomenon which might be a 
trivial explanation of the present data. In a repeated-measurement design in which subjects are 
tested twice, their scores tend to regress towards the mean. This regression to the mean (also 
known as the law of initial value) describes the statistical phenomenon that if a variable is 
extreme on its first measurement, it will tend to be closer to the average on a second 
measurement, and if it is extreme on a second measurement, it will tend to have been closer to 
the average on the first measurement (Bland and Altman 1994, Wilder 1958). This statistical 
phenomenon might also explain why initially low-performing subjects improve on the second 
testing session and high-performing subjects performing less well on the second testing 
session. We checked the present antisaccade error data for this issue by breaking down the 
three-way interaction of Treatment (placebo, nicotine)×Group (low-accuracy probands, high-
accuracy probands)×Order (placebo/nicotine, nicotine/placebo). This interaction was not 
significant (F(1,23)=3.36, p=.08), though one could argue there is a trend towards 
significance. However, mean values revealed that probands with low accuracy always 
exhibited a lower antisaccade error rate in the nicotine condition regardless whether they 
received nicotine first or placebo first. Those probands with lower accuracy who had received 
nicotine first exhibited a mean error rate of 47.22% under placebo and a mean error rate of 
40.01% under nicotine. Those probands with lower accuracy who had received placebo first 
exhibited a mean error rate of 40.45% under placebo and a mean error rate of 32.85% under 
nicotine. Mean values from the probands from the group with high accuracy revealed that 
they showed a practice effect from Session 1 to Session 2: Those who received placebo at 
Session 1 showed poorer performance during the placebo session (mean error rate = 15.12%) 
than during the nicotine session (mean error rate = 10.45%) and those who received nicotine 
at Session 1 showed poorer performance during the nicotine session (mean error rate = 
21.74%) compared with the placebo session (mean error rate = 13.79%). These result patterns 
argue against a regression to the mean and in favor of the notions that the performance 
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enhancement of the probands with lower accuracy can be attributed to the nicotinic treatment, 
whereas the pattern of mean values in the probands with high accuracy revealed that they 
displayed a practice effect which cannot be connected with the nicotine administration. In 
addition, the pattern of results regarding the response time variability of antisaccade latency 
(i.e. ICV of antisaccade latency) also argues against a regression to the mean: The interaction 
Treatment × Eccentricity × Group × Order was also not significant (F(1,23)=1.31 p=.27). 
We did not observe any effects of nicotine on mean antisaccade latency, contrary to a 
few previous studies (Ettinger et al., 2009; Larrison-Faucher et al., 2004; Rycroft et al., 2007). 
However, for ICV of antisaccade latency, we did find a trend for an interaction of nicotine 
and eccentricity condition indicating a nicotine-induced decrease in variability of antisaccade 
latency for only the 12° eccentricity condition. There was a significant three-way interaction 
of nicotine treatment, eccentricity condition and group for ICV of antisaccade latency. This 
three-way interaction indicated that the simple interaction of nicotine and 12° eccentricity 
condition was influenced by the factor group. Post hoc comparisons showed that the two-way 
interaction of nicotine and 12° eccentricity condition was only significant in the low-
performing group but not in the high-performing group. There are two published studies 
examining the effects of stimulus eccentricity on antisaccade latencies in human subjects. In a 
study by Fischer and Weber (1997), a decrease in antisaccade latencies was seen with 
increasing stimulus eccentricity (ranging from 1° to 12° stimulus eccentricity). Fischer and 
Weber also found that antisaccade error rate increased with increasing eccentricity (Fischer & 
Weber, 1997). On the contrary, Dafoe et al. (2007) did not find a significant effect of 
eccentricity on antisaccade latencies. However, Dafoe et al. (2007) found that a near stimulus 
eccentricity provoked more antisaccade errors than a far eccentricity condition. Given these 
contradictory findings on effects of eccentricity on antisaccade performance, we can only 
speculate why we found a specific effect of nicotine on a more distant 12° stimulus 
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eccentricity condition. In the present study, there were no significant effects of eccentricity on 
antisaccade error rate and antisaccade latency, although mean values indicate that the 6° 
condition tended to provoke more antisaccade errors and tended to lead to longer antisaccade 
latencies. Thus, we would have expected that nicotine effects will emerge on the (presumably) 
more difficult 6° condition. Therefore, the present finding of a decrease in variability of 
antisaccade latency for the 12° eccentricity condition only is somewhat unexpected. It is 
possible that the 12° condition is more sensitive to nicotine effects than the 6° condition. If 
one inspects the mean values of antisaccade error rate under placebo and nicotine in the low-
performing group, it becomes obvious that nicotine led to a reduction in antisaccade error rate 
of about 3% in the 6° condition, while there was a nicotine-induced reduction of antisaccade 
errors of about 10% in the 12° condition. Analogous to this tendency of a more pronounced 
effect of nicotine in the 12° condition for antisaccade errors, variability of antisaccade 
latencies was reduced with nicotine treatment to a greater extent in the 12° condition. 
We did not find nicotine effects on mean prosaccade latency indicating that there was 
no general speeding in reaction time of saccadic eye movements by nicotine in our study. 
There was, however, a trend for a main effect of nicotine on intra-individual coefficient of 
variation (ICV) of prosaccade latencies revealing a tendency for a reduction in reaction time 
variability under nicotine. Possibly, this intra-subject reaction time variability or ICV might 
be a sensitive measure to detect nicotine effects in a similar way as measures of intra-subject 
variability were particularly impaired in patients with ADHD (Klein et al. 2006). The 
increased intra-subject variabilty in ADHD has been replicated consistently and is not part of 
a general performance decrement; rather, increased intra-subject variability seems to represent 
a specific deficit (Klein et al. 2006). Hence, parameters of intra-subject variability should be 
recognized in future drug-challenge studies beside the traditional measures of central 
tendency like the arithmetic mean. The notion that parameters of intra-subject variability 
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might be worthwhile to investigate in drug-challenge studies is further supported by recent 
findings in a study testing the effects of methylphenidate in a stop-signal reaction time 
(SSRT) task in 24 healthy young men (Nandam et al., 2011). The SSRT is a task measuring 
response inhibition as this task requires subjects to cancel a prepotent “go” response upon 
presentation of an infrequent “stop” signal (Nandam et al., 2011). In that study, 
methylphenidate did not affect mean reaction time to go-stimuli, rather methylphenidate 
decreased response time variability (as measured by the ICV) of the go-reaction (Nandam et 
al., 2011). Similar to the effects of nicotine we found on ICV of prosaccade latency, the 
results by Nandam et al. (2011) argue against a simple enhancement of motor or processing 
speed but indicate that the stimulant methylphenidate reduced behavioral variability. 
The influence of baseline performance on subsequent response to a drug-challenge has 
been previously discussed by a number of other authors (Kimberg et al. 1997; Mattay et al. 
2000; Mehta, 2002; Mehta et al. 2000; Robbins and Sahakian, 1979) demonstrating that 
despite the absence of an overall effect of a drug, the drug might still be beneficial to a 
subgroup of individuals. Our results indicate that it might be useful to stratify probands in 
clinical trials according to their performance level in order to test the efficacy of a compound. 
Future clinical trials might stratify patients into subgroups with and without cognitive deficits 
or with more pronounced versus less pronounced deficits. Especially in disease states 
involving attentional and executive functioning impairments such as schizophrenia and 
ADHD, those patients exhibiting persistent and severe attentional deficits might benefit from 
adjunctive treatment with nAChR agonists. While acetylcholinesterase inhibitors have been 
found to ameliorate deficits in memory and attention in schizophrenia patients (Ribeiz et al. 
2010), the evidence on the partial α7 nAChR agonist DMXB-A is more ambiguous. DMXB-
A improved some aspects of attention and memory in healthy subjects (Kitagawa et al. 2003) 
and in schizophrenia (Olincy et al. 2006), although it showed no effects on cognitive 
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performance in another extensive study with schizophrenia patients (Freedman et al. 2008). 
Future studies might consider subdividing schizophrenia patients into a group of individuals 
with severe impairment and a group with only slight or no impairment. Results that further 
support this idea come from a study by Larrison-Faucher et al. (2004) which investigated the 
effects of nicotine on antisaccade performance in schizophrenia patients. Nicotine treatment 
significantly decreased antisaccade errors in task-impaired schizophrenia patients, whereas no 
nicotine effects were demonstrated for non-impaired schizophrenic subjects or controls 
(Larrison-Faucher et al. 2004). Although there is evidence for specific α7 nAChR 
pathophysiology in schizophrenia (De Luca et al. 2006; Freedman et al. 1995; Severance and 
Yolken, 2008), future clinical trials should also target at α3 nAChR as polymorphisms of the 
α3 subunits are associated with prepulse inhibition – another schizophrenia endophenotype 
and a measure of early attentional gating (Petrovsky et al. 2010). 
Limitations of the present study include that double-blindness in our design was 
partially uncovered by the participants as they could correctly guess which patch they had 
received above chance level, especially after session two. Secondly, we appreciate the 
limitations of the median split approach. With turning a continuous variable into a categorical 
one there is reduced power to detect interaction effects due to loss of information in contrast 
to a regression approach. In addition, median splits are sample-dependent. Although the 
present study was adequately powered, future studies might want to opt for a regression 
model when analyzing what predicts a nicotine effect. Thirdly, we did not measure nicotine 
plasma levels, but we chose our nicotine dosages in line with previous studies. Fourthly, a 
larger dose of nicotine might have produced larger performance changes in the subjects; 
therefore future studies might use higher nicotine doses preferably in combination with a 
nausea-preventing substance such as domperidone. Finally, it would also be of interest to 
conduct a multi-dose study in a stratified study population, similar to the study with repeated 
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nicotine administration by Heishman et al. (2000): tolerance to the aversive effects of nicotine 
might develop with repeated exposure and performance changes might be more readily 
observed. 
In conclusion, the present study showed that nicotine significantly enhanced 
antisaccade performance in the low-accuracy probands while leaving performance of the 
high-accuracy probands unaffected. The results are in favour of the notion that baseline 
cognitive performance influences the effect of acute nicotine administration in healthy non-
smokers. Additionally, the findings suggest that stimulation of the nAChR system might be an 
effective way to treat deficits in executive control. Future studies on nicotine and nicotine-like 
drugs should account for inter-individual differences in task performance as this appears to be 
an important predictor of treatment effectiveness. Further research is needed to clarify other 
predictors of response to nicotinic stimulation such as genetic variation in nicotinic receptors. 
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3. Discussion 
 
 
 The discussion will review molecular genetic studies of antisaccade performance and 
will illustrate how genetic findings might contribute to future pharmacogenetic investigations 
with the antisaccade paradigm. Subsequently, the dopaminergic system will receive special 
emphasis, as it will be discussed whether cholinergic modulation of antisaccade performance 
is mediated by enhanced dopaminergic neurotransmission. A theory regarding the effects of 
nicotinic receptor stimulation on neurotransmitter release and attentional function will try to 
integrate the beneficial effects of nicotine on antisaccade performance and on other cognitive 
tasks. Finally, methodological issues, strength and limitations of the present studies will be 
discussed and some concluding remarks will be made. 
3.1 Molecular genetic studies of antisaccade performance and 
suggestions for future pharmacogenetic investigations 
 To date, there are a number of studies which have investigated the association of a 
genetic polymorphism in the cholinergic system with cognitive performance and other studies 
which tested the effect of a single dose of nicotine on cognition. However, studies which will 
combine these two research approaches is still needed. In recent years, only a few studies 
have started to examine these pharmacogenetic interactions, that is, examine the role of 
genetic polymorphisms in modulating individual response to nicotine administration. So far, 
there are only a few published pharmacogenetic studies on the procognitive effects of nicotine 
and not a single pharmacogenetic study related to nicotine and antisaccade performance. 
Since there are no published pharmacogenetic investigations using the antisaccade task, the 
following sections will combine the findings of molecular genetic studies of antisaccade 
performance with the data of pharmacogenetic studies which employed other cognitive 
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paradigms. Accordingly, suggestions for future pharmacogenetic investigations using the 
antisaccade task will be made based on this data. First, findings with cholinergic 
polymorphisms will be discussed, followed by findings regarding the dopaminergic and 
serotonergic polymorphisms. Finally, data stemming from genetic polymorphisms in 
candidate risk genes for schizophrenia (such as the Neuregulin gene) will be introduced. 
3.1.1 Cholinergic polymorphisms 
Study 1 investigated the association of CHRFAM7A genotype and antisaccade 
performance measures. No significant associations of 2bp deletion or CHRFAM7 copy 
number with antisaccade performance were found. However, given that the stimulation of the 
cholinergic system via nicotine administration influences antisaccade performance (e.g. see 
Study 2 in the present work; Depatie et al., 2002; Ettinger et al., 2009; Rycroft et al., 2006), it 
is still likely that genetic polymorphisms of the cholinergic system are associated with 
antisaccades. So far, very little is known about the genetics of antisaccade performance in 
general, and even less is known about how genetic polymorphisms in the cholinergic system 
might affect antisaccade performance. A recent analysis of 94 candidate genes and 12 
endophenotypes of schizophrenia from the “Consortium on the Genetics of Schizophrenia 
(COGS)” in 534 subjects revealed that antisaccades were not associated with the CHRNA7 
gene (Greenwood et al., 2011). These findings indicate that polymorphisms in the CHRNA7 
and CHRFAM7A genes are unlikely to be associated with antisaccade performance. However, 
these findings need to be replicated and extended. Future studies should further investigate a 
possible association between CHRNA7 polymorphisms and antisaccade performance. Perhaps 
there are functionally relevant genetic polymorphisms in the CHRNA7 gene that have an 
impact on antisaccade performance. 
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Other cholinergic genes, such as the CHRNA4, CHRNB2 and CHRNA3 genes, should 
also be investigated in connection with antisaccades. Polymorphisms in the CHRNA4 and 
CHRNB2 genes might be meaningful candidates to test, because these genes encode the α4β2 
nAChR – the most abundant nicotinic receptor sub-type in the brain beside the α7 nAChR 
sub-type. The CHRNA4 rs1044396 SNP is a candidate that could be tested in connection with 
antisaccade performance, as this SNP has been repeatedly linked to visuospatial attention and 
functioning (Espeseth et al., 2006; Espeseth et al., 2007; Greenwood et al., 2005; 
Parasuraman et al., 2005; Reinvang et al., 2010; Winterer et al., 2007). 
A recent pharmacogenetic study by Rigbi et al. (2011) tested the effect of the 
CHRNA7 SNP rs2337980 on three different cognitive tests and its modulation by nicotine. 
Twenty-four female smokers performed the Matching Familiar Figures Test (MFFT), the 
Tower of London Test, and the Continuous Performance Task (CPT) – three tests that 
measure impulsivity or response inhibition. Eight subjects were rs2337980 CC homozygotes 
and 16 subjects were T-allele carriers (CT: N=10 and TT: N=6). Results showed that CC 
homozygotes benefited from nicotine in the MFFT task (that is, they made fewer errors 
compared to placebo) whereas the CT/TT group was not affected by treatment with nicotine. 
The paper by Rigbi et al. (2011) does not report on the main effect of genotype, that is, 
whether CC homozygotes performed significantly poorer than the T-allele carriers when 
given the placebo. However, the authors refer to a previous paper in which CC homozygotes 
manifested poorer MFFT performance (Rigbi et al., 2008). This was also the rationale for 
choosing the CHRNA7 rs2337980 SNP: It was one of the SNPs which remained significant in 
the regression models applied by Rigbi et al. (2008) that significantly predicted cognitive 
performance on the MFFT, Tower of London, and CPT. It would be interesting to extend the 
findings by Rigbi et al. (2011) to a sample of non-smokers, especially as Rigbi et al. (2008) 
found that the rs2337980 genotype had opposite effects in smokers and non-smokers: The T 
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(minor) allele was associated with decreased MFFT errors (better response inhibition) in 
smokers, while it was associated with increased errors (poorer response inhibition) in non-
smokers (Rigbi et al., 2008). 
The CHRNA7 rs2337980 SNP would be an interesting candidate for a 
pharmacogenetic study investigating antisaccade performance and thereby extending the 
present findings of Study 1 and Study 2, for in the study by Rigbi et al. (2011), this SNP 
modulated the response to nicotine in a response inhibition paradigm. The antisaccade 
paradigm also involves the inhibition of a prepotent response (the automatic prosaccade). 
Thus, one hypothesis would be that the rs2337980 genotype might modulate antisaccade error 
rate. Furthermore, the SNP is also associated with schizophrenia (Peng et al., 2008), which 
fits to the notion that antisaccades are considered to be an endophenotype of schizophrenia. 
Finally, rs2337980 is also associated with the severity of nicotine dependence (Greenbaum et 
al., 2006), which is in line with the assumed triad of nicotine addiction, cognitive deficits, and 
nAChR variation. 
3.1.2 Dopaminergic polymorphisms 
 A recent study by Haraldsson et al. (2010) found that carriers of the Val allele of the 
COMT rs4680 SNP (COMT Val158Met polymorphism) displayed shorter and less variable 
antisaccade latency and tended to exhibit less antisaccade errors that carriers of the Met allele. 
Haraldsson et al. (2010) tested schizophrenia patients (N=105) and healthy controls (N=95); 
however, they did not find any group-by-genotype interactions. The COMT gene is also 
considered a candidate gene for schizophrenia. Interestingly, the COMT Val allele is 
considered to be the risk allele for schizophrenia and carriers of the Val allele are more likely 
to develop a schizophreniform disorder if they used cannabis during adolescence (Caspi et al., 
2005). The authors of the study by Haraldsson et al. (2010) suggest that their results may be 
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reconciled with a recent theory suggesting that the COMT Val allele is associated with better 
performance on tasks involving cognitive plasticity while the Met allele is hypothesized to be 
beneficial on tasks requiring cognitive stability (see also Bilder et al., 2004), an assumption 
supported further at the neural level by Ettinger et al. (2008b). The antisaccade task can be 
conceptualized as a measure of cognitive plasticity, such as inhibition of inappropriate 
responses, online monitoring of errors, and rapid generation of corrections (Haraldsson et al., 
2010). The authors also acknowledge that the antisaccade task, like most complex cognitive 
tasks, also entails elements of cognitive stability because constant alertness and sustained 
attention is necessary for adequate performance (Haraldsson et al., 2010). In addition, the 
authors point out that there are indications that genotype-phenotype relationships in single 
gene association studies may be complicated by factors such as undetected copy number 
variations, epigenetic phenomena, and epistasis between several genes (Haraldsson et al., 
2010). 
 The COGS study by Greenwood et al. (2011) also genotyped the COMT Val158Met 
polymorphism and did not find an association of the COMT gene with antisaccade 
performance. Therefore, further studies are needed on the COMT Val158Met polymorphism 
in connection with antisaccade performance in large samples. It would be particularly useful 
to account for epistatic gene effects as the role of the COMT gene in schizophrenia and 
antisaccade performance seems to be a complex one. A pharmacogenetic study of the possible 
modulating role of the COMT gene on the procognitive effects of nicotine in the antisaccade 
paradigm would be also of interest. One hypothesis, based on the findings by Haraldsson et al. 
(2010) and Bilder et al. (2004), would be that carriers of the Val allele display better 
antisaccade performance and will therefore be unlikely to benefit from nicotine, while carriers 
of the Met allele display impaired antisaccade performance and will therefore exhibit a 
nicotine-induced improvement of antisaccade performance. 
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 A pharmacogenetic study by Jacobsen and colleagues (2006) tested 36 subjects 
(including smokers and non-smokers) genotyped for the DRD2 gene SNP rs6277 (C957T) 
with nicotine administration on working memory performance. C957T is a synonymous 
substitution polymorphism in the DRD2 gene, which has been shown to affect mRNA 
stability in vitro and striatal DRD2 binding in vivo (Duan et al., 2003; Hirvonen et al., 2004; 
Jacobsen et al., 2006). In vitro, the T allele has been associated with decreased translation of 
DRD2 mRNA and decreased DRD2 mRNA stability (Duan et al., 2003). However, a human 
positron emission tomography (PET) study demonstrated that the binding availability of 
DRD2 increases with each T allele, suggesting either increased numbers of DRD2 receptors or 
increased DRD2 binding affinity with each T allele (Hirvonen et al., 2004). Furthermore, a 
clinical human study showed that smokers homozygous for the T allele are significantly more 
likely to stop smoking in response to treatment with a nicotine patch than are carriers of the C 
allele (Lerman et al., 2006). The study by Jacobsen et al. (2006) suggests that during 
performance of a verbal working memory task with high working memory load, nicotine 
administration worsened performance in carriers of the T allele (N=15) while performance in 
the CC homozygotes (N=21) remained unaffected.  In addition, the fMRI data acquired 
during the performance of the working memory task indicated that the activation of a network 
of regions, including left anterior insula, increased during nicotine administration among T 
allele carriers and decreased during nicotine administration among CC homozygotes 
(Jacobsen et al., 2006). The authors consider the inverted U model of the relationship between 
dopamine levels in the brain and working memory performance in order to explain their 
findings. They suggest that dopamine release induced by nicotine administration pushed the 
dopaminergic stimulation of the neurocircuits supporting working memory beyond optimal 
levels in the T allele carriers, leading to worsened performance and reduced efficiency in 
regions of the brain that support phonological rehearsal. The authors acknowledge that due to 
the small number of TT homozygotes (N=4), it was necessary to combine TT homozygotes 
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with the 11 CT heterozygotes. In a future study, it would be interesting to analyze all three 
genotype groups in order to test whether the genetic load of the T allele has an effect 
(hypothesizing that with an increasing number of T alleles, performance worsens with 
nicotinic stimulation). Furthermore, overall sample size was relatively small and did not allow 
for a separate assessment of the effects of genotype in smokers and non-smokers; this would 
also be of interest to be addressed in future studies in order to extend the findings. In sum, the 
study by Jacobsen et al. (2006) provides an apt example of the pharmacogenetic approach and 
shows how a genetic polymorphism contributes to the prediction of response to nicotine 
administration. 
 Regarding possible pharmacogenetic studies on antisaccade performance, it would be 
beneficial to test the aforementioned C957T SNP in the DRD2 gene (as in the Jacobsen et al., 
2006 study), especially as a recent association study by the Consortium on the Genetics of 
Schizophrenia (COGS) showed that the DRD2 gene was significantly associated with 
antisaccades in 130 families with a case of schizophrenia (Greenwood et al., 2011). One 
hypothesis could be that T-carriers of SNP rs6277 (C957T) will exhibit poorer antisaccade 
performance after nicotine administration similar to the findings by Jacobsen et al. (2006) 
who found declined working memory performance in T-carriers. 
 Another recently published pharmacogenetic study by Millar et al. (2011) investigated 
the role of a polymorphism in the DAT (dopamine transporter) gene on P50 sensory gating 
and its modulation by nicotine. The authors chose the DAT1 SLC6A3 VNTR (variable 
number of tandem repeats) polymorphism. Alleles ranging from 3 to 13 copies of the 40-bp 
repeats have been described, though alleles with 9 (9R) and 10 repeats (10R) are the most 
common (Kang et al., 1999; Millar et al., 2011; Mitchell et al., 2000). Dopaminergic 
neurotransmission is initiated by presynaptic release of dopamine and terminated largely by 
its reuptake of dopamine transporter (DAT) molecules. The 9R allele (lower gene expression 
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allele, less DAT available) is therefore associated with greater tonic striatal dopamine levels, 
whereas the 10R allele (higher gene expression allele, more DAT available) is associated with 
decreased striatal dopamine tone. Millar et al. (2011) tested 24 healthy non-smokers and 
found that individuals carrying the 9R allele tended to exhibit greater gating under placebo 
than carriers of the 10R allele. Furthermore, acute nicotine administration reduced gating in 
the 9R carriers while gating in the 10R carriers was not affected by nicotine. The authors 
demonstrated, consistent with an inverted U model of gating performance and nicotine’s 
ability to increase dopamine levels, that 9R carriers tended to exhibit higher gating 
performance than the 10R carriers. Moreover, the already high-performing 9R carriers were 
“overstimulated” with the acute nicotine administration, that is, nicotine led to putative 
“overdosing” of dopamine levels and therefore had detrimental effects on gating performance. 
Gating in the 10R carriers was not influenced by nicotine, although one would predict a 
nicotine-induced enhancement of gating in the lower performing 10R carriers. The authors 
suggest that gating improvements in healthy individuals might require a greater dose of 
nicotine that required disruption in healthy volunteers (Millar et al., 2011). Further, they 
suggest that future studies should implement a more systematic dosing regimen that can 
produce dose-response curves for gating (Millar et al., 2011). A minor limitation of the study 
is the small sample size and the fact that the authors only offered genotype distribution of the 
sample in means of frequencies (60.86% 10/10 R homozygotes and 39.14% 9R carriers), but 
they did not offer the absolute numbers of the genotypes. Therefore, it remains unclear 
whether they tested 9/10 R and 9/9 R carriers or only 9/10 R carriers.  It might be interesting 
to know, as there might be an effect of “genetic load,” that is, homozygous 9/9 R carriers 
might exhibit even higher gating performance than 9/10 R carriers. 
 Polymorphisms in the DAT1 gene, as in the study by Millar et al. (2011), might also be 
interesting to investigate with respect to antisaccade performance. A recent review by Barnes 
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et al. (2011) on the molecular genetics of executive function suggests that variants of the 
DAT1 gene and the DRD4 gene show promise for explaining significant variance in 
individual differences in both behavioral and neural measures of inhibitory control (Barnes et 
al., 2011). In addition, this review suggests that functional variants of the DRD2 gene are 
reliably associated with performance monitoring, error processing, and reinforcement learning 
(Barnes et al., 2011). Thus, dopamine transporter and dopamine receptor genes might be 
promising candidate genes in connection with antisaccade performance, as this task involves 
both inhibitory control (i.e. suppressing the reflexive prosaccade) and performance 
monitoring/error processing (i.e. detecting and correcting antisaccade errors). 
3.1.3 Serotonergic polymorphisms 
In addition to pharmacogenetic studies testing cholinergic and dopaminergic genetic 
variants, there is one recent study which examined the interaction between a serotonergic 
polymorphism and the effects of nicotine on spatial working memory (Carlson et al., 2009). 
Carlson et al. (2009) administered nicotine and placebo to 64 deprived smokers genotyped for 
the serotonin transporter-linked polymorphic region (5-HTTLPR), a region in the SLC6A4 
gene which codes for the serotonin transporter. A deletion/insertion polymorphism in the 5-
HTTLPR results in a short (S) allele and a long (L) allele. Individuals that are homozygous 
for the L allele are thought to have greater serotonin reuptake and potentially lower synaptic 
serotonin levels than carriers of the S allele (Heils et al., 1997; Lesch et al., 1996). Carlson et 
al. (2009) employed a computerized dot recall spatial working memory task and found that 
nicotine enhanced spatial working memory (SWM) in S allele carriers relative to those with 
two L alleles. Moreover, this enhancement in S allele carriers was greater for individuals with 
higher levels of depressive symptoms (Carlson et al., 2009). Carlson et al. (2009) offer several 
interpretations for their findings. First, 5-HTT S allele carriers with high depressive symptoms 
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might benefit to a greater extent from nicotine after abstaining from using nicotine because S 
allele carriers experience greater negative affect-related symptoms during nicotine withdrawal 
and might be more responsive to stressors in general (Carlson et al., 2009). Second, the 
authors suggest that the hippocampal system might be a substrate in which nicotine influences 
SWM: Depression may be associated with a dysregulated hypothalamic-pituitary-adrenal 
(HPA) axis response, which could contribute to depressive symptoms and hippocampal 
volume loss (Carlson et al., 2009). Furthermore, the hippocampus is strongly involved in 
spatial memory tasks and animal studies demonstrated that the hippocampus is a site of 
nicotine action on the 5-HT system (Carlson et al., 2009). Finally, the authors point out that 5-
HTT S allele carriers who are prone to depression do not respond well to stressful situations 
and experience greater negative affect during nicotine withdrawal. Thus, they may be 
especially susceptible to self-medicate cognitive/SWM deficits and associated 
stress/frustration (Carlson et al., 2009). Carlson et al. (2009) acknowledge that a limitation of 
their study is that the observed SWM deficits under placebo might simply reflect more severe 
withdrawal symptoms in those individuals with low cognitive reserves. Therefore, it would be 
desirable to extend their findings to a sample of non-smokers. 
With regard to antisaccade performance, there are no published molecular genetic 
association studies with serotonergic polymorphisms. However, the serotonergic system 
might also be involved in antisaccade behavior since there is evidence that 5-HT2A receptor 
antagonists, such as risperidone, ameliorate antisaccade error rate in patients with 
schizophrenia (Burke & Reveley, 2002). The authors argue that the distribution of the 5-HT2A 
receptor type shows high concentrations in the prefrontal cortex, an area which has been 
identified as the focus of antisaccade errors, which could help to explain the effectiveness of 
risperidone in correcting such antisaccade abnormalities (Burke & Reveley, 2002). However, 
the atypical antipsychotic drug risperidone also blocks the D2 dopaminergic receptor (Uchida 
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et al., 2009). D2 receptor blockage might actually be detrimental to cognitive functioning, as 
dopamine levels are reduced via dopamine receptor blockage. The study by Uchida et al. 
(2009) demonstrated that D2 receptor blockage by risperidone correlated with attention 
deficits in late-life schizophrenia. Although a causal attribution cannot be made, the study 
suggests that under certain constraints risperidone’s dopaminergic mechanism of action might 
be unfavorable for cognition. Nevertheless, other authors argue that it is the preponderance of 
5-HT2A receptor antagonism over dopamine D2 blockage exerted by atypical antipsychotics 
which contributes to their cognitive-enhancing effects (Reuter et al., 2007a). 
Evidence that serotonergic polymorphisms influence executive functioning also stems 
from a molecular genetic investigation by Reuter et al. (2007a). The authors employed the 
attention network test (ANT) which is a task designed to measure alerting, orienting, and 
executive control, all of which are regarded as sub-components of attention according to the 
model by Posner and Peterson (1990). Reuter et al. (2007a) investigated the possible 
association between ANT performance and a polymorphism in the TPH2 gene. According to 
Reuter et al. (2007a), the tryptophan hydroxylase (TPH) gene is a promising candidate gene 
for cognitive functioning because it is the rate-limiting enzyme of 5-HT synthesis. Reuter et 
al. (2007a) chose the -703 G/T SNP (rs4570625), a promoter polymorphism, because this 
polymorphism might be a functional polymorphism, as it has been previously to modulates 
amygdala responsiveness to emotional stimuli (Canli et al., 2005). 
In the ANT, alerting is defined as achieving and maintaining an alert state, orienting is 
the selection of information from sensory input, and executive control is defined as resolving 
conflict among responses (Fan et al., 2002). The ANT is a combination of the cued reaction 
time task by Posner (1980) and the Eriksen flanker task (Eriksen & Eriksen, 1974). To assess 
executive control, a central arrow is flanked by either two arrows on each side pointing in the 
same direction as the central arrow (congruent condition), or the central arrow is flanked by 
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arrows pointing in the opposite direction (incongruent condition). The subject’s task is to 
indicate the direction of the central arrow. The incongruent condition represents a conflict 
between central arrow and the flanking arrows, as the flankers are distracting to the subjects. 
Therefore, solving the incongruent condition involves an increase in mean reaction time. The 
efficacy of the executive control network is assessed by subtracting the mean reaction time in 
congruent flanking conditions from the mean reaction time in incongruent flanking conditions 
(Fan et al., 2002); higher differences in reaction time (i.e. higher conflict scores) indicate 
poorer performance. 
Reuter and colleagues (2007a) found that TT carriers of the TPH2 -703 G/T 
polymorphism (SNP rs4570625) exhibited higher conflict scores in the ANT compared to 
carriers of the GT or GG genotypes. Moreover, TT carriers made significantly more errors 
than GT or GG carriers (Reuter et al., 2007a). The effect sizes for both results were quite 
large, approximately 11 and 12% explained variance, respectively (Reuter et al., 2007a). 
Reuter et al. (2007a) conclude that their results indicate the relevance of the 5-HT system for 
impulse control processes. However, the authors acknowledge that further studies have to 
replicate the findings and other studies need to demonstrate that a variation in rs4570625 is 
indeed associated with altered rates of 5-HT synthesis, an indicator of functionality of this 
promoter SNP (Reuter et al., 2007a). 
Assuming that the 5-HT system is important for executive control and especially for 
inhibitory control processes, polymorphisms in the serotonin system should also have an 
impact on antisaccade performance. Since there are no published molecular genetic 
association studies with serotonergic polymorphisms and the antisaccade paradigm, one new 
hypothesis to be tested would be the assumption that the TPH2 -703 G/T polymorphism has 
an effect on antisaccade parameters. Based on the findings by Reuter et al. (2007a), one could 
hypothesize that TT carriers of the TPH2 -703 G/T polymorphism exhibit an increased 
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antisaccade error rate compared to GT and GG carriers. On the basis of this hypothesis, a 
pharmacogentic study might aim to test whether the effects of nicotine on antisaccade 
performance are modulated by the TPH2 -703 G/T polymorphism. Since there is some 
evidence that smoking behavior is associated with the TPH2 -703 G/T polymorphism (Reuter 
et al., 2007b), this polymorphism might also affect acute nicotine administration. However, in 
the study investigating the role of the TPH1 and TPH2 genes for nicotine dependence, GG 
carriers of the TPH2 -703 G/T SNP started smoking significantly earlier than carriers with a T 
allele (Reuter et al., 2007b). This result argues against a simple interrelationship between 
TPH2 genotype, executive control, and smoking; the assumption that the T allele is the 
“disadvantageous” allele and TT carriers will benefit most from nicotine administration is 
oversimplified since the G allele seems to play a role in nicotine dependence. Thus, in a future 
study, one might postulate a unidirectional rather than a directional hypothesis about the 
possible modulating effect of the TPH2 -703 G/T genotype on the effects of nicotine on 
antisaccade performance.  
3.1.4 Polymorphisms in risk genes for schizophrenia  
 Since antisaccade performance is a well-founded endophenotype of schizophrenia 
(Calkins et al., 2008; Hutton & Ettinger, 2006; Turetsky et al., 2007), the risk genes for 
schizophrenia are also of interest in connection with antisaccade performance. Some of the 
aforementioned genes encoding for neurotransmitter receptors (such as CHRNA7, COMT and 
DRD2) are also considered to be risk genes of schizophrenia. As their possible modulating 
role on antisaccade performance has already been discussed in the previous paragraphs, the 
following section will address other risk genes of schizophrenia. 
 A recent paper by Schmechtig et al. (2010) reported that antisaccade performance was 
associated with a polymorphism in the Neuregulin 1 gene NRG1 – NRG1 being one of the 
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leading candidate genes for schizophrenia (Harrison & Law, 2006). Schmechtig et al. (2010) 
tested a sample of 114 healthy volunteers and showed that the A allele of the NRG1 
rs3924999 SNP is associated with impaired spatial accuracy on the antisaccade task (i.e. 
hypermetric performance). 
 Neuregulins are a family of proteins which are involved in neural development, 
Schwann cell and oligodendrocyte differentiation, the formation of neuromuscular synapses, 
and, interestingly, acetylcholine receptor synthesis (Burden & Yarden, 1997). There are three 
major forms of NRG1 (Types I-III) in addition to Types IV-VI (Steinthorsdottir et al., 2004). 
Type I NRG1 plays a role in synapse development by influencing the upregulation of 
acetylcholine receptor genes and is important in nAChRs’ post-synaptic expression (Sandrock 
et al., 1997). Therefore, Type I NRG1 is also known as ARIA (= Acetylcholine Receptor 
Inducing Activity) (Li et al., 2006). The upregulation of nAChRs by neuregulins has been 
demonstrated at the neuromuscular junction, the developing interneuron synapse, and in the 
hippocampus (Liu et al., 2001; Usdin & Fischbach, 1986; Yang et al., 1998). Moreover, the 
human postmortem brain study by Mathew et al. (2007) showed that the schizophrenia-
associated allelic variations within the NRG1 gene (SNP8NRG221132 and rs6994992) were 
associated with α7 nAChR mRNA expression and receptor density in the DLPFC, but not in 
the hippocampus. 
 The findings by Mathew et al. (2007) also fit nicely to the idea that neuregulins, in 
connection with cholinergic neurotransmissions, might play a role for antisaccade 
performance, for  the antisaccade task partially relies on DLPFC function. Indeed, the authors 
conclude that functional relationships between NRG1 and nAChR neurotransmission may 
explain some of the intermediate phenotypes associated with schizophrenia (Mathew et al., 
2007), and, that within the DLPFC, nAChR α7 receptors are located on pyramidal neurons 
and GABAergic interneurons (Mathew et al., 2007). However, the precise mechanism by 
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which specific NRG1 isoforms influence α7 nAChR mRNA and protein levels is unknown 
and requires additional investigation (Mathew et al., 2007). Since there are functional 
relationships on the neural level between NRG1 and α7 nAChRs in the DLPFC, an 
antisaccade study with the pharmacogenetic approach involving polymorphisms within NRG1 
and nicotine would be necessary. As a starting point, based on the findings by Schmechtig et 
al. (2010), one could hypothesize that the deficient spatial accuracy of antisaccades in carriers 
of the A allele of the NRG1 rs3924999 SNP will be improved by nicotine administration. 
Another risk gene of schizophrenia that might be of interest is the GRIK4, a gene 
encoding for a glutamate receptor sub-type. The study by Greenwood et al. (2011) within the 
COGS research program revealed a highly significant association between GRIK4 and 
antisaccade performance, explaining 5.4% of the genetic variation in antisaccade 
performance. Besides the GRIK4 result for antisaccades (which was one of the strongest 
associations), the COGS study found several other risk genes of schizophrenia to be 
associated with antisaccade performance in their sample: DISC1, ERBB4, RELN, SLC18A1, 
DRD2, HTR2A, CRHR1, and PRODH (Greenwood et al., 2011). Since the association with 
GRIK4 was of such large effect size, it would be feasible to be able to replicate the finding. 
Furthermore, nicotine intake also triggers the release of glutamate and antisaccade 
performance is probably sensitive to the modulation of several neurotransmitter systems. 
Therefore, it is possible that one might find an association between GRIK4 polymorphisms 
and nicotine administration in connection with the antisaccade task.  
3.2 Cholinergic modulation of antisaccade performance – 
mediated by the effects of dopamine? 
In the following paragraphs, it will be discussed whether cholinergic modulation of 
antisaccade performance is mediated by enhanced dopaminergic neurotransmission. Nicotine 
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intake stimulates not only the release of acetylcholine, but also the release of several other 
neurotransmitters such as dopamine, noradrenalin, serotonin, GABA, and glutamate 
(Barazangi & Role, 2001; Fu et al., 1998; Li et al., 1998; Lopez et al., 2001; Rowell et al., 
1987; Summers & Giacobini, 1995). The rewarding and addictive properties of nicotine are 
modulated by release of dopamine, mainly in the nucleus accumbens (Fu et al., 2000). In 
addition, glutamate secretion in the ventral tegmental area (VTA) is also involved in the 
nicotine-stimulated dopamine secretion within the nucleus accumbens (Fu et al., 2000). 
Animal studies in rats demonstrated that self-administered nicotine activates the mesolimbic 
dopamine system through the VTA and that the effect of nicotine in the VTA initiates 
processes which are critical to the reinforcing properties of the substance (Corrigall et al., 
1994; Fu et al., 2000). Moreover, nicotine induces the upregulation of dopamine D1 and D2 
receptors in the nucleus accumbens, in the caudate-putamen region, and in the olfactory 
tubercle as shown by another study in rats by Bahk et al. (2002). Finally, both β2 nAChRs and 
α7 nAChRs can modulate dopamine release in the rat prefrontal cortex in vitro and in vivo 
(Livingstone et al., 2009). Hence, the interaction of the cholinergic and the dopaminergic 
systems seems to be crucial to the rewarding properties of nicotine. 
Are the cognitive-enhancing properties of nicotine also ultimately mediated by the 
effects of dopamine? The interaction between the nAChR system and the dopaminergic 
system with respect to cognitive functioning has not been very well studied so far. However, 
there is some evidence that nicotine-induced enhanced dopaminergic neurotransmission 
seems to play a role in improving cognitive performance. 
An animal study involving DAT knockout mice showed that these knockout mice 
exhibited deficits in the elevated plus maze task, that is, spatial learning and memory (Weiss 
et al., 2007). Interestingly, acute and chronic nicotine (administered via the drinking water) 
improved these spatial learning and memory deficits without eliciting tolerance (Weiss et al., 
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2007). The authors speculate that the procognitive effects of nicotine in DAT knockout mice 
are related to the upregulation of α7 nAChRs (Weiss et al., 2007). A recent review by Herman 
and Sofuoglu (2010) which also reviewed this animal study also suggests that the 
improvement in the DAT knockout mice might have occurred through nicotine-induced up-
regulation of DAT mRNA, as this process has been demonstrated by Li et al. (2004) in the 
two mid-brain structures of the rat brain, the substantia nigra and the ventral tegmental area 
(Herman & Sofuoglu, 2010).  
The aforementioned study in humans by Millar et al. (2011) of the moderating role of 
the DAT1 SLC6A3 VNTR polymorphism on the effects of nicotine on P50 sensory gating 
also stresses the possible direct connection of dopamine transporter expression and cognitive 
effects of nicotine. Indeed, the authors interpreted their findings that the 9R carriers of the 
DAT1 polymorphism (exhibiting less available DAT and therefore greater levels of tonic 
dopamine) were impaired by nicotine due to further nicotine-induced release of dopamine 
leading to an “overstimulation” of dopamine or an “overdosing” of dopamine levels (Millar et 
al., 2011). However, it remains speculative whether nicotine directly modifies dopamine 
transporter mRNA expression in humans and is therebyresponsible for the procognitive effect 
of nicotine administration. Similar to the findings on the effects of nicotine and 
polymorphisms on the DAT gene, Jacobsen et al. (2006) also interpreted their findings on the 
DRD2 rs6277 SNP (C957T polymorphism) in a way that carriers of the T allele already 
exhibit optimal or near-to-optimum levels of dopamine; thus,further stimulation of 
dopaminergic neurotransmission via nicotine leads to an overdose of dopamine and therefore 
poorer working memory performance. 
A recent gene-gene interaction study by Markett et al. (2010) investigating the 
association between three DRD2 SNPs and one CHRNA4 SNP and working memory 
performance also provides indirect evidence for the role of dopamine in the nicotine-induced 
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cognitive improvement. Markett et al. (2010) tested 101 healthy subjects with a visuospatial 
working memory task (i.e. a brief visual array task) in which working memory load was 
systematically varied. They genotyped their subjects for the DRD2 SNPs rs1800497, rs6277, 
and rs2283265 and for the CHRNA4 SNP rs1044396. The authors constructed haplotypes on 
the DRD2 gene and tested these haplotype blocks on an interaction with the CHRNA4 SNP. 
Markett et al. (2010) found that carriers of the DRD2 TCT+ haplotype who were also 
homozygous T/T allele carriers of the CHRNA4 rs1044396 SNP exhibited better performance 
on the working memory task than non-carriers. Moreover, the gene effects were only visible 
when the working memory load was high (Markett et al., 2010). Markett et al. (2010) chose 
functional DRD2 SNPs in their study: All three SNPs are associated with altered or reduced 
DRD2 density in the striatum. The authors speculate that TCT+ carriers have generally 
reduced receptor availability with an additionally shifted proportion of presynaptic to 
postsynaptic receptors. Moreover, the authors suggest that the CHRNA4 polymorphism alters 
the affinity of presynaptical nAChRs on dopaminergic neurons, thereby affecting 
dopaminergic neurotransmission. This and the decreased D2 receptor density might lead to an 
optimal saturation of D2 receptors (Markett et al., 2010), thereby providing an optimal 
dopaminergic tone for working memory function. 
With regard to the antisaccade task, there is a pharmacological study by Rycroft et al. 
(2007) comparing the effects of the wakefulness-promoting agent modafinil and the effects of 
nicotine. Modafinil is a drug designed for the treatment of narcolepsy and other sleep and 
arousal-related disorders; however, modafinil's mechanism of action is largely unclear 
(Dopheide et al., 2007). On the one hand, modafinil is believed to serve as a selective α1-
adrenergic receptor agonist (Milgram et al., 1999); on the other hand modafinil has shown to 
increase the levels of several monoamines. Animal studies in rats demonstrated that modafinil 
enhances extracellular levels of dopamine in the nucleus accumbens (Murillo-Rodriguez et 
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al., 2007) and evokes dopamine release from striatal neurons (Dopheide et al., 2007). 
Modafinil also triggers the release of noradrenalin in the hypothalamus and the release of 
serotonin in the prefrontal cortex (de Saint Hilaire et al., 2001).  
Rycroft et al. (2007) tested 44 male non-smokers and employed a double-blind 
between-subjects design: 15 participants received a modafinil capsule (200 mg) and placebo 
spray, 15 received a placebo capsule and a nicotine nasal spray (1 mg), and 14 received a 
placebo capsule and a placebo spray before antisaccade testing. In this study, both modafinil 
and nicotine reduced antisaccade latencies. However, contrary to previous research (Depatie 
et al., 2002; Larrison-Faucher et al., 2004; Rycroft et al., 2006), nicotine did not lead to a 
reduction in antisaccade errors. Modafinil also failed to reduce antisaccade errors. The lack of 
an effect of both compounds on antisaccade error rate could not be attributed to ceiling 
effects. There was, however, a clear practice effect on antisaccade errors, with all three groups 
demonstrating reduced errors at post-test compared to baseline.  
Unfortunately, other studies investigating the effects of dopaminergic drugs on 
antisaccade error rate provide ambiguous results: While both the dopaminergic agonists 
levodopa (Duka & Lupp, 1997) and amphetamine (Dursun et al., 1999) lead to increased 
antisaccade errors in healthy volunteers, the antipsychotic drugs risperidone and 
chlorpromazine that reduce dopaminergic neurotransmission also induced a reduction in 
antisaccade error rate in healthy probands (Barrett et al., 2004). Based on these results from 
other studies, Rycroft et al. (2007) conclude that at present there are insufficient data to 
determine whether these conflicting findings are due to differences in methodology, or 
whether the results suggest that there is an optimal level of dopamine required for successful 
antisaccade performance.  
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Further studies are needed to determine whether dopaminergic compounds act on 
antisaccade error rate and whether nicotine leads to a reduction in antisaccade error rate via 
the modulation of dopamine levels. However, both modafinil and nicotine reduced 
antisaccade latencies in the study by Rycroft et al. (2007). Based on these findings, the 
authors suggest that the reduction in antisaccade latencies achieved by both compounds might 
be mediated by common actions on a single neurotransmitter system, e.g. the dopamine 
system (Rycroft et al., 2007). Further, the authors acknowledge that this explanation might be 
“parsimonious” – both nicotine and modafinil also increase the release of noradrenalin 
(Rycroft et al., 2007). The release of noradrenalin leads to increased arousal and such a 
heightened state of alertness may reduce reaction times in general (Rycroft et al., 2007).  
Another study on nicotine and antisaccades did not find that nicotine affected 
prosaccade latencies (Larrison-Faucher et al., 2004), a more recent study by Bowling and 
Donnelly (2010) found reduced prosaccade latencies after the administration of nicotine. 
Therefore, it cannot be ruled out completely that the modulation by noradrenalin is the 
common ground for the effects of nicotine and modafinil on antisaccade latencies. In 
summary, the findings by Rycroft et al. (2007) indicate that the improvements in antisaccade 
performance that have previously been demonstrated with nicotine are not necessarily 
mediated exclusively by the cholinergic system (Rycroft et al., 2007) and that the 
dopaminergic, the noradrenergic, or another common neurotransmitter system might be 
stimulated by both nicotine and modafinil. 
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3.3 Cognitive effects of nicotine: Do nicotinic acetylcholine 
receptors act as moderator variables in complex cortical 
networks? 
 As outlined in the previous chapter, it remains to be shown which neurotransmitter 
systems mediate the nicotine-induced improvements in antisaccade performance and in other 
cognitive functions.  Perhaps neuronal nicotinic acetylcholine receptors play a modulatory 
role in neuronal circuits that are engaged in cognitive processes. The following paragraphs 
will attempt to integrate the beneficial effects of nicotine on antisaccade performance and on 
other cognitive tasks in a theory regarding the effects of nAChRs stimulation on 
neurotransmitter and attentional function. 
 Newhouse and colleagues (2004) proposed such a model for testing the effects of 
nicotinic receptor stimulation on neurotransmitter release and attentional function (see Figure 
3-1). In their model, stimulation of nAChRs leads to enhanced release of various 
neurotransmitters (dopamine, noradrenalin, glutamate, serotonin, GABA, and acetylcholine). 
This enhanced neurotransmission takes place in various areas of the brain which are relevant 
to focused attention, arousal, inhibition, and processing/motor speed. The parallel activation 
of these areas of the brain induces sensory selectivity and acts on the central executive 
component of working memory (Baddeley, 2003), which eventually improves the acquisition 
of information. This conceptual model by Newhouse is a comprehensive description of how 
nicotine might exert its influence on attentional processing; however, it only offers minor 
explanatory value. For instance, it does not explain in which particular areas of the brain 
nAChR activation is initiated and how it is regulated. If one tries to transfer the idea of 
nAChRs acting as “modulator variables” or “adjustable screws” in cortical networks to the 
antisaccade paradigm, one could hypothesize that cholinergic neurotransmission in the 
prefrontal cortex is crucial for antisaccade performance. The review by Sarter and Parik 
(2005) suggests that increases in prefrontal cholinergic transmission triggers complex patterns 
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of recruitment of other cholinergic modules in the cortex, for example, to enhance the 
detection and processing of stimuli of a particular modality (Sarter & Parikh, 2005). Sarter 
and Parikh (2005) argue against the idea of the cholinergic system being a diffuse modulatory 
input system that innervates the entire cortical mantle and is primarily designed to enhance 
sensory input processing. Rather, they point out that the cortical cholinergic input system 
consists of modules that target specific cortical areas and have individual afferent 
organizations; thus they have the potential for region-specific regulation of cortical functions 
(Sarter & Parikh, 2005). Therefore, the prefrontal cortex might be able to systematically 
recruit cholinergic transmission in order to initiate executive functioning (Sarter & Parikh, 
2005).
 
Figure 3-1 
Proposed model for the effects of nAChRs stimulation on neurotransmitter function and 
attentional functioning, modified by Newhouse et al. (2004). DA=dopamine, 
NA=noradrenalin, GLU=glutamate, 5-HT=serotonin, GABA=gamma-aminobutyric acid, 
ACh=acetylcholine. 
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 In a hypothetical model for antisaccade performance, based on the suggestions by 
Newhouse et al. (2004) and Sarter and Parikh (2005), using nicotine to stimulate nAChRs in 
the dorsolateral prefrontal cortex (DLPFC) could lead to enhanced suppression of 
prosaccades, thereby improving antisaccade performance. By cholinergic top-down signaling 
of the DLPFC to the frontal eye fields and the superior colliculi, the preparation and execution 
of voluntary antisaccade eye movements might be further enhanced. Cholinergic signaling in 
the DLPFC likely also leads to the activation of other neurotransmitters, such as dopamine 
and noradrenalin. After the nAChRs have been activated by nicotine, the subsequent release 
of other neurotransmitters such as dopamine, noradrenalin, and serotonin might further 
support antisaccade performance. Dopamine release in the DLPFC should be beneficial for 
working memory processes, such as maintaining and updating information about a current 
antisaccade trial. Noradrenalin might increase arousal; however, noradrenalin release might 
also increase processing/motor speed, thereby leading to faster saccadic eye movements. 
Since there are high concentrations of serotonin receptors in the prefrontal cortex, nicotine-
induced serotonin release in the DLPFC might also support DLPFC functioning in 
suppressing antisaccade errors. 
 The idea that nAChRs act as “modulator variables” or “adjustable screws” in cortical 
networks is an interesting one and should initiate further research. How does nicotinic 
stimulation exert its influence on the neural level and how does it induce long-term changes in 
synapses? A recent review by Mansvelder et al. (2009) reports on the idea that nicotinic 
stimulation alters synaptic transmission, which in turn can induce synaptic plasticity, thereby 
causing long-term changes in cortical circuits. Mansvelder et al. (2009) suggest that rather 
than turning neuronal systems on and off, it appears that cholinergic tuning involves changes 
in the balance between inhibitory and excitatory inputs. Synaptic plasticity in the prefrontal 
cortex has been linked to attention and working memory (Laroche et al., 2000). In mice, 
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nicotine strongly affects synaptic plasticity in the prefrontal cortex (PFC): Nicotine influences 
the relative timing of action potentials in pre- and postsynaptic neurons (Mansvelder et al., 
2009). This coordinated neuronal firing can induce long-term potentiation (LTP) or long-term 
depression (LTD). The phenomenon of timing-dependent synaptic plasticity is also called 
spike-timing-dependent plasticity (STDP) (Mansvelder et al., 2009). GABAergic interneurons 
in the PFC layer 5 express nAChR sub-units on their soma that activate these neurons when 
nicotine is present (Mansvelder et al., 2009). In mice, nicotine both directly activates somato-
dendritic nAChRs of GABAergic interneurons and indirectly activates these GABAergic 
interneurons by presynaptic glutamatergic input. Thus, inhibitory GABA interneurons are 
activated via nicotine, leading to increased inhibitory tone. The authors acknowledge that it is 
somewhat counterintuitive that nicotine decreases the likelihood of LTP induction in the PFC. 
They suggest that nicotine alters the rules for synaptic plasticity by increasing the threshold 
for STDP which is supposed to enhance the signal-to-noise ratio in PFC information 
processing, thereby improving cognitive performance (Mansvelder et al., 2009). 
 In summary, cholinergic tone can regulate neuronal circuit activity, yet we are only 
beginning to understand the exact mechanisms by which nicotine alters the code of synaptic 
plasticity. Given that (1) nAChRs are located on different cell types, (2) there are various sub-
types of nAChRs, and (3) the different nAChR sub-types differ in their affinity and 
desensitization for nicotine, there are a variety of possible ways in which nicotine regulates 
neuronal activity. There is some recent evidence that both α7 nAChRs and β2 nAChRs play a 
pivotal role in modulating neurotransmitter release and in initiating calcium (Ca
2+
) signaling, 
a precondition for inducing persistent neuronal changes (Dickinson et al., 2008; Mansvelder 
et al., 2009). In conclusion, the concept of nAChRs as “moderators” or “modulating entities” 
in cortical networks is an interesting one, yet further in vitro and in vivo studies are needed to 
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clarify how nicotine induces long-term changes in synapses and how nAChRs modulate 
synaptic plasticity. 
3.4 Methodological issues, strengths and limitations of the 
present studies 
In the present two investigations, the possible cholinergic modulation of antisaccade 
performance was examined. A molecular genetic approach and pharmacological study 
accounted for inter-individual differences in the response to nicotine in order to gain more 
insight regarding what predicts the effectiveness of cholinergic treatment. Study 1 
investigated whether CHRFAM7A copy number and 2bp deletion polymorphisms were 
associated with antisaccade performance. Study 2 tested the hypothesis that baseline 
performance level may be a behavioral predictor of the effects of nicotine on antisaccade 
performance. No association was found between CHRFAM7A polymorphisms and 
antisaccade performance (Study 1), while the effects of nicotine on antisaccade error rate and 
response variability depended on inter-individual differences in baseline antisaccade 
performance (Study 2). 
One of the strengths of Study 1 lies in the investigation of the relationship of 
CHRFAM7A polymorphisms and antisaccade performance in the absence of clinical and 
treatment confounds. Moreover, to the knowledge of our research group, this is the first 
investigation to explore the association of CHRFAM7A and measures of executive 
functioning. A limitation of Study 1 is the sample size: 103 healthy volunteers were tested and 
genotyped for the CHRFAM7A polymorphisms. A power calculation revealed that it would 
have been necessary to assess more than 600 subjects to be able to detect small effects of 
d=0.2 with a power of greater than 80%. Therefore, it cannot be ruled out completely that 
CHRFAM7A genotype does in fact impact on antisaccade performance, but we were not able 
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to detect it due to relatively small sample size. A possible solution could be to conduct a 
multicenter study in order to be able to recruit a very large sample of subjects similar to the 
COGS study (Greenwood et al., 2011; Radant et al., 2010). The fact that antisaccades can be 
measured accurately across multiple study sites was demonstrated in another COGS study by 
Radant et al. (2007). This further supports the concept of a multicentered approach, provided 
that in doing so one uses standardized equipment, training, tasks, and test procedures (Radant 
et al., 2007). 
Study 2 has its strong point in the fact that it is the first investigation to explore the 
effect of nicotine in a sample which was stratified according to performance level, i.e. in a 
sample which was divided into high- and low-performing groups. A minor limitation is the 
employed-median split procedure. With turning a continuous variable (i.e. antisaccade error 
rate) into a categorical one there is reduced power to detect interaction effects due to loss of 
information in contrast to a regression approach. In addition, median splits are sample-
dependent. Although Study 2 was adequately powered, future studies might want to opt for a 
regression model when analyzing what predicts a nicotine effect.  A strength of Study 2 is that 
a 6° and a 12° eccentricity condition was employed in the antisaccade paradigm. Thus, we 
made task demands difficult and provoked a sufficiently large antisaccade error rate in our 
sample, thereby ensuring we could detect subjects who would exhibit difficulties with the 
task. Hence, by making task demands difficult, we were able to mimic executive control 
impairment in the low-performing group as it is observed in different clinical populations 
such as schizophrenia or ADHD. At the same time, we were able to investigate the effect of 
nicotinic stimulation in a sample free of psychiatric disorder and other confounding variables, 
such as estrous cycle and medication, which could also have affected antisaccade 
performance. Thus, we studied an unbiased sample while maximizing the probability that the 
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observed performance enhancement was truly caused by nicotine and was not the effect of 
any other variable. 
One strength and limitation at the same time pertains to the use of a repeated-
measurement design. One the one hand, a repeated-measurement design offers higher 
statistical power to find an effect, as each subject serves as its own control, thereby keeping 
the variance down. In addition, fewer subjects are needed than in a between-subjects design. 
On the other hand, practice effects are always an issue in repeated-measurement designs. A 
limitation of Study 2 is the fact that we did not employ baseline testing before the two testing 
sessions. While some drug-challenge studies employed a baseline session in order to 
minimize practice effects between drug and placebo sessions (Allmann et al., 2010; 
Vollenweider et al., 2006), other drug-challenge studies did not (Csomor et al., 2008; Knott et 
al., 2010). As between-session practice effects have been observed for the antisaccade task 
(Ettinger et al., 2003a), an initial baseline session is recommended in future drug-challenge 
studies using the antisaccade paradigm. Nevertheless, we addressed the problem of practice 
effects in several ways. First, by making task demands sufficiently difficult, we ensured that 
our subjects did not perform at ceiling during testing Session 2. Second, we counter-balanced 
the order of the patches in our low- and high-performing groups; the groups did not differ 
regarding order of patch. Third, we included order of patch (nicotine first, placebo first) as 
between-subjects factors in all of our statistical analyses. There was neither a significant main 
effect of order nor interactions of order with any of the variables. Fourth, in a repeated-
measurement design in which subjects are tested twice, their scores tend to regress towards 
the mean. This statistical phenomenon is known as the “regression to the mean” (also referred 
to as: “the law of initial value”) (Bland & Altman, 1994; Wilder, 1958) (see also paragraph 
2.2.6.). We checked the present antisaccade error data and our data regarding the variability in 
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antisaccade latency for this issue and concluded that our results are not simply explainable in 
terms of a regression to the mean (see also paragraph 2.2.6.). 
Finally, an important strength of Study 2 lies in the assessment of blindness. At each 
testing session, the participants were asked to make a guess about which patch they had 
received. Results indicated that double-blindness was partially uncovered as participants were 
able to correctly guess which patch they had received, especially after Session 2, revealing a 
limitation of Study 2. Perhaps the participants could tell the difference between the placebo 
and the nicotine patch because they experienced physical side effects such as itching and mild 
nausea from the nicotine treatment but not from the placebo condition. In the whole sample, 
there was no significant association of experienced adverse side effects with correct guessing 
(testing Session 1: Fisher’s exact test p=.21, testing Session 2: Fisher’s exact test p=.57). 
However, it might be better to test the association between the side effects that were 
experienced and correct guessing of patch identity only in those probands who reported side 
effects during the nicotine session but not during the placebo session, as they should be the 
ones whose discomfort was actually caused by nicotine and they should reliably attribute their 
experienced discomfort to the nicotine treatment. Nineteen of the twenty-eight probands 
reported experiencing side effects during the nicotine session and no side effects during the 
placebo session. These 19 probands were the ones who guessed correctly 68.42% of the time 
when asked about patch identity at testing Session 1 and 100% of the time when asked about 
patch identity at testing Session 2. Therefore, probands who exhibited side effects from 
nicotine administration were those probands who uncovered double-blindness of the 
experiment, as they were all able to correctly identify the patches they received at Session 2. 
One solution to better mask the identity of the patches could be to additionally use capsaicin 
cream in combination with the placebo patch, as capsaicin mimics the itching and tingling 
sensations evoked by a nicotine patch. In fact, a recent study by Wignall and de Wit (2011) 
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employed this strategy. Like in Study 2, they used a 7 mg nicotine patch and a placebo patch 
in healthy non-smokers. The placebo patch additionally contained a small amount of capsaicin 
cream (Wignall & de Wit, 2011). Unfortunately, Wignall and de Wit (2011) did not ask their 
probands about patch identity. However, the participants’ ratings on perceived drug effects 
indicate that the participants experienced some aversive side effects of the nicotine treatment, 
as nicotine significantly increased ratings on the question whether the participants “are 
currently feeling any drug effects” and nicotine significantly decreased ratings on the question 
whether participants “like the effects they feel” (Wignall & de Wit, 2011). Thus, it is possible 
that double-blindness was uncovered, as probands probably attributed their experienced 
discomfort to the nicotine treatment. Cancelling out all aversive side effects caused by 
nicotine will be difficult in subjects who do not usually consume nicotine; however, one 
possible solution might be to administer an additional nausea-preventing drug (e.g. a tablet of 
domperidone) with nicotine treatment and an analogous placebo tablet with placebo 
treatment. 
3.5 Conclusions 
In summary, the present work did not find an association between CHRFAM7A 
polymorphisms and antisaccade performance (Study 1) and demonstrated that effects of 
nicotine on antisaccade error rate and response variability depend on inter-individual 
differences in baseline antisaccade performance (Study 2). To date, little is known about the 
genetics of antisaccade performance, therefore future studies should continue to investigate 
genetic effects on antisaccade parameters. In addition, future clinical studies should account 
for inter-individual differences in baseline performance when testing a new cholinergic 
compound for the remediation of cognitive deficits. The results from Study 2 indicate that a 
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possible cognitive enhancer does not necessarily have to be effective for everyone. Instead, 
inter-individual differences in performance form one important predictor of drug response. 
Previous studies have focused on the strategy “one medication for the whole patient 
group,” e.g. the partial α7 nAChR agonist DMXB-A for schizophrenia patients (Freedman et 
al., 2008). That study, however, was not effective in enhancing the cognitive function in the 
schizophrenia patients. Hence, future studies might want to stratify their study populations in 
probands with and without cognitive deficits or in patients with only mild cognitive 
impairment and patients with severe cognitive impairment. It is possible that the substance 
DMXB-A might only be effective in a sub-population of schizophrenia patients; that is, in 
those patients with more severe cognitive deficits. 
It is also possible that the effectiveness of a cholinergic substance highly depends on 
the patient’s genetic make-up. Patients exhibiting “disadvantageous” cholinergic 
polymorphisms (i.e. cholinergic polymorphism which are associated with poorer cognitive 
performance) might be those patients who are equipped with a suboptimal cholinergic system 
and will benefit from further cholinergic stimulation. Indeed, this pharmacogenetic research 
strategy of taking inter-individual differences in the genetic makeup into account when giving 
medications has received growing interest in recent years. Pharmacogenetic drug therapy can 
be related to the “personalized medicine” approach – personalizing treatment in general with 
all decisions in healthcare being tailored to the individual whenever possible. However, 
pharmacogenetic treatment strategies are still in a very experimental stage in basic science 
and are not being routinely applied in clinical practice. It would be very helpful for clinicians 
to predict which patient will benefit from which medication and which medication is likely to 
be ineffective in the patient. This is especially true for the treatment of psychiatric diseases. 
Today, trying out several psychotropic drugs is the routine and quite often it takes a few 
weeks for the drug to unfold its desired effects. Avoiding this “trying out procedure” would 
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help to cut down the exposure of patients to ineffective drugs, provide them with more 
effective and efficient treatment of their symptoms, and would also help to reduce costs. 
 In conclusion, future studies should continue to investigate the effectiveness of new 
cholinergic substances on executive function. The antisaccade task might serve as a useful 
laboratory tool to test the effectiveness of such new compounds. Further, future studies should 
account for the notion that it is not disease status per se which predicts poorer cognitive 
performance and the response to a cholinergic substance. Rather, other predictors of response 
such as baseline performance and genetic differences should also be considered in future 
investigations. 
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German Summary (Deutsche Zusammenfassung) 
 
Cholinerge Modulation der Antisakkadenleistung 
 
Die Bedeutung von CHRFAM7A-Polymorphismen und differentielle Effekte von Nikotin in 
Abhängigkeit vom Ausgangsleistungsniveau 
 
Einleitung. Die vorliegende Arbeit untersuchte inwiefern das nikotinerge 
Acetylcholinrezeptor-(nAChR)System eine Rolle für die Antisakkadenleistung spielt. 
Insbesondere die Bedeutung von interindividuellen Unterschieden bezüglich der Reaktivität 
auf eine cholinerge Stimulation wurde untersucht. Zwei Forschungsstrategien wurden dabei 
verfolgt: ein molekulargenetischer Ansatz, bei dem untersucht wurde, ob Polymorphismen im 
CHRFAM7A-Gen interindividuelle Varianz in der Antisakkadenleistung erklären können, 
sowie ein verhaltensexperimenteller und pharmakologischer Ansatz, bei dem geprüft wurde, 
ob interindividuelle Unterschiede im anfänglichen Antisakkadenleistungsniveau die Reaktion 
auf eine cholinerge Stimulation durch Nikotin beeinflussen. 
Patienten mit Schizophrenie, ihre Angehörigen und Individuen mit einem erhöhten 
Psychoserisiko zeigen Antisakkadendefizite (Hutton & Ettinger, 2006; Nieman et al., 2007; 
Petrovsky et al., 2008) – dies spricht dafür, dass die Antisakkadenleistung einen 
Endophänotyp der Schizophrenie darstellt. Bisher ist sehr wenig über die Genetik der 
Antisakkadenleistung bekannt. Cholinerge Polymorphismen könnten eine Rolle spielen, da 
ein verändertes nAChR-System möglicherweise zur Pathophysiologie der Schizophrenie 
beiträgt (Freedman et al., 1995). Außerdem kann Nikotin (ein Agonist des nAChRs) die 
Antisakkadenleistung positiv beeinflussen, die Antisakkadenleistung wird sowohl in 
Schizophreniepatienten (Depatie et al., 2002), als auch in gesunden Probanden (Rycroft et al., 
2006) durch Nikotin verbessert. Ein Forschungsansatz, um herauszufinden, ob nAChRs eine 
Rolle für die Antisakkadenleistung spielen, stellt die Suche nach nAChR-Genen dar, die 
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zumindest teilweise die interindividuellen Unterschiede in der Antisakkadenleistung erklären 
könnten. 
Als Startpunkt für die vorliegende Arbeit wurde das CHRNA7-Gen gewählt. CHRNA7 steht 
nachweislich mit der P50-Suppression, einem anderen Schizophrenie-Endophänotyp, in 
Verbindung (Freedman et al., 1997; Leonard et al., 2002). Ein schwacher Zusammenhang 
direkt zur Erkrankung Schizophrenie besteht ebenfalls (Freedman et al., 1997) und das 
häufigere Vorkommen von funktionalen Polymorphismen im CHRNA7-Promoter ist mit 
Schizophrenie assoziiert (Leonard et al., 2002). In den meisten Individuen ist das CHRNA7-
Gen teilweise doppelt vorhanden, was zur Folge hat, dass ein Hybridgen entsteht, 
CHRFAM7A, welches die Exons 5-10 von CHRNA7 enthält zusammen mit vier Exons des 
unverwandten FAM7A-Gens. Es sind Chromosomen mit und ohne das CHRFAM7A-Duplicon 
identifiziert worden, es besteht also ein Genkopienpolymorphismus (englisch: copy number 
variation, CNV) hinsichtlich der Exons 5-10 (Flomen et al., 2006). Reduzierte 
Genkopienanzahl ist schwach aber signifikant mit Psychose assoziiert (Flomen et al., 2006). 
Wenn das CHRFAM7A-Gen vorhanden ist, dann existiert es als polymorphe Inversion 
entweder in derselben oder in der entgegengesetzten Ausrichtung wie das CHRNA7-Gen 
(Flomen et al., 2008). Zusätzlich enthält das CHRFAM7A-Gen eine 2-bp Deletion in Exon 6, 
welche mit Defiziten in der P50-Suppression (Raux et al., 2002) und mit episodischer 
Gedächtnisleistung (Dempster et al., 2006) assoziiert ist. Die 2-bp Deletion steht im starken 
Linkage-Disequilibrium mit der Ausrichtung des CHRFAM7A-Gens in Bezug auf das 
CHRNA7-Gen. Daher könnte auch die Ausrichtung des CHRFAM7A-Gens die eigentliche 
Variante sein, die für die oben erwähnte Assoziation verantwortlich ist. Wie diese 
CHRFAM7A-Varianten die Schizophrenie-Endophänotypen beeinflussen, ist noch nicht 
erforscht. Möglicherweise beeinflusst die CHRFAM7A-Genexpression die Genexpression von 
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CHRNA7, indem ein Wettbewerb um Transkriptionsfaktoren besteht; dies könnte durch die 
Ausrichtung des CHRFAM7A-Gens beeinflusst sein (Flomen et al., 2008). 
Das Ziel von Studie 1 war es deshalb, herauszufinden, ob Varianten im nAChR Gen Varianz 
in einem fronto-parietalen Schizophrenie-Endophänotyp erklären können. Daher wurde die 
mögliche Assoziation von CHRFAM7A-Genkopienanzahl-/2-bp Deletionspolymorphismen 
und Antisakkadenleistung untersucht. Studie 1 war hierbei auf gesunde Probanden 
beschränkt, um Gen-Kognition Beziehungen ohne klinische und medikamentöse Störfaktoren 
zu testen.  Auch konnte auf diese Weise ein stärkerer Effekt erwartet werden, da vorherige 
Studien gezeigt haben, dass CHRFAM7A-Genotypeffekte auf Kognition stärker in gesunden 
Probanden als in Patienten mit Schizophrenie auftreten (Raux et al., 2002). 
Studie 2 beschäftigte sich mit der möglichen Beeinflussung der Antisakkadenleistung durch 
ein cholinerges Pharmakon, nämlich mit der Wirkung von Nikotin, einem bekannten nAChR-
Agonisten. Eine Meta-Analyse von Heishman et al. (2010) hat bereits gezeigt, dass Nikotin 
auf eine Reihe von kognitiven Funktionen positive Wirkungen hat, unter anderem verbessert 
Nikotin Aufmerksamkeits- und Arbeitsgedächtnisleistungen. Manche kognitiven Domänen 
konnten allerdings nicht in diese Meta-Analyse einfließen, weil zu ihnen noch zu wenige 
Studien durchgeführt wurden, u.a. der Bereich der vorliegend untersuchten exekutiven 
Funktionen. (Unter dem Begriff exekutive Funktionen bzw. exekutiver Kontrolle fasst man 
verschiedene höhere kognitive Prozesse zusammen, u.a. inhibitorische Kontrollprozesse wie 
z.B. die Hemmung einer vorherrschenden Reaktion, zielgerichtetes Initiieren und 
Sequenzieren von Handlungen, sowie die Beobachtung von Handlungsergebnisse und die 
evtl. erforderliche Selbstkorrektur.) Besonders im Zusammenhang mit Schizophrenie ist die 
Wirkung von Nikotin auf exekutive Funktionen interessant, da die Behandlung mit den 
bisherigen Medikamenten hier kaum zu Verbesserungen führt und diese kognitiven Störungen 
einen ungünstigen Einfluss auf den Verlauf der Erkrankung haben (Friedman et al., 1999). 
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Zudem gibt es Hinweise darauf, dass cholinerge Substanzen nützlich bei der Behandlung von 
kognitiven Störungen bei Schizophrenie-Patienten sein könnten (Ribeiz et al., 2010). Daher 
könnten cholinerge Substanzen möglicherweise die Störungen exekutiver Kontrolle bei 
Patienten mit Schizophrenie verbessern und so einen neuen, zusätzlichen Behandlungsansatz 
darstellen für die bisher nicht ausreichend behandelbaren exekutiven Störungen. Bisherige 
Studien berücksichtigten aber kaum den Aspekt interindividueller Unterschiede bei der 
Reaktion auf die Behandlung mit einer cholinergen Substanz. Diese interindividuellen 
Unterschiede können wahrscheinlich zumindest teilweise erklären, warum manche Studien 
positive Effekte einer Nikotingabe zeigten und andere Studien nicht. Parallel zu Theorien, die 
sich auf das dopaminerge System beziehen, haben Newhouse und Kollegen (2004) eine 
umgekehrte U-Funktion des Ausgangsleistungsniveaus und der nikotinergen Stimulation 
postuliert. Abhängig vom Ausgangsleistungsniveau kann eine äquivalente nikotinerge 
Stimulation entweder die Leistung steigern oder beeinträchtigen. In Probanden mit einem 
niedrigen anfänglichen Leistungsniveau führt die Nikotingabe zu einer Leistungssteigerung, 
das heißt die Probanden werden näher an das optimale Leistungsniveau herangebracht. Bei 
Probanden mit einem hohen anfänglichen Leistungsniveau, das bereits nahe am Optimum 
liegt, führt die Nikotingabe zu einer „Überstimulation“ des Systems, die Probanden 
verschlechtern sich in ihrer Leistung (Newhouse et al., 2004). In Studien, die die Effekte von 
cholinergen Agonisten wie Nikotin auf kognitive Leistungen untersuchen, könnte es daher 
wichtig sein, Unterschiede im Ausgangsleistungsniveau systematisch zu beachten, um in der 
Lage zu sein, mögliche Effekte der Substanz zu beurteilen. 
In Studie 2 wurde hierfür das Antisakkadenparadigma gewählt, um zu untersuchen, ob 
anfängliche Leistungsunterschiede in exekutiven Funktionen die Effekte von Nikotin 
modulieren können. Das Antisakkadenparadigma wurde gewählt, weil es ein relativ simples 
Modell exekutiver Kontrolle okulomotorischer Reaktionen darstellt (Reuter & Kathmann, 
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2004). Außerdem wird die  Antisakkadenaufgabe durch ein gut erforschtes neuronales 
Netzwerk vermittelt, das frontale, parietale und subkortikale Strukturen umfasst (Ettinger et 
al., 2008a; Munoz & Everling, 2004). Des Weiteren stellt die Antisakkadenleistung einen 
bekannten Schizophrenie-Endophänotyp dar (Calkins et al., 2008), der eine hohe Retest-
Reliabilität aufweist (Ettinger et al., 2003a). Schließlich zeigten schon einige wenige Studien, 
dass die Antisakkadenaufgabe auf eine Stimulation durch Nikotin anspricht; Nikotineffekte 
fanden sich sowohl in Schizophrenie-Patienten (Depatie et al., 2002; Larrison-Faucher et al., 
2004), als auch in gesunden Probanden (Bowling & Donnelly, 2010; Dawkins et al., 2007; 
Depatie et al., 2002; Ettinger et al., 2009; Rycroft et al., 2006; Rycroft et al., 2007). Basierend 
auf dem Modell von Newhouse und Kollegen (2004) wurde die Hypothese aufgestellt, dass 
Probanden mit einem niedrigen Leistungsniveau in der Antisakkadenaufgabe von einer 
Nikotingabe profitieren würden, und dass Probanden mit einem hohen Leistungsniveau in der 
Antisakkadenaufgabe durch nikotinerge Stimulation beeinträchtigt würden. 
Genetikstudie = Studie 1: CHRFAM7A Genkopien-/2-bp-Deletionspolymorphismen und 
Antisakkadenleistung. 
Methoden. Probandenrekrutierung. Die Probanden wurden durch Aushänge an der 
Universität und in der örtlichen Gemeinde rekrutiert. Abgefragt wurden Alter, Geschlecht, 
Ethnizität, Rauchstatus (Raucher, Nichtraucher), Bildungsjahre, mütterlicher und väterlicher 
sozio-ökonomischer Status (gemessen auf einer 1-4 Skala, 1=elementary, 4=professional). 
Ausschlusskriterien waren DSM-IV Achse I Störungen, die Probanden wurden dazu mithilfe 
des SKID-I Interviews gescreent. Weitere Ausschlusskriterien waren erlittene 
Kopfverletzungen mit Bewusstlosigkeit >1 min, neurologische Erkrankungen, ein 
Angehöriger ersten Grades mit einer psychotischen Erkrankung, Drogenmissbrauch oder 
Drogenabhängigkeit und Sehbehinderungen. Die Probanden füllten Gesundheitsfragebögen 
bezüglich ihres allgemeinen Gesundheitszustandes aus. Außerdem füllten die Probanden 
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standardisierte Persönlichkeitsfragebögen aus, um mögliche Genotypeneffekte auf 
Persönlichkeitsmerkmale zu erfassen: Rust Inventory of Schizotypal Cognitions (RISC) 
(Rust, 1988; Fragebogen zur Schizotypie), den Adult ADHD Self-Report Scale (ASRS) 
(Kessler et al., 2005; Fragebogen der Weltgesundheitsorganisation zu Symptomen der 
Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung), das Obsessive-Compulsive Inventory 
(OCI) (Foa et al., 2002; Fragebogen zur Erfassung von Zwangsgedanken und 
Zwangshandlungen), Neurotizismus-Skala des Eysenck Personality Questionnaire – Revised 
(EPQ-R) (Eysenck & Eysenck, 1991; Fragebogen zur Erfassung des Persönlichkeitsmerkmals 
Neurotizismus). Die Zulassung der lokalen Ethikkommission wurde eingeholt und alle 
Probanden unterzeichneten eine schriftliche Einverständniserklärung. 
Antisakkadenparadigma. Die Augenbewegungen wurden per Infrarotokulographie (IRIS 
Skalar 6500, Skalar Instruments GmbH, Deutschland) aufgezeichnet; die Abtastrate betrug 
500 Hz. Die Teilnehmer saßen mit einem Abstand von 57 cm vor einem 17-Zoll 
Computermonitor. Kopfbewegungen wurden dadurch minimiert, dass die Teilnehmer ihr 
Kinn auf einer Kinnstütze ablegten. Der Zielreiz war ein weißer Punkt (0.3 Sehwinkel 
Durchmesser) auf schwarzem Hintergrund. Zunächst wurde eine 3-Punkt-Kalibrierung 
vorgenommen (0°, ±12°), anschließend folgten 60 Antisakkadendurchgänge. Ein Durchgang 
beinhaltete die Darbietung des Zielreizes in der Bildschirmmitte für eine randomisierte Dauer 
von 1000-2000 ms, anschließend wurde der Zielreiz an einer von vier möglichen Positionen 
(±6°, ±12°) für 1000 ms gezeigt. Die Teilnehmer wurden instruiert, auf den Zielreiz zu 
schauen, wenn er sich in der Bildschirmmitte befindet und genau zur spiegelbildlichen Stelle 
zu blicken wenn der Zielreiz zur Seite springt. Die Auswertung der Augenbewegungen 
erfolgte mittels Eyemap (AMTech GmbH, Deutschland) mit den folgenden automatischen 
Kriterien zur Detektion einer Sakkade: minimale Amplitude (1°), Geschwindigkeit (30°/s), 
minimale Latenz (100 ms), sowie Einstufung je nach Richtung der Sakkade als korrekte 
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Antisakkade oder Antisakkadenfehler. Als Antisakkadenvariablen wurden die 
Antisakkadenlatenz (in ms), die Antisakkadenfehlerrate (in %, d.h. reflexive Sakkaden zum 
Zielreiz hin geteilt durch die Gesamtanzahl der Durchgänge), der Antisakkaden-Gain (d.h. das 
Antisakkadenamplitudenverhältnis in % = Sakkadenamplitude geteilt durch 
Zielreizamplitude) und der räumliche Antisakkadenfehler berechnet. Der räumliche 
Antisakkadenfehler berechnete sich folgendermaßen: die Zielreizamplitude wurde von der 
Sakkadenamplitude abgezogen und das daraus resultierende Ergebnis durch die 
Zielreizamplitude geteilt. Der absolute Wert wurde anschließend durch alle Sakkaden geteilt 
und mit 100 multipliziert. 
Genotypisierung. Genotypisiert wurden die Probanden hinsichtlich zweier CHRFAM7A-
Polymorphismen: Copy Number Variation (CNV) Polymorphismus (=Anzahl der Kopien des 
CHRFAM7A-Gens) und 2bp-Deletionspolymorphismus. Daraus ergaben sich fünf Genotypen-
Gruppen: „1C0D“: eine Kopie und keine Deletion (N=16), „1C1D“: eine Kopie und eine 
Deletion (N=12), „2C0D“: zwei Kopien und keine Deletion (N=15), „2C1D“: zwei Kopien 
und eine Deletion (N=42), sowie „2C2D“: zwei Kopien und zwei Deletionen (N=18). Der 
sehr seltene Genotyp, der keinerlei Kopie von CHRFAM7A aufweist, fand sich bei den 
Probanden nicht. 
Statistische Auswertung. Die statistischen Analysen wurden mit SPSS 15.0 (SPSS Inc., USA) 
durchgeführt. Der Genotyp (1C0D, 1C1D, 2C0D, 2C1D, 2C2D) fungierte dabei als 
unabhängige Variable, soziodemographische Variablen (Alter, Bildung, mütterlicher und 
väterlicher sozio-ökonomischer Status) und Antisakkdenvariablen (Fehlerrate, Latenz, Gain, 
räumlicher Fehler) waren die abhängigen Variablen in separaten univariaten Varianzanalysen 
(ANOVA). Die Beziehung zwischen Genotyp und Geschlecht wurde mittels des χ²-Tests 
untersucht. Rauchstatus (Raucher, Nichtraucher) wurde als zusätzliche unabhängige Variable 
zum ANOVA-Modell hinzugefügt. Außerdem wurde mittels χ²-Test untersucht, ob 
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Rauchstatus mit dem Genotyp assoziiert war. (Mittelwerte (M) und Standardabweichungen 
(SD) sind im Folgenden als M±SD dargestellt.) 
Resultate. Insgesamt wurden 111 gesunde Probanden untersucht. Bei acht Probanden schlug 
die Genotypisierung fehl, was zu einer endgültigen Stichprobe von N=103 führte. Die 
Stichprobe von N=103 Probanden enthielt 57 männliche Probanden, das Durchschnittsalter 
betrug 25,87±5,50 Jahre, die Probanden wiesen durchschnittlich 17,64±3,36 Bildungsjahre 
auf, der väterliche sozio-ökonomische Status betrug im Durchschnitt 3,12±0,84, der 
mütterliche sozio-ökonomische Status betrug im Durchschnitt 2,83±1,02; 27 der untersuchten 
Probanden waren Raucher. Alle Probanden waren kaukasisch. 
Die Genotypen-Gruppen unterschieden sich statistisch signifikant in keiner der 
soziodemographischen Variablen (alle p-Werte>0,20). Die Genotypen-Verteilung unterschied 
sich ebenfalls nicht signifikant vom Hardy-Weinberg-Equilibrium (χ²=4,51, d.f.=3, p=0,21). 
Die Analysen der Antisakkadenvariablen zeigten keine Assoziation der Genkopien-
/Deletionsgenotypen mit den Antisakkadenvariablen (alle p-Werte>0,37). Die Gruppierung 
der Probanden in Probanden nach 2-bp Deletionspolymorphismus (N=31 ohne Deletion, 
N=72 mit mindestens einer Deletion) und in Probanden nach Anzahl Genkopien (N=28 mit 
einer Kopie, N=75 mit zwei Kopien) zeigte in separaten Analysen ebenfalls keine 
signifikanten Effekte (jeweils p>0,34 und p>0,59). 
Auch bei Hinzufügung des Rauchstatus als unabhängige Variable blieben die 
Genotypeneffekte  blieben unverändert, es gab keine signifikanten Haupt- oder 
Interaktionseffekte mit dem Faktor Rauchstatus (alle p-Werte>0,18). Des Weiteren gab es 
keine Assoziationen der kombinierten Genkopien-/Deletionsgenotypen mit den Daten aus den 
Persönlichkeitsfragebögen (alle p-Werte>0,48). Die Gruppierungen der Probanden nach 
Deletionspolymorphismus alleine sowie nach Anzahl Genkopien alleine zeigten ebenfalls 
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keine signifikanten Effekte (P-Werte jeweils p>0,25 und p>0,22). Ebenfalls gab es keine 
Haupt- oder Interaktionseffekte der Faktoren Rauchstatus und Genotyp auf die erzielten 
Werte in den Persönlichkeitsfragebögen. 
Nikotinstudie = Studie 2: Differentielle Modulation der Antisakkadenleistung durch Nikotin in 
gesunden männlichen Nichtrauchern, die nach niedriger und hoher Leistung eingeteilt 
wurden. 
Methoden. Probandenrekrutierung und Nikotinapplikation. Dreißig gesunde, kaukasische, 
nichtrauchende, männliche Versuchsteilnehmer wurden über Aushänge an der Universität und 
aus einer Zufallsstichprobe aus der Allgemeinbevölkerung durch das örtliche Melderegister 
rekrutiert. Als Nichtraucher wurden dabei Personen qualifiziert, die in ihrem Leben nicht 
mehr als 100 Zigaretten und im letzten Jahr überhaupt nicht geraucht haben. Die 
Versuchsteilnehmer mussten zwischen 18 und 55 Jahren alt sein und wurden mit dem SKID-
Interview hinsichtlich möglicher DSM-IV Diagnosen untersucht. Ausschlusskriterien waren 
eine aktuelle oder eine lebenszeitliche Achse I Störung, ein Angehöriger ersten Grades mit 
einer psychotischen Erkrankung, eine neurologische Erkrankung, andere schwere körperliche 
Erkrankungen, erlittene Kopfverletzungen mit einer Bewusstlosigkeit >5 min, eine 
Lebenszeitdiagnose Alkoholmissbrauch oder Alkoholabhängigkeit, Sehbehinderungen, 
Adipositas (BMI>30), die Einnahme von zentralnervös-wirksamen Medikamenten. Weitere 
Ausschlusskriterien, um schwere nachteilige Wirkungen der Nikotingabe auszuschließen, 
waren: kardiovaskuläre Erkrankungen, Hypertonie, Ekzeme und atopische Dermatitis, 
schwere Nieren- und Leberfunktionsstörungen, Magen- und Zwölffingerdarmgeschwüre, 
Schilddrüsenüberfunktion, Phäochromozytom, insulinpflichtiger Diabetes, 
Überempfindlichkeit hinsichtlich Pflaster, Nikotin oder sonstiger Bestandteile von Pflastern. 
Um keine negativen Effekte durch Koffein-„Entzug“ zu erzeugen, durften die Probanden ihre 
gewohnte Menge an Kaffee, Tee oder anderen koffeinhaltigen Getränken trinken. Der 
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Koffeinkonsum der Teilnehmer wurde für beide Testsitzungen dokumentiert. Der 
bildungsabhängige Verbal-IQ wurde mit dem Mehrfachwahl-Wortschatz-Intelligenztest 
(MWT-B, Lehrl, 1989) eingeschätzt. Die Zulassungen der lokalen Ethikkommission sowie 
des BfArMs wurden eingeholt und alle Probanden unterzeichneten eine schriftliche 
Einverständniserklärung. Die Studie wurde unter http://www.clinicaltrials.gov 
(ClinicalTrials.gov Identifier: NCT01315002) registriert. 
Bei allen Probanden wurde der Blutdruck gemessen, um eine Hypertonie auszuschließen 
(diastolischer Wert nicht größer als 90). An beiden Testtagen wurde ein Urin-Drogen-Test 
durchgeführt, um den akuten Konsum von Amphetaminen, Benzodiazepinen, Kokain, 
Cannabis und Opiaten auszuschließen. Das Nikotin wurde sodann in einem doppel-blinden, 
Placebo-kontrollierten, ausbalancierten Messwiederholungsdesign verabreicht, jeder Proband 
erhielt also einmal Nikotin und einmal Placebo. Die Nikotingabe erfolgte über ein 
Nikotinpflaster (NiQuitin Clear 7 mg, GlaxoSmithKline Deutschland), das Placebopflaster 
war ein sehr ähnlich aussehendes Pflaster (Fink and Walter GmbH Deutschland). Beide 
Pflaster wurden (für den Probanden nicht sichtbar) von einem Studienassistenten, der nicht 
Testleiter war, auf das rechte Schulterblatt geklebt. Drei Stunden nach Applikation der 
Pflaster begannen die Antisakkadentestungen. Am Ende einer Testsitzung wurden die 
Probanden aufgefordert, einzuschätzen, welches Pflaster sie bekommen hatten. Die Stimmung 
und körperliche Symptome wurden über visuelle Analogskalen erfasst. Den Probanden 
wurden die visuellen Analogskalen vor der Pflasterapplikation (=erster Messzeitpunkt) und 
drei Stunden nach der Pflasterapplikation (=zweiter Messzeitpunkt) vorgelegt. Folgende Items 
wurden mit den Analogskalen erfasst: „entspannt“, „munter“, „nervös“, „schläfrig“, 
„angenehm“, „unruhig“, „konzentriert“, „benommen“, „angeregt“, „aufmerksam“, „Mir 
gefällt die Wirkung der Substanz“, „Ich bin schlechter Stimmung“, „Mir ist übel“ und „Ich 
bin guter Stimmung“. 
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Antisakkadenparadigma. Die Augenbewegungen wurden per Elektrookulographie (EOG) 
aufgezeichnet. Alle Teilnehmer führten zunächst einen Block Prosakkaden, anschließend 
einen Block Antisakkaden aus. Die Teilnehmer saßen mit einem Abstand von 41 cm vor 
einem 17-Zoll Computermonitor. Zunächst erschien zufällig für 1000, 1500, 2000 oder 2500 
ms ein weißes Fixationskreuz auf schwarzem Hintergrund. Anschließend wurde der Zielreiz, 
ein weißer Punkt, an einer von vier möglichen Positionen (±6°, ±12°) für 1000 ms gezeigt. 
Das Fixationskreuz erlosch beim Auftauchen des Zielreizes (Step-Paradigma). Es wurden 48 
Prosakkaden- und 48 Antisakkadendurchgänge gezeigt. Die Reihenfolge der 
Zielreizpositionen war pseudorandomisiert. Vor dem Pro- und dem Antisakkadenblock 
erfolgten 5 Übungsdurchgänge. Die Instruktion für die Prosakkaden-Aufgabe erfolgte 
dahingehend, bei Erscheinen des Punktes so schnell und so genau wie möglich auf den Punkt 
zu schauen, die Instruktion für die Antisakkadenaufgabe lautete, bei Erscheinen des Punktes 
so schnell und so genau wie möglich auf die spiegelbildliche Stelle des Punktes zu schauen. 
Die Auswertung der Augenbewegungen erfolgte mittels Brain Vision Analyzer. Eine Sakkade 
wurde dabei angenommen, wenn eine Abweichung von mindestens 1.5 
Standardabweichungen von der Baselineamplitude vorlag, anschließend erfolgte die 
Einstufung je nach Richtung der Sakkade als korrekte Prosakkade, Prosakkadenfehler, 
korrekte Antisakkade oder Antisakkadenfehler. Diese Einstufung wurde anschließend manuell 
überprüft und gegebenenfalls korrigiert, wobei dies verblindet, also ohne Kenntnis der 
experimentellen Bedingung (Placebo/Nikotin), erfolgte. 
Als Outcome-Variablen wurden Prosakkadenfehler, Prosakkadenlatenz, ICV der 
Prosakkadenlatenz, Antisakkadenfehler, korrigierte Antisakkadenfehler, Antisakkadenlatenz 
und ICV der Antisakkadenlatenz berechnet. Mit ICV wird ein Maß für die 
Reaktionszeitvariabilität dargestellt (englisch: ICV= intra-individual coefficient of variation, 
deutsch: intraindividueller Variabilitätskoeffizient der Reaktionszeit). Der ICV berechnet sich 
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aus der Standardabweichung der Reaktionszeit geteilt durch die mittlere Reaktionszeit 
(Nandam et al., 2011). Somit stellt der ICV ein Maß für die Konsistenz von Reaktionen 
innerhalb eines Individuums dar. Ein Vorteil des ICVs als Maß gegenüber der reinen 
Standardabweichung ist, dass der ICV adjustiert für den Einfluss der 
Reaktionsgeschwindigkeit der jeweiligen Person ist und somit ein vorteilhafteres 
Variablitätsmaß darstellt.  
Statistische Auswertung. Die statistischen Analysen wurden mit SPSS 18.0 (SPSS Inc., USA) 
durchgeführt. Um zu testen, ob Nikotin differentielle Effekte auf Probanden mit einer hohen 
Genauigkeit (d.h. einer niedrigen Antisakkadenfehlerrate) versus einer niedrigen Genauigkeit 
(d.h. mit einer hohen Antisakkadenfehlerrate) im Antisakkadenparadigma hat, wurden die 
Probanden mittels eines Mediansplits in Probanden mit niedriger bzw. hoher Leistung 
eingeteilt. Die Nikotineffekte auf die Sakkadenvariablen wurden mit einer 2×2×2×2 
Kovarianzanalyse mit Messwiederholung analysiert mit Pflaster (Placebo, Nikotin) und 
Exzentrizität (6° Exzentrizität, 12° Exzentrizität) als Innersubjektfaktoren, sowie Gruppe 
(Probanden mit niedriger Leistung, Probanden mit hoher Leistung) und Reihenfolge (Nikotin 
zuerst, Placebo zuerst) als Zwischensubjektfaktoren. Verbal-IQ wurde als Kovariate in alle 
Analysen eingefügt, weil sich die Probandengruppen hinsichtlich dieser Variable 
unterschieden. Die Blindheit der Probanden für die Pflaster wurde mittels Chi-Quadrat-Test 
überprüft. Die Daten der visuellen Analogskalen wurden mittels einer 2×2×2 Varianzanalyse 
mit Messwiederholung mit Pflaster (Placebo, Nikotin) als Innersubjektfaktor, sowie 
Messzeitpunkt (erster Messzeitpunkt, zweiter Messzeitpunkt) und Gruppe (Probanden mit 
niedriger Leistung, Probanden mit hoher Leistung) als Zwischensubjektfaktoren analysiert. 
(Mittelwerte (M) und Standardabweichungen (SD) sind im Folgenden als M±SD dargestellt.) 
Resultate. Dreißig Probanden nahmen an der Studie teil. Die explorative Analyse der Daten 
ergab, dass dabei ein Proband ein Ausreißer war; er lag hinsichtlich Antisakkadenfehlerrate 
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mehr als drei Standardabweichungen außerhalb des Interquartilsabstand des Boxplots und 
wurde deshalb bei den weiteren Analysen nicht berücksichtigt. Der Median der 
Antisakkadenfehlerrate betrug 25.91%. Der Ausschluss des Median-Probanden führte zu zwei 
gleich großen Probandengruppen mit jeweils N=14 Probanden. Die zwei Probandengruppen 
unterschieden sich nicht signifikant hinsichtlich Alter (Probanden mit niedriger Leistung: 
30,50±11,71 Jahre, Probanden mit hoher Leistung: 25,71±5,21 Jahre), Bildungsjahren 
(Probanden mit niedriger Leistung: 16,21±2,75 Jahre, Probanden mit hoher Leistung: 
16,29±0,73 Jahre), täglichem Koffeinkonsum (Probanden mit niedriger Leistung: 
31,07±46,93 mg, Probanden mit hoher Leistung: 39,00±68,20 mg) und BMI (Probanden mit 
niedriger Leistung: 24,04±3,68, Probanden mit hoher Leistung: 23,97±1,53) (alle p-
Werte>0,17). Allerdings unterschieden sie sich hinsichtlich des Verbal-IQs (Probanden mit 
niedriger Leistung: 126,07±18,21, Probanden mit hoher Leistung: 111,57±15,41) (p=0,03). 
Daher wurde der Verbal-IQ kovarianzanalytisch in den weiteren statistischen Analysen 
berücksichtigt. 
Die Probanden konnten die Art der verabreichten Pflaster signifikant korrekt erraten: bei der 
jeweiligen ersten Sitzung rieten 69,2% der Probanden korrekt – dies war signifikant besser als 
Zufallsniveau (χ2(1)=4,14; p=0,042), bei der zweiten Sitzung rieten 92,3% der Probanden 
korrekt (χ2(1)=16,45; p=0,0001). Die Ergebnisse der visuellen Analogskalen zeigten, dass die 
Probanden sich unter Nikotin beim zweiten Messzeitpunkt unruhiger fühlten (p=0,017), 
ebenso war den Probanden unter Nikotin beim zweiten Messzeitpunkt übler (p=0,034). 
Tendenziell fühlten sich die Probanden unter Nikotin beim zweiten Messzeitpunkt auch 
weniger angenehm (p=0,050). 
Die Korrekturrate der Antisakkadenfehler war generell hoch – dies zeigt, dass die Probanden 
die Antisakkadenaufgabe verstanden hatten und auch gewillt waren, sie korrekt auszuführen. 
Die Probandengruppen unterschieden sich nicht hinsichtlich dieser Variable (F(1,23)=0,80, 
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p=0,78): Probanden mit niedriger Leistung: 92,97±9,66% in der Placebobedingung,  in der 
Nikotinbedingung 89,90±17,92%; Probanden mit hoher Leistung: 98,30±3,46% in der 
Placebobedingung, 91,74±17,72% in der Nikotinbedingung. Es gab keine weiteren Haupt- 
oder Interaktionseffekte hinsichtlich Antisakkadenfehler-Korrekturrate (alle p-Werte>0,35). 
Die explorative Datenanalyse ergab, dass es so gut wie keine Varianz innerhalb der 
Prosakkadenfehlerrate gab, die Probanden machten so gut wie gar keine Prosakkadenfehler. 
Daher wurde diese Variable von weiteren Analysen ausgeschlossen. Es gab weder einen 
Haupteffekt des Faktors Reihenfolge (Nikotin zuerst, Placebo zuerst) noch Interaktionseffekte 
mit dem Faktor Reihenfolge (alle p-Werte>0,14). Es gab keine Effekte der Nikotingabe auf 
die Prosakkadenlatenz (alle p-Werte>0,18). Für den ICV der Prosakkadenlatenz fand sich ein 
Trend für einen Haupteffekt des Pflasters: unter Nikotin war die Variabilität der 
Prosakkadenlatenzen geringer (F(1,23)=3,78, p=0,064, ηp
2
=0,14). Es gab keine weiteren 
Haupt- oder Interaktionseffekte für diese Variable (alle p-Werte>0,15). Aufgrund der 
Mediansplit-Prozedur gab es einen signifikanten Haupteffekt von Gruppe für die 
Antisakkadenfehlerrate: die Probanden mit der niedrigen Leistung machten mehr 
Antisakkadenfehler als die Probanden mit der hohen Leistung (F(1,23)=34,93, p=5×10
-7
, 
ηp
2
=0,60). Für die Antisakkadenfehlerrate gab es keinen Haupteffekt des Pflasters 
(F(1,23)=1,06, p=0,31). Die aufgestellte Hypothese bestätigte sich teilweise: es gab eine 
signifikante Pflaster×Gruppe Interaktion (F(1,23)=6,45, p=0,018, ηp
2
=0,14): die Probanden 
mit schlechter Leistung machten weniger Fehler unter Nikotin als unter Placebo (post hoc 
Vergleich: F(1,12)=6,83, p=0,023, ηp
2
=0,36), hingegen gab es bei den Probanden mit guter 
Leistung keinen Unterschied zwischen Placebo- und Nikotinsitzung (post hoc Vergleich: 
F(1,12)=0,30, p=0,596, ηp
2
=0,02). Es gab keine weiteren Haupt- oder Interaktionseffekte für 
diese Variable (alle p-Werte>0,08). Für die Antisakkadenlatenz fanden sich keine 
signifikanten Haupt- oder Interaktionseffekte bezüglich Exzentrizität und Nikotingabe (alle p-
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Werte>0,09). Der ICV der Antisakkadenlatenz zeigte keinen signifikanten Haupteffekt des 
Pflasters (F(1,23)=0,04, p=0,84), aber es fand sich ein Trend für eine Pflaster×Exzentrizität 
Interaktion (F(1,23)=4,07, p=0,056, ηp
2
=0,15). Post-hoc Vergleiche zeigten, dass die 
Variabilität unter Nikotin für die 12° Exzentrizitätsbedingung vermindert wurde 
(F(1,27)=4,52, p=0,043, ηp
2
=0,14), diese Reduktion der Reaktionszeitvariabilität fand sich 
nicht für die 6° Exzentrizitätsbedingung ((F(1,27)=0,03, p=0,87, ηp
2
=0,001). Des Weiteren 
gab es eine signifikante Interaktion der Faktoren Pflaster×Exzentrizität×Gruppe 
(F(1,23)=5,39, p=0,029, ηp
2
=0,19). Post hoc Vergleiche zeigten, dass die Interaktion von 
Pflaster×Exzentrizität nur in den Probanden mit niedriger Leistung signifikant war 
(F(1,11)=4,97, p=0,048, ηp
2
=0,31), nicht aber in den Probanden mit hoher Leistung 
(F(1,11)=0,10, p=0,76, ηp
2
=0,009). Es gab keine weiteren Haupt- oder Interaktionseffekte 
(alle p-Werte>0,23). 
Diskussion. In Studie 1 fanden sich keine signifikanten Assoziationen zwischen den 
CHRFAM7A Genkopien-/2-bp-Deletionspolymorphismen und der Antisakkadenleistung. Die 
Stichprobengröße war für molekulargenetische Standards relativ klein, dies schränkt die 
Aussagekraft der Studie ein. Kleine Geneffekte der CHRFAM7A Genkopien-/2-bp-
Deletionspolymorphismen auf kognitive Leistungen können daher nicht ausgeschlossen 
werden. Um diese mögliche Effekte sichtbar zu machen, müssten allerdings sehr große 
Stichproben getestet werden, d.h. bei einem angenommenen kleine Effekt mit einer 
Effektstärke von d=0,2 und einer Teststärke (Power) von über 80% müssten über 600 
Probanden gemessen werden. Die Durchführung einer Multi-Center-Studie wäre hierfür eine 
realistische Möglichkeit, um diese große Probandenanzahl zu erreichen. 
Es ist auch denkbar, dass die CHRFAM7A-Polymorphismen spezifische Effekte auf durch den 
Hippocampus vermittelte kognitive  Funktionen haben, da die bisherigen Effekte von 
CHRFAM7A auf episodisches Gedächtnis (Dempster et al., 2006) und auf die P50-
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Suppression (Raux et al., 2002) beide durch den Hippocampus vermittelt werden. 
Nichtsdestotrotz stellt die Antisakkadenaufgabe einen Schizophrenie-Endophänotyp mit hoher 
Erblichkeit dar, daher kann das Antisakkadenparadigma zur weiteren Aufklärung genetischer 
Unterschiede dienen, die interindividuelle Unterschiede in der Leistung erklären. 
Zukünftige Studien sollten neben Varianten in den CHRNA7- und CHRFAM7A-Genen auch 
andere cholinerge Polymorphismen im Zusammenhang mit Antisakkaden untersuchen, wie 
z.B. Polymorphismen in den α4β2 nikotinergen Acetylcholinrezeptoren. Neben den α7 
nikotinergen Acetylcholinrezeptoren, stellt der α4β2 nikotinerge Acetylcholinrezeptor-
Subtypus den Rezeptorsubtypus dar, der am häufigsten im Gehirn vorkommt (Boess et al., 
2007). Daher ist es möglich, dass auch genetische Varianten im α4β2 nAChR 
interindividuelle Unterschiede in der Antisakkadenleistung erklären könnten. Diese 
Erweiterung auf andere Polymorphismen legt auch eine kürzlich publizierte Studie an 534 
Probanden nahe, wonach die Antisakkadenleistung nicht mit dem CHRNA7-Gen assoziiert ist 
(Greenwood et al., 2011). Insoweit kämen Polymorphismen in CHRNA4 und CHRNB2 in 
Betracht, um sie hinsichtlich ihres möglichen Einflusses auf die Antisakkadenleistung zu 
untersuchen. 
Studie 2 zeigte, dass Nikotin die Antisakkadenfehlerrate bei Probanden mit einem niedrigen 
Leistungsniveau verringert, hingegen hatte Nikotin bei Probanden mit einem hohen 
Leistungsniveau keinen Effekt auf die Antisakkadenfehler. Außerdem verringerte Nikotin 
tendenziell bei allen Probanden die Variabilität der Prosakkadenlatenzen. Schließlich gab es 
noch einen weiteren differentiellen Effekt der Nikotingabe: Nikotin verringerte die 
Reaktionszeitvariabilität der Antisakkaden in der 12° Exzentrizitätsbedingung nur bei 
Probanden mit niedrigem Leistungsniveau, nicht aber bei Probanden mit hohem 
Leistungsniveau. Die Ergebnisse von Studie 2 bestätigen das erwähnte Modell von Newhouse 
und Kollegen (2004), das differentielle Wirkungen von Nikotin abhängig vom anfänglichen 
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Leistungsniveau annimmt. Allerdings wurden in Studie 2 – anders als das Modell hätte 
erwarten lassen – keine nachteiligen Wirkungen des Nikotins bei Probanden mit hohem 
Leistungsniveau gefunden. Möglicherweise war die Nikotindosis nicht hoch genug um eine 
beeinträchtigende Wirkung bei Probanden mit hohem Leistungsniveau zu entfalten. Eine 
höhere Nikotindosis könnte diesen Effekt herbeiführen und würde außerdem möglicherweise 
zu einer noch stärkeren Verbesserung bei Probanden mit niedrigem Leistungsniveau führen. 
Die Wirkung von Nikotin auf Variablen, die Reaktionszeitvariabilität abbilden, zeigt, dass 
diese Variablen sensitiv auf eine cholinerge Stimulation reagieren und Nikotin zu 
konsistenteren Reaktionen führt. In zukünftigen Studien mit cholinergen Agonisten sollten 
daher Variablen der Reaktionszeitvariabilität berücksichtigt werden. Studie 2 zeigt auch, dass 
klinische Prüfstudien, die die Wirkung von neuen cholinergen Agonisten zur Behandlung von 
kognitiven Defiziten testen, das anfängliche Leistungsniveau der Testpersonen 
berücksichtigen sollten. Die bisherige Strategie, möglichst ein Medikament für die 
Gesamtgruppe von Patienten eines Störungsbildes zu entwickeln, muss möglicherweise 
verfeinert werden. Es ist denkbar, dass lediglich eine Subgruppe von Patienten von einem 
bestimmten Medikament profitiert. Eine Idee wäre daher, Patienten bei einer 
Medikamentenprüfstudie in eine Gruppe von Patienten mit keinen oder nur leichten 
kognitiven Einschränkungen und in eine Gruppe mit persistierenden schwereren 
Einschränkungen einzuteilen. Hinweise darauf, dass diese Strategie erfolgreich sein könnte, 
gibt auch eine Studie von Larrison-Faucher et al. (2004), die zeigte, dass Nikotin nur in 
denjenigen Schizophrenie-Patienten zu Verbesserungen in der Antisakkadenaufgabe führte, 
die bei dieser Aufgabe beeinträchtigt waren. 
Die Aussagekraft von Studie 2 ist insoweit eingeschränkt, als dass die Probanden die Art des 
Pflasters (Placebo/Nikotin) erkennen konnten. Daher sollten zukünftige Studien versuchen, 
die Gewährleistung der Doppelblindheit zu verbessern. Dies könnte durch die zusätzliche 
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Verwendung einer Capsaicin-Salbe zum Placebopflaster geschehen, um hierdurch das Jucken 
des Nikotinpflasters nachzuahmen und die Art des Pflasters besser zu verdecken. Dies wurde 
in einer kürzlich publizierten Nikotinstudie von Wignall und de Wit (2011) praktiziert. 
Allerdings haben Wignall und de Wit ihre Probanden leider nicht zur vermuteten Art des 
Pflasters befragt, sodass unklar bleibt, ob die Capsaicin-Salbe tatsächlich zur besseren 
Verblindung beitragen konnte. Nichtraucher verspüren nämlich oftmals Nebenwirkungen 
durch die Nikotingabe. Studie 2 konnte insoweit zeigen, dass diejenigen Probanden, die 
zuverlässig unter Nikotin, nicht aber unter Placebo Nebenwirkungen verspürten, das 
Nikotinpflaster richtig identifizieren konnten. Alle Nebenwirkungen durch eine Nikotingabe 
wird man in zukünftigen Studien wahrscheinlich nicht vermeiden können. Man könnte 
allerdings versuchen, Nebenwirkungen wie z.B. Übelkeit zu minimieren, indem man 
zusätzlich zur Nikotingabe ein Medikament verabreicht, das gegen die Übelkeit wirkt (z.B. 
eine Kapsel) und dementsprechend zusätzlich zur Placebogabe eine Placebokapsel 
verabreicht.  
Zusammenfassend lässt sich sagen, dass in der vorliegenden Arbeit kein Einfluss von 
Polymorphismen im CHRFAM7A-Gen auf die Antisakkadenleistung gefunden wurde. Jedoch 
konnte gezeigt werden, dass interindividuelle Unterschiede im anfänglichen 
Antisakkadenleistungsniveau das Ansprechen auf eine cholinerge Stimulation beeinflussen. 
Zukünftige Studie sollten auch die Kombination aus genetischem Forschungsansatz und 
pharmakopsychologischem Experiment in pharmakogenetischen Untersuchungen verfolgen, 
um so zum besseren Verständnis beizutragen, welche genetischen Faktoren prädiktiv für eine 
cholinerge Wirkung sind. 
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5-HT   serotonin 
5-HTT  serotonin transporter 
5-HTTLPR   serotonin transporter-linked polymorphic region 
ACh   acetylcholine 
AChEI   acetylcholinesterase inhibitor 
AChR   acetylcholine receptor 
AD   Alzheimer’s disease 
ADHD  attention deficit/hyperactivity disorder 
ANCOVA   analysis of covariance 
ANOVA  analysis of variance 
ANT   attention network test 
APOE   apolipoprotein E gene 
ASRS   Adult ADHD Self-Report Scale 
BfArM   German Federal Institute for Drugs and Medical Devices 
BMI   body mass index 
BOLD   blood oxygen level-dependent response 
Ca
2+
   calcium ions 
CGI   Clinical Global Impressions scale 
CHRFAM7A   hybrid gene, fusion of CHRNA7 (exons 5-10) and FAM7A (exons A-E) 
CHRNA1  α1 nicotinic acetylcholine receptor sub-unit gene 
CHRNA2  α2 nicotinic acetylcholine receptor sub-unit gene 
CHRNA3  α3 nicotinic acetylcholine receptor sub-unit gene 
CHRNA4  α4 nicotinic acetylcholine receptor sub-unit gene 
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CHRNA5  α5 nicotinic acetylcholine receptor sub-unit gene 
CHRNA7  α7 nicotinic acetylcholine receptor sub-unit gene 
CHRNB2   β2 nicotinic acetylcholine receptor sub-unit gene 
CHRNB4  β4 nicotinic acetylcholine receptor sub-unit gene 
CNS    central nervous system 
CNV   copy number variation 
COGS   Consortium on the Genetics of Schizophrenia 
COMT  Catechol-O-methyltransferase gene 
CPT   Continuous Performance Test 
CRHR1  corticotropin releasing hormone receptor 1 gene 
DA   dopamine 
DAT   dopamine transporter 
DAT1   dopamine active transporter 1 gene (also known as SLC6A3) 
DISC1   disrupted in schizophrenia 1 gene 
DLPFC  dorsolateral prefrontal cortex 
DMXB-A  3-(2,4-dimethoxybenzylidene) anabaseine (also known as GTS-21) 
DNA   deoxyribonucleic acid 
DRD2   dopamine receptor D2 gene 
DRD3   dopamine receptor D3 gene 
DRD4    dopamine receptor D4 gene 
DSM-IV  Diagnostic and Statistical Manual of Mental Disorders, 4th edition 
EEG   electroencephalography 
EOG    electroocculography 
EPQ-R   Eysenck Personality Questionnaire – Revised 
ERBB4 v-erb-a erythroblastic leukemia viral oncogene homolog 4 (avian) gene, 
receptor tyrosine-protein kinase erbB-4 gene 
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ERP event-related potential 
 
FAM7A  family with sequence similarity 7A gene 
FEF   frontal eye fields 
fMRI   functional magnetic resonance imaging 
GABA  gamma-aminobutyric acid 
GLU   glutamate 
GRIK4   glutamate receptor, ionotropic, kainate 4 gene 
HEOG   horizontal electroocculogram 
HPA axis   hypothalamic-pituitary-adrenal axis 
HTR2A  5-hydroxytryptamine (serotonin) receptor 2A gene 
ICC   intraclass correlations 
ICV   intra-individual coefficient of variation 
IQ   intelligence quotient 
LTD   long-term depression 
LTP   long-term potentiation 
mAChR  muscarinic acetylcholine receptor 
MFFT   Matching Familiar Figures Test 
MMN   mismatch negativity 
mRNA  messenger ribonucleic acid 
MWT-B Mehrfachwahl-Wortschatz-Intelligenztest, a standardized German 
vocabulary test 
 
NA   noradrenalin 
Na
+
   sodium ions 
nAChR  nicotinic acetylcholine receptor 
NRG1   neuregulin 1 gene 
OCI   Obsessive-Compulsive Inventory 
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PD   Parkinson’s disease 
PET    positron emission tomography 
PFC   prefrontal cortex 
PPI    prepulse inhibition 
PRODH   proline dehydrogenase (oxidase) 1 gene 
RBANS  Repeatable Battery for the Assessment of Neuropsychological Status 
RELN   reelin gene 
RISC   Rust Inventory of Schizotypal Cognitions 
RT   reaction time, response time 
SC   superior colliculus 
SCID   Structured Clinical Interview for DSM-IV Disorders 
SES   socio-economic status 
SLC18A1  solute carrier family 18 (vesicular monoamine), member 1 gene 
SLC6A4 solute carrier family 6 (neurotransmitter transporter, serotonin), 
member 4, serotonin transporter gene 
 
SNP   single nucleotide polymorphism 
SPEM   smooth pursuit eye movement 
SSRT   stop-signal reaction time 
STDP    spike-timing-dependent plasticity 
SWM   spatial working memory 
THC   tetrahydrocannabinol 
TOL   Tower of London test 
TPH1   tryptophan hydroxylase 1 gene 
TPH2   tryptophan hydroxylase 2 gene 
VAS   visual analogue scale 
VEOG   vertical electroocculogram 
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VTA   ventral tegmental area 
WCST  Wisconsin card sorting test 
WDYWS  “Why do young women smoke?” sample 
WHO   World Health Organization
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Term Definition and reference 
allele An alternative form of a gene at a locus. 
(Plomin et al., 2001) 
agonist 
 
Drugs that increase the effectiveness of neurotransmission at a 
particular receptor are called agonists for that receptor. 
(Kolb & Wishaw, 2003) 
antagonist Drugs that decrease the effectiveness of neurotransmission at a 
particular receptor are called antagonists for that receptor. 
(Kolb & Wishaw, 2003) 
base pair (bp) One step in the spiral staircase of the double helix of DNA, 
consisting of adenine (A) bonded to thymine (T) or Cytosine (C) 
bonded to guanine (G). 
(Plomin et al., 2001) 
copy number variation 
(CNV) 
A copy number variation (CNV) is when the number of copies of 
a particular gene varies from one individual to the next. 
(National Institutes of Health, National Human Genome 
Research Institute, USA, 2011) 
deletion 
 
A deletion is a type of mutation involving the loss of genetic 
material. It can be small, involving a single missing DNA base 
pair, or large, involving a piece of a chromosome. 
(National Institutes of Health, National Human Genome 
Research Institute, USA, 2011) 
DNA 
(deoxyribonucleic acid) 
The double-stranded molecule that encodes genetic information. 
The two strands are held together by hydrogen bonds between 
two of the four bases, with adenine bonded to thymine and 
cytosine bonded to guanine. 
(Plomin et al., 2001) 
electroencephalography 
(EEG) 
A technique used to noninvasively measure electrical brain 
activity via sensors placed on the scalp. EEG measures volume 
conduction currents from apical dendrites of post synaptic 
cortical pyramidal cells. The electrical signals recorded by the 
scalp sensors result from the summation of the coordinated 
electrical activity of thousands of neurons in a given region. 
(Ettinger (Ed.) & Klein (Ed.) 2008, Glossary, Brain Cogn 68) 
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electrooculography 
(EOG) 
Method for measuring eye movements based on changes in the 
electrostatic field with changes in the concurrent changes in eye 
position as the eyes rotate in the orbit. The resulting electrical 
potential differences are measured using skin electrodes placed 
around the eye. 
(Ettinger (Ed.) & Klein (Ed.) 2008, Glossary, Brain Cogn 68) 
endophenotype A biobehavioral characteristic that appears to reflect the action of 
genes predisposing an individual to a specific disorder even in 
the absence of diagnosable pathology. As a measurable, reliable 
manifestation of genetic risk for a disorder, an endophenotype: 
(1) is associated with an illness, (2) is heritable, (3) shows trait-
like properties, (4) co-segregates with illness in the family, and 
(5) identifies individuals at increased genetic risk for the 
disorder. 
(Ettinger (Ed.) & Klein (Ed.) 2008, Glossary, Brain Cogn 68) 
epistasis 
 
Nonadditive interaction between genes at different loci. The 
effect of one gene depends on that of another. 
(Plomin et al., 2001) 
exon DNA sequence transcribed into messenger RNA and translated 
into protein. (Compare with intron.) 
(Plomin et al., 2001) 
functional magnetic 
resonance imaging 
(fMRI) 
fMRI is a neuroimaging method that allows in-vivo 
measurements of blood oxygen level dependent (BOLD) changes 
in the vasculature that supports neuronal activity. While a subject 
lies inside a magnetic bore performing a task, magnetic 
resonance pulse sequences are used that allow the relative 
changes in oxygenated and deoxygenated hemoglobin during 
neuronal activity to be measured localizing brain regions that 
support task performance. 
(Ettinger (Ed.) & Klein (Ed.) 2008, Glossary, Brain Cogn 68) 
gene The basic unit of inheritance. A sequence of DNA bases that 
codes for a particular product. Includes DNA sequences that 
regulate transcription. 
(Plomin et al., 2001) 
genetic association study A class of genetic research designs whose goal is to test whether 
a genetic variant (a particular allele, genotype, or haplotype of a 
polymorphism) is associated with a particular disease or trait. If 
association is present, the variant will be seen in an affected 
individual more often than expected by chance. Genetic 
association strategies include case-control, family-based, 
quantitative trait loci (QTL), and genome wide association 
studies. 
(Ettinger (Ed.) & Klein (Ed.) 2008, Glossary, Brain Cogn 68) 
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genetic polymorphism A locus with two or more alleles. Greek for “multiple forms”. 
(Plomin et al., 2001) 
haplotype A haplotype is a set of DNA variations, or polymorphisms, that 
tend to be inherited together. A haplotype can refer to a 
combination of alleles or to a set of single nucleotide 
polymorphisms (SNPs) found on the same chromosome. 
(National Institutes of Health, National Human Genome 
Research Institute, USA, 2011) 
Hardy-Weinberg-
equilibrium 
Allelic and genotypic frequencies remain the same generation 
after generation in the absence of forces, such as natural 
selection, that change frequencies. If a two-allele locus is in 
Hardy-Weinberg-equilibrium, the frequency of genotypes is p² + 
2pq + q², where p and q are the frequencies of the two alleles. 
(Plomin et al., 2001) 
homologous 
recombination 
 
Homologous recombination is a type of genetic recombination 
that occurs during meiosis (the formation of egg and sperm 
cells). Paired chromosomes from the male and female parent 
align so that similar DNA sequences from the paired 
chromosomes cross over each other. Crossing over results in a 
shuffling of genetic material and is an important cause of the 
genetic variation seen among offspring. 
(National Institutes of Health, National Human Genome 
Research Institute, USA, 2011) 
infrared oculography Method for measuring eye movements based on the reflection of 
infrared light illumination by the border of the sclera and the 
pupil (called the “limbus”) or by the depth of the pupil. The 
reflection is measured using infrared photodetectors placed with 
the source of infrared light into goggles. 
(Ettinger (Ed.) & Klein (Ed.) 2008, Glossary, Brain Cogn 68) 
intron DNA sequence within a gene that is transcribed into messenger 
RNA but spliced out before translation into protein. (Compare 
with exon.) 
(Plomin et al., 2001) 
inversion 
 
An inversion polymorphism describes a genetic polymorphism 
which consists of a duplicated segment of a gene which is in 
opposite orientation to the DNA strand. 
(Makoff & Flomen, 2009) 
linkage Close proximity of loci on a chromosome. Linkage is an 
exception to Mendel’s second law of independent assortment 
because closely linked loci are inherited together instead of being 
inherited independently. 
(Plomin et al., 2001) 
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linkage disequilibrium 
(LD) 
The nonrandom association between two or more alleles such 
that certain combinations of alleles are more likely to occur 
together on a chromosome than other combinations of alleles. 
(The American Heritage Medical Dictionary, 2007) 
locus (plural, loci) The site of a specific gene on a chromosome. Latin for “place”. 
(Plomin et al., 2001) 
microsatellite 
polymorphism 
Also known as simple sequence repeat marker. Two, three, or 
four base pairs are repeated at a particular locus. The number of 
repeats at each locus differs among individuals. For example, a 
microsatellite polymorphism might have three alleles, in which 
the two-base sequence C-G repeats 14, 15, or 16 times. 
(Plomin et al., 2001) 
mRNA 
(messenger RNA) 
Processed RNA that leaves the nucleus of the cell and serves as a 
template for protein synthesis in the cell body. 
(Plomin et al., 2001) 
mutation A heritable change in DNA base pair sequences. 
(Plomin et al., 2001) 
nucleobase (also: base) Basic building blocks of DNA and RNA. There are four DNA 
bases: adenine (A), thymine (T), guanine (G), and cytosine (C). 
As a result of the structural properties of these bases, A always 
pairs with T, and G always pairs with C. 
(Plomin et al., 2001) 
positron emission 
tomography (PET) 
PET is a neuroimaging method. Either a small amount of water, 
containing radioactive molecules to label it, is injected into the 
bloodstream of the subject, or a gas containing the radioactive 
molecule is inhaled. Positrons from the radioactivity are released, 
they collide with electrons in the brain, and photons are produced 
(i.e gamma ray), this gamma ray exits the head and is recorded 
by pairs of radiation detectors. Active Areas of the brain will use 
more blood and thus will emit more photons. On PET scan 
images, differences are usually portrayed by a color gradient with 
active areas being depicted in yellows and reds, and less active 
areas depicted in greens and blues. It is also possible to record a 
receptor PET with a radioactive tracer binding to specific brain 
receptors in order to measure receptor distribution and activity. 
(Kolb & Wishaw, 2003) 
promoter A promoter is a sequence of DNA needed to turn a gene on or 
off. The process of transcription is initiated at the promoter. 
Usually found near the beginning of a gene, the promoter has a 
binding site for the enzyme used to make a messenger RNA 
(mRNA) molecule. 
(National Institutes of Health, National Human Genome 
Research Institute, USA, 2011) 
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single nucleotide 
polymorphism (SNP) 
A single-base mutation. This single nucleotide change may or 
may not alter the function of the relevant protein depending on 
whether the affected mRNA triplet (codon) results in a different 
amino acid. 
(Plomin et al., 2001) 
splicing Splicing is a modification of the RNA after transcription, in 
which introns are removed (i.e. spliced out) and exons are joined 
(i.e. spliced back together). 
(Plomin et al., 2001) 
transcription(al) factor A transcription factor is a protein that binds to sequences of DNA 
adjacent to genes, thereby influencing transcription either 
positively or negatively. Thus, transcription factors influence the 
rate at which genes produce proteins. In some cases introns 
regulate gene transcription. 
(Latchman, 1997; Plomin et al., 2001) 
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